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ABSTRACT 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, characterized 
by early deficits in learning and memory with eventual loss of higher cognitive 
functions. Although considerable progress in the understanding of the histological 
changes during the disease has been made, all therapies available today are 
symptomatic and the mechanisms which underly initial AD development are still 
unclear. In a screen of human brain tissue from different AD stages as represented by 
Braak staging,  the brain-specific protein phosphatase 1E (PPM1E) stuck out for its 
strong up-regulation in early AD stages.  
 
PPM1E has not been associated with neurological disorders or dementia before, 
however it was reported to negatively regulate the Ca2+/calmodulin dependent kinases 
(CaMK) IV and II and the p21-activated kinase (PAK) 1. These kinases are important 
regulators of the actin cytoskeleton in dendritic spines and neuronal dendrites. The loss 
of dendritic spines and dystrophy of dendrites can be observed in the AD-affected 
brain. A negative regulation of the CaMKII, CaMKIV and PAK1 kinases might be 
potentially interrelated with these early changes. This study evaluated the influence of 
PPM1E on neuronal morphology in primary neuronal culture and aimed to characterize 
the previously poorly understood phosphatase in greater detail. 
 
The present study showed that the elevation of PPM1E mRNA levels in human brain 
samples in early stages of Alzheimer’s disease was also reflected on the protein level. 
PPM1E exhibited conserved subcellular, predominantly cytoplasmic localization and 
protein truncation in human brain tissue in different Braak stages, in rat brain tissues 
and in mature rat dissociated primary culture. The subcellular localization of PPM1E 
changed gradually during maturation of the dissociated primary culture from a 
predominantly nuclear localization during the first week, towards a predominantly 
cytoplasmatic localization in more mature primary culture. Moreover PPM1E was 
enriched at sites of mitochondria accumulation in dendrites of mature dissociated 
hippocampal neurons. 
 
Although CaMKIIĮ, CaMKIV and PAK1 were proposed to be deposphorylated by 
PPM1E, the present study found that increased PPM1E levels had no significant effect 
on the phosphorylation state of the kinases in mature dissociated primary neurons, 
whereas it significantly affected the overall CaMKIV expression. Further, increased 
levels of PPM1E had a degenerative effect on the number of dendritic mushroom 
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spines in mature neuronal culture, whereas downregulation of PPM1E lead to an 
increase in the number of stubby spines. The number of primary dendrites was 
negatively affected by down- as well as upregulation of PPM1E in these dissociated 
cultures. 
 
Consequently, an early-onset dysregulation of PPM1E in Alzheimer’s disease could 
negatively affect the dendrite and dendritic spine morphogenesis or homeostasis. 
Inhibiting PPM1E in an early stage of Alzheimer’s disease may delay or at best even 
halt the progression of cognitive decline. PPM1E might therefore provide a promising 
new drug target for neurodegenerative diseases and especially for AD. 
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ABBREVIATIONS 
A      alanine (Ala) 
aa   amino acid(s) 
AAV   adeno-associated virus 
$ȕ    amyloid beta  
AD    Alzheimer’s disease 
a.k.a    also known as 
AMPA   Į-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate 
APP   amyloid precursor protein 
ATP    adenosine triphosphate 
ARHGEF6  Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 (ĮPIX) 
ARHGEF7  Rac/Cdc42 guanine nucleotide exchange factor (GEF) 7 (ȕPIX) 
au   arbitrary unit 
BACE   ȕ-site APP-cleaving enzyme 1 
BLAST-N  basic local alignment search tool, for nucleotide sequences 
BLAST-P  basic local alignment search tool, for polypeptide sequences 
C    cysteine (Cys) 
CaMK    Ca2+/calmodulin-dependent kinase 
co   cortex / cortices 
conc.   concentration(s) 
COS-7 CV-1 (simian) in origin, carrying the SV40 genetic material 
(kidney derived cell line) 
COXII   cytochrome oxidase subunit II 
CSF    cerebrospinal fluid 
dbl   diffuse B-cell lymphoma 
D    aspartic acid (Asp) 
DAPI   4',6-diamidino-2-phenylindole 
Dcvp   DNA containing viral rAAV particles 
DG    dendate gyrus 
DIV    day in-vitro 
D.melanogaster Drosophila melanogaster 
DMSO   dimethyl sulfoxide 
dNTP    deoxyribonucleotide 
E    glutamic acid / glutamate (Glu) 
E/Fhd domain  PPM1E/1F homology domain 
EC50    half maximal effective concentration 
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ECL    enhanced chemiluminescence  
EGFP    enhanced green fluorescence protein 
EOAD   early-onset Alzheimer’s disease 
ER    endoplasmatic reticulum 
EST   expressed sequence tag 
F    phenylalanine (Phe) 
FA    formaldehyde 
F-actin   filamentous actin 
G    glycine (Gly) 
G-actin  globular actin 
GAL yeast transcription activator protein, specifically binds to UAS 
promoter region and activates transcription 
GAPDH   glyceraldehyde 3-phosphate dehydrogenase 
GEF   guanine nucleotide exchange factor 
GFAP    glial fibrillary acid protein 
h   hour(s) 
H    histidine (His) 
hc   hippocampus 
hARHGEF6 Homo sapiens Rac/Cdc42 guanine nucleotide exchange factor 6  
HBSS   Hanks’s balanced salt solution 
HeLa human cervical cancer derived cell line (from patient Henrietta 
Lacks) 
hshRNA  shRNA construct targeting rat PPM1E 
H.sapiens  Homo sapiens 
hPPM1E Homo sapiens protein phosphatase 1E (PP2C domain 
containing)  
hPPM1F Homo sapiens protein phosphatase 1F (PP2C domain 
containing)  
hSYN   human synapsin promoter 
I    isoleucine (Ile) 
JNK    c-Jun N-terminal kinase 
K    lysine (Lys) 
L    leucine (Leu) 
LOAD   late-onset Alzheimer’s disease 
LTP   long-term potentiation 
LTD   long-term depression 
M    methionine (Met) 
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MAP2   microtubule associated protein 2 
MCI   minimal/mild cognitive impairment 
MEM   minimum essential medium 
MWCO   molecular weight cut off 
N    asparagine (Asn) 
NBB    Netherlands Brain Bank 
NCBI   National Center for Biotechnology Information 
NeuN   neuron specific nuclear antigen 
NFT   neurofibrillary tangles 
NLS   nuclear localization signal 
NMDA   N-methyl-D-aspartic acid 
P    proline (Pro) 
pAAV plasmid DNA encoding elements for adeno associated virus 
production 
PAGE     polyacrylamide gel electrophoresis 
PAK   p21-activated kinase 
PB   phosphate buffered saline 
PCR   polymerase chain reaction 
PMT   post-mortem delay time 
PPIB   peptidylprolyl isomerase B (=cyclophilin B) 
Q    glutamine (Gln) 
qRT-PCR   quantitative real-time polymerase chain reaction 
R    arginine (Arg) 
RT    room temperature 
rAAV   recombinant adeno associated virus 
rARHGEF6 Rattus norvegicus Rac/Cdc42 guanine nucleotide exchange 
factor  
R.norvegicus Rattus norvegicus 
RNA   ribonucleic acid 
rPPM1E Rattus norvegicus protein phosphatase 1E (PP2C domain 
containing)  
rPPM1F Rattus norvegicus protein phosphatase 1F (PP2C domain 
containing)  
rr   ramp rate  
rshRNA  shRNA construct targeting rat PPM1E 
RT    room temperature 
S    serine (Ser) 
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SA    spine apparatus 
SDS    sodium dodecylsulfate  
SEC   size exclusion chromatography 
SER   smooth endoplasmic reticulum 
Sf9    Spodoptera frugiperda cell line 
shRNA   short hairpin ribonucleic acid 
SYN    synapsin 
SYP    synaptophysin 
T    threonine (Thr)  
TAMRA  tetramethyl-6-carboxyrhodamine dye 
TRIM37  tripartite motif-containing protein 37 
trunc.   truncated 
UAS    upstream activation sequence  
V    valine (Val) 
W     tryptophan (Trp) 
WHO    World Health Organization 
WPRE   woodchuck postregulatory element 
Y    tyrosine (Tyr) 
zPPM1E  zebrafish protein phosphatase 1E (PP2C domain containing) 
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1 INTRODUCTION 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, characterized 
by early deficits in learning and memory with eventual loss of higher cognitive 
functions. Although considerable progress in the understanding of the histological 
changes during the disease has been made, all treatment available today is 
symptomatic and the mechanisms which underly initial AD development are still 
unclear. Conventional approaches to identify drugs mainly addressed late stages of the 
disease and the nowadays available drugs fail to increase cognition in AD patients 
considerably. Moreover, it is likely that much of the neuronal damage, which is 
reflected in increased cognitive decline in late stages of AD, is presumably irreversible. 
It would therefore be desirable to prevent the disease before cognitive decline 
becomes apparent.  
 
To identify genes that might be associated with the development of very early events in 
the disease, Evotec Neurosciences GmbH conducted a screen for genes that are 
differentially regulated in early AD. The brain-specific protein phosphatase 1E (PPM1E) 
stuck out in this screen for its strong up-regulation in early AD stages. PPM1E had not 
been associated with neurological disorders or dementia before, however it was 
reported to negatively regulate the Ca2+/calmodulin dependent kinases (CaMK) IV and 
II and the p21-activated kinase (PAK) 1. These kinases are important regulators of the 
actin cytoskeleton. Thus, negative regulation of these kinases and defects in the actin 
cytoskeleton in neurons in the AD-affected brain might be interrelated. This study 
evaluates the influence of PPM1E on the actin cytoskeleton in primary neuronal culture 
as model system and aims to characterize the previously poorly understood 
phosphatase in greater detail. 
 
To provide a basis for the understanding of potential molecular links between PPM1E 
and Alzheimer’s disease-related changes in the brain, this introduction will provide a 
short review of current AD research and clinical treatment.  A screen of human brain 
tissues in different AD stages will be described afterwards, in which PPM1E expression 
is correlated with early disease development. Finally, the potential role which PPM1E 
might play in CaMK and PAK associated pathways and their respective relevance for 
spine development will be introduced.  
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1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is a slowly progressing, heterogenous neurodegenerative 
disorder of uncertain etiology. It is the most common form of all brain degenerations 
and presumably caused by multiple factors. The greatest risk factor for AD is 
increasing age, wherefore AD becomes a major social and economic problem for the 
ageing society in post-industrialized countries. The total societal worldwide costs of 
dementia have been estimated to be $422 billion in 2009 (Wimo et al., 2010). 
1.1.1 Cognitive phenotype, diagnostic and treatment 
Alzheimer’s disease is characterized by a severe impairment of cognitive function while 
sensory and motor functions are very well preserved during early disease stages. 
Initially, AD is manifested as a series of mild cognitive impairments, deficits in short-
term memories, loss of spatial memory and emotional imbalances (Selkoe, 2001). 
Declarative as well as nondeclarative memories become profoundly impaired during 
the course of the disease and are accompanied by a growing disability to learn new 
information. The ability for reasoning, abstraction and language also declines. During 
the progress of the disease, these symptoms become more severe, and ultimately 
result in the complete loss of executive functions. 
1.1.2 Ante-mortem diagnostic 
Progressive memory deficits are still the main diagnosis criterium for Alzheimer’s 
disease1 after elimination of other potential causes for dementia like vascular brain 
disease, Acquired immunodeficiency syndrome, morbus Parkinson and alcohol abuse. 
Other diagnostic approaches have advanced, namely the identification of biomarkers in 
the cerebrospinal fluid and in vivo positron emission tomography (PET) scans 
(Nordberg et al., 2010;Blennow et al., 2010;Dubois et al., 2007). The levels of Aȕ and 
amyloid precursor protein (APP) isoforms, Aȕ oligomers, and ȕ-site APP-cleaving 
enzyme 1 (BACE1) levels in cerebrospinal fluid (CSF) have been proposed as 
biomarkers for AD (Zetterberg et al., 2010), but are not yet in clinical use. The 
relevance of APP, Aȕ and BACE1 for the disease is described below in 1.1.7 Etiology 
of Alzheimer’s disease (page 22). 
 
PET scans have been successfully used for diagnostic purposes in clinical trials and 
are even able to distinguish Alzheimer’s disease from other types of dementia with 
                                               
1 according to the “International Statistical Classification of Diseases and Related Health Problems 10, ICD-10 (F00-
F03)”, WHO 
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similar pathological brain alterations. However, diagnosis based on these physiological 
alterations remains difficult, because AD is a multifactorial disease and few AD-related 
physiological changes correlate consistently with the progress of dementia and can at 
the same time be diagnosed in the living patient with current technology. A significant 
correlation with cognitive disease progression has only consistently been described for 
the loss of dendritic spines and synapses on neurons and for the levels of soluble Aȕ 
peptides in the interstitium2 (spines and synapses: (Scheff et al., 2007;Lopez and 
DeKosky, 2003;Sisodia and St George-Hyslop, 2002;Terry et al., 1991); soluble Aȕ 
peptides: (McLean et al., 1999;Lue et al., 1999)).  
 
The diagnosis of AD is additionally complicated due the poor characterization of the 
transition modi between mild cognitive impairments (MCI) and AD. Currently, a 
diagnosis of MCI or mild physiological alterations in the brain is a poor predictor of 
disease development. 
1.1.3 Treatment of Alzheimer’s disease – state of the art 
In addition to the outlined diagnostic challenges, no medical treatment is currently able 
to cure or prevent AD. However, some drugs which are able to delay disease 
progression or severity are used routinely for AD treatment. Today, five drugs are 
approved from the ‘US Food and Drug Administration’ (FDA): Four 
acetylcholinesterase inhibitors, which are applied for the enhancement of cognition and 
memory in moderate AD cases and which inhibit degradation of the neurotransmitter 
acetylcholin (Donepezil, ENA-713, Galantamine and Tacrine), and one ‘N-methyl-D-
aspartic acid’ (NMDA) receptor antagonist, which is applied in moderate to severe 
cases and which modulates excess glutamatergic signaling (memantine). A number of 
alternative, but not FDA approved therapies are in use: Many patients additionally take 
antioxidants like Vitamin E or selenium, which are thought to be protective against 
damage caused by oxygen radicals. Women also take estrogen, which has been 
shown to reduce the risk of developing AD. Non-steroidal anti-inflammatory drugs 
(NSAIDs) may also be taken to prevent neuroinflammation-induced brain damage. 
However, neither antioxidants, nor estrogen, nor NSAIDs are proven to be beneficial in 
patients with manifested AD pathology.  
                                               
2 The relevance of Aȕ peptides for the disease is described in 1.1.7 Etiology of Alzheimer’s disease, page 22. 
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1.1.4 Treatment of Alzheimer’s disease - outlook 
Many drug trials have been discontinued during the last years, however a number of 
clinical trials in phase III are still running and represent the diversity of therapeutic 
approaches very well: anti-Aȕ antibodies (AAB-001; Gammagard; Solanezumab), anti-
oxidants (Į-tocopherol, vitamine E), omega-3 fatty acids (docosahexanoic acid), 
estrogen (premarin), anti-inflammatory agents (ibuprofen), conditioners of cognitive 
function (Leuprolide acetate), Ȗ-secretase inhibitors (LY450139 dihydrate), 
neuroprotectants (trans-3,4',5-trihydroxystilbene), anti-diabetics (rosiglitazone), 3-
hydroxy-3-methylglutaryl-coenzyme-A-(HMG-CoA) reductase inhibitors (simvastatin) 
and agitation preventing agents (divalproex sodium) are currently tested for their 
effects on disease progression or severity. 
 
A description of the whole range of proposed working mechanisms for these drugs is 
beyond the scope of this introduction. However, the roles of Aȕ peptides and the Ȗ-
secretase in AD will be depicted below3.  
1.1.5 Histological phenotype 
On the histological level AD is generally characterized by the presence of two hallmark 
lesions: extracellular ȕ-amyloid (Aȕ)-containing neuritic plaques (Masters et al., 
1985;Glenner and Wong, 1984a;Glenner and Wong, 1984b) and intracellular 
neurofibrillary tangles of hyperphosphorylated tau protein (Ballatore et al., 2007;Selkoe 
and Schenk, 2003;Brion et al., 2001;Braak and Braak, 1998;Hardy, 1997). Neuritic 
plaques are roughly spherical, extracellular deposits of amyloid ȕ-protein (Aȕ) fibrils, 
surrounded by dystrophic dendrites and axons, reactive astrocytes and activated 
microglia. Aȕ peptides are cleavage products from the membrane protein ‘amyloid 
precursor protein’ (APP).  Neurofibrillary tangles are non-membrane bound paired 
helical filaments in which hyperphosphorylated tau protein is enriched. They are mainly 
located in the perinuclear cytoplasm of many limbic and cortical neuronal cell bodies 
and cortical dystrophic dendrites.  
 
The spatial and temporal connections between plaques and tangles are not completely 
understood. While hyperphosphorylated tau and insoluble tangles initially appear in the 
limbic system, i.e. the entorhinal cortex, hippocampus and dendate gyrus, and then 
progress to cortical areas, the plaques first appear in the frontal cortex to spread then 
over the entire cortical region (Smith, 2002;Braak and Braak, 1998;Bouras et al., 1994). 
                                               
3 see 1.1.7 Etiology of Alzheimer’s disease, page 22 
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While it has been observed that Aȕ accumulation precedes and ultimately initiates the 
aggregation of wild-type tau protein in AD, the reverse sequence of pathogenesis has 
not been documented (Selkoe, 2002b). 
 
A third invariant feature observed in AD patients, which has lately gained more 
attention in the research community, is the loss of multiple neuronal populations and 
synapses in selected brain regions (Lopez and DeKosky, 2003;Sisodia and St George-
Hyslop, 2002;Terry et al., 1991).  
 
In addition to neuritic dystrophies and eventual neuron loss, a progressive deprivation 
in dendritic spine numbers occurs on hippocampal pyramidal neurons (El Hachimi and 
Foncin, 1990;Ferrer and Gullotta, 1990;Scheibel, 1979), on dentate granule cells  
(Einstein et al., 1994;De Ruiter and Uylings, 1987;Gertz et al., 1987), and on 
neocortical pyramidal neurons   (Baloyannis et al., 1992;Catala et al., 1988;Scheibel, 
1983). Dendritic spines protrude from the dendrites of most principal neurons in the 
mammalian brain and represent the postsynaptic compartment for the majority of 
excitatory glutamatergic synapses (Carlisle and Kennedy, 2005;Sorra and Harris, 
2000). Besides spine loss also morphological changes in dendritic spines were 
observed in the acoustic cortex of patients (Baloyannis et al., 2007).  
 
A variety of other histological changes is observed in some AD patients. Among these 
changes are mild brain atrophy, ‘diffuse’ plaques with non-fibrillar accumulations of Aȕ 
peptides and accumulation of Aȕ in small blood vessels of the meninges and the 
cerebral cortex (Selkoe and Schenk, 2003). 
1.1.6 Post-mortem diagnostic 
Whether a dementia was of the Alzheimer type is usually assessed histologically in 
post-mortem tissue considering the presence of neuritic plaques and neurofibrillary 
tangles in neocortex and the limbic system (Ball and Murdoch, 1997). The severity of 
the disease is then expressed in scores determined in accordance with the ‘Consortium 
to Establish a Registry for Alzheimer's Disease’ (CERAD) (Mirra et al., 1993;Mirra et 
al., 1991), and Braak criteria (Braak and Braak, 1991). The revised CERAD protocol 
diagnoses the probability for AD in a specific brain sample by semi-quantitative and 
age-related estimation of the frequency and relative proportions of both neuritic and 
diffuse plaques, which contain non-fibrilar Aȕ, and on the basis of a clinical history in 
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dementia. The Braak staging makes use of differentiation between early, intermediate 
and late disease stages by semi-quantitative examination of neurofibrillary tangles.  
1.1.7 Etiology of Alzheimer’s disease 
A great number of structural and biochemical changes in the brain during late-stage AD 
have been documented. However, only minor mechanistic insight into the initial 
development of the disease could be gained to date. The research has focussed to a 
great extend on the mechanisms underlying “familial” AD, also referred to as 
‘autosomal-dominant early-onset AD’ (EOAD), presuming that they resemble those 
underlying the development of sporadic forms of AD. About 5 % of AD cases are 
“familial”, in that they are associated with mutations in APP or presenilin genes.  
 
Presenilins 1 and 2 are members of the catalytic core of the Ȗ-secretase complex which 
is involved in APP cleavage (Selkoe and Wolfe, 2007;De Strooper, 2003). The normal 
physiological function of APP is unknown (Hardy, 2009). Most EOAD mutations alter 
APP processing, often resulting in increased levels of Aȕ1-42, a 42 amino acid peptide, 
which is more prone to aggregation and formation of plaques than other Aȕ fragments 
(Scheuner et al., 1996).  Aȕ1-42 is proteolytically released from APP through cleavage 
by ȕ-secretases (BACE) and subsequently by Ȗ-secretases (Selkoe, 2001), whereas 
cleavage by Į- and Ȗ-secretases releases APPsĮ (Sisodia et al., 1990;Esch et al., 
1990).  
 
The amyloid hypothesis 
Based on data derived from EOAD causing mutations and mouse models, which carry 
these mutations, the “amyloid hypothesis” was established (Tanzi and Bertram, 
2005;Hardy and Selkoe, 2002). It suggests that elevation of Aȕ peptide levels, by 
increased production or decreased clearance, causes a series of events and triggers 
other deleterious changes including hyperphosphorylation of tau protein, which 
culminate in neuronal death and thus cause AD (Pimplikar, 2009;Hardy and Higgins, 
1992;Selkoe, 1991).  
 
However memory deficits and cognitive decline in AD patients do not correlate well with 
the Aȕ plaque burden and learning and synaptic dysfunction appear even before the 
formation of plaques (Selkoe, 2002a;Terry et al., 1991). Although two previous studies 
on AD animal models found correlations between amyloid plaque burden and cognitive 
decline  (Gordon et al., 2001;Chen et al., 2000), most studies have failed to detect such 
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a correlation (Braak and Braak, 1998;Arriagada et al., 1992;Terry et al., 1991). 
Moreover, some mouse models show memory deficits even before plaques can be 
seen in the brain. This is frequently interpreted as evidence that amyloid plaques 
represent end-stage remains or byproducts of the pathological processes in AD.  
 
The original amyloid hypothesis was adapted: Instead of amyloid plaques, soluble 
aggregates of toxic Aȕ oligomers are thought to be the disease causing pathogenic 
agent (Walsh and Selkoe, 2007;Glabe, 2005;Walsh and Selkoe, 2004;Klein et al., 
2001). This is supported by the fact that elevated levels of soluble Aȕ peptides 
(McLean et al., 1999;Lue et al., 1999) correlate with cognitive decline. A growing 
amount of evidence suggests that soluble amyloid beta 1-42 (Aȕ1-42) peptides are toxic 
and might induce synaptic dysfunction and neuronal death during the course of AD 
(Selkoe, 2002b).  
 
As described above, dendritic spine loss and alterations, and the resulting loss of 
synapses, appear to be early events during the development of AD: Patients with mild 
AD already were described to have 55% less synapses in the stratum radiatum of the 
CA1 hippocampal area (Scheff et al., 2007). Additionally, the most prevalent early 
features found in cortical biopsies and animal models are synaptic loss and dysfunction 
(Coleman and Yao, 2003;Selkoe, 2002a). 
 
The reduction in synapses during AD progression in humans also correlates well with 
tests for cognitive impairment, therefore dendritic spine and synapse alterations might 
be the structural correlates for cognitive decline (Scheff et al., 2007;Lopez and 
DeKosky, 2003;Sisodia and St George-Hyslop, 2002;Terry et al., 1991). Still other 
studies have shown correlations between abnormal dendritic spine morphology and 
brain dysfunction (Irwin et al., 2000;Wisniewski et al., 1991;Purpura et al., 1982). 
  
It has been suggested that Aȕ causes degeneration in presynaptic terminals and the 
loss of synapses and spines (Adalbert et al., 2007). Defects in axonal delivery of APP 
and in axosynaptic processing of APP have been proposed to be one cause for this 
process. Aȕ-induced neuronal changes might also occur through direct binding of 
soluble Aȕ peptides to excitatory synapses.   
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1.2 Neuronal and dendritic spine morphology  
Changes in neuronal and dendritic spine morphology and numbers can be found in AD 
and many other cognitive disorders. Therefore neuronal morphology with a special 
focus on spine dynamics and morphogenesis is described in the following paragraph. 
1.2.1 Neurons in the hippocampus 
Neurons are highly specialized cells and can be distinguished into the signal receiving 
somatodendritic and the signal-transducing axonal compartment (reviewed in 
(Yoshihara et al., 2009;Sekino et al., 2007;Ethell and Pasquale, 2005;Yuste and 
Bonhoeffer, 2004)). Complex cell-cell interactions of single neurons and groups of 
synchronized neurons which create neuronal circuits are responsible for neurological 
processes.  Neurons can be categorized according to their shape, size, neurochemical 
characteristics, connectivity and location. 
 
Very well characterized and tightly organized neuronal circuits are found in the 
hippocampus, a structure of the mammalian limbic system in the medial temporal brain 
lobe, which is important for the formation of long-term memory (Figure 1.1). The 
hippocampus is one of the most plastic regions in the brain, and - together with the 
ventricular zone - the hippocampal dendate gyrus (DG) is one of only two structures in 
the brain known to retain the capability of de novo formation of neurons in the adult 
brain (Drew and Hen, 2007;Christie and Cameron, 2006;Goldman and Sim, 2005). The 
hippocampus is also one of the first affected brain regions during the development of 
AD, which is one of the reasons for the usage of primary dissociated hippocampal 
neurons as a model system for neurodegeneration in this study4.  Densely packed 
pyramidal neurons and dendate granule cells of the DG constitute the majority of 
neurons in the hippocampus, however few inhibitory interneurons can also be found. 
 
The neuronal circuits and populations in the hippocampus are well characterized 
(Morris and Johnston, 1995): The hippocampal DG receives the major afferent input 
from the entorhinal cortex (EC) via the perforant path (Figure 1.1 B). The axons of the 
granule cells of the dentate gyrus, the mossy fibers, in turn innervate the CA3 region. 
The pyramidal neurons of the CA3 region project via the Schaffer collaterals to the CA1 
pyramidal neurons. The principal output of the hippocampus finally forms the 
connection of the CA1 to the subiculum (Sb) and on to the entorhinal cortex. 
                                               
4 see also 1.5.1 Animal and cellular models for Alzheimer’s disease, page 46 
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Figure 1.1: The hippocampus: (A) Saggital total mouse brain slice and (B) rat 
hippocampus slice. Neurons labeled by NeuN stain. (A) CC: Corpus callosum. LV: 
lateral ventricle. HC: hippocampus. (B) DG: dendate gyrus. Sb: subiculum. EC: 
entorhinal cortex. Arrows indicate the direction of neuronal circuits (compare text). 
Circuits adapted from (Morris and Johnston, 1995). Scale bars: (A) 1 mm, (B) 200 µm. 
(A, B) anti-NeuN labeled brain slices from this study. 
1.2.2 Dendritic spine morphology  
Dendritic spines are highly specialized actin-rich protrusions from the surface of 
dendrites (Figure 1.2 A, B). They were discovered by Santiago Ramon y Cajal in 1888, 
after visualization with a silver impregnation method developed by Golgi in 1873. 
Spines have characteristic bulbous enlargements of their tips, the spine heads (Figure 
1.2 B), and volumes between less than 0.01 up to 0.8 µm3 (Harris and Kater, 1994). 
Spines receive about 90% of all glutamatergic excitatory presynaptic boutons in the 
mature central nervous system, and some inhibitory input (Harris and Kater, 1994). 
Mature neuronal dendrites can have up to 10 spines per µm.  
 
Figure 1.2: Different types of dendritic spines on an EGFP expressing neuron in 
dissociated hippocampal culture on day-in-vitro (DIV) 21 (A, B). (C) Schematic view of 
different spine types and a filopodium, adapted from Ethell and Pasquale (2005). (A, 
B) DIV 21, medium dense, dissociated primary hippocampal culture, transfected with 
pAAV/EGFP on DIV 7. Scale bars (A) 10 µm and (B) 1.5 µm. 
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Dendritic spines have been classified into thin, stubby and mushroom shaped spines 
based on their head-to-neck ratio (Peters and Kaiserman-Abramof, 1970). Thin spines 
have a small head and narrow neck with a head diameter of less than 0.6 µm (Figure 
1.2 C). Their head is not bulbous. Stubby spines have no constriction between their 
head and their attachment to the dendritic shaft. Mushroom spines have a large 
irregular head which can have a diameter of more than 0.6 µm and a constricted 
narrow neck. Some mushroom spines have an irregularly shaped head (Yuste and 
Bonhoeffer, 2004). It has been suggested that mushroom spines represent more stable 
“memory” spines whereas thin spines could be “learning” spines (Tackenberg et al., 
2009). Another type of dendritic protrusion is the dendritic filopodium, which is long, 
thin and headless and especially abundant in developing neurons, but also in adult 
neurons after certain events like induction of plasticity (Jourdain et al., 2003). 
 
Irregularly shaped dendritic spines and abnormal spine densities or lengths have been 
also found in a number of cognitive disorders other than AD, like Fragile X syndrome, 
Down and Rett syndromes (Kaufmann and Moser, 2000).  
1.2.3 Dendritic spine motility 
Time-lapse imaging of spine dynamics shows that spines are not static, but can move 
along the dendrite and alter their morphology continuously even in the adult brain (Zuo 
et al., 2005;Holtmaat et al., 2005;Trachtenberg et al., 2002;Lendvai et al., 2000).  Spine 
formation and remodelling in mature neurons can be induced by certain patterns of 
synaptic activity, learning and memory formation, hormonal fluctuations and changes in 
temperature (Roelandse and Matus, 2004;Yuste and Bonhoeffer, 2001;Engert and 
Bonhoeffer, 1999;Maletic-Savatic et al., 1999;Kirov and Harris, 1999;Hosokawa et al., 
1995;Woolley et al., 1990;Fifkova and Delay, 1982).  The activity of glutamate 
receptors, like Į-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) and NMDA 
receptors, is involved in this morphological change (Matus, 1999).  
 
There is also evidence that the smaller spines preferentially undergo long-term 
potentiation (LTP), an experimentally induced strengthening of a synapse, while larger 
spines are more stable and show less plasticity (Matsuzaki et al., 2004). Classical 
mushroom-shape structures are more stable structures than thin and elongated spines 
(Bourne and Harris, 2008). Evidence suggests that activity and induction of plasticity 
participate in the selection of persistent spines. 
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Spine stability is developmentally regulated and increases during aging: In young mice 
73 % of spines are persistant spines and have a lifetime longer than 8 days, whereas 
96 % were stable in old animals (Holtmaat et al., 2005). This remarkable stability might 
indicate that neuronal circuits maturate and stabilize, which might provide the structural 
basis for long-term memory. 
1.2.4 Synapses on dendritic spines 
Asymmetric chemical synapses are transcellular junctions capable of converting 
presynaptic changes in electrical charge into an extracelluar chemical signal, which is 
received and integrated by the postsynaptic membrane. Presynaptic membrane 
depolarizations in the form of action potentials induce the opening of voltage 
dependent Ca2+ channels which allows Ca2+ influx. Then Ca2+ dependent exocytosis of 
presynaptic vesicles, filled with neurotransmitters, into the synaptic cleft between the 
post- and the presynaptic membrane is induced. The released neurotransmitters bind 
and activate receptors at the postsynaptic membrane which translate the chemical 
signal back to an electrical and to further signaling pathways.  
 
The size of the post-synaptic spine head and the strength of the synapse correlate 
strongly, presumably associated with the higher levels of AMPA-type neurotransmitter-
gated ion channels in larger spines (Kasai et al., 2003;Matsuzaki et al., 2001;Harris 
and Stevens, 1989;Harris and Stevens, 1988).   
1.2.5 Compartimentalization and organelles in spines 
One function of spines is to compartmentalize chemical and electrical changes within 
individual synapses (Nimchinsky et al., 2002;Yuste et al., 2000;Yuste et al., 
1999;Segev and Rall, 1998;Svoboda et al., 1996). A correlation between the spine 
neck and the postsynaptic calcium response has been shown, implying that the spine 
serves as a calcium compartment (Korkotian and Segal, 2000). Ca2+ functions both as 
a charge carrier and as a signaling molecule (Nimchinsky et al., 2002;Yuste et al., 
2000). It enters the spine either through neurotransmitter gated ion channels, like the 
NMDA receptor, AMPA receptor subtypes or voltage gated ion channels or through 
intracellular stores like the endoplasmic reticulum. 
 
Electron microscopic investigation identified a dense structure, the post-synaptic 
density (PSD) below the postsynaptic membrane in the spine head juxtaposed to the 
acitive zone of the presynaptic terminal (Li and Sheng, 2003;Scannevin and Huganir, 
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2000); for review see (Kennedy, 1997).  The PSD can be continuous or perforated 
(Tashiro and Yuste, 2003), and it is assembled from densely packed ion channels, cell 
surface receptors and cytoplasmic scaffolding and signaling proteins. Perforated PSDs 
are associated with more AMPA receptors than the non-perforated PSDs. Mushroom 
spines are more likely to have a perforated PSD whereas thin spines contain macular 
PSD, shaped like a disc (Sala, 2002). Dendritic filopodia do not contain a PSD 
(Jourdain et al., 2003). 
 
Some dendritic spines contain smooth endoplasmic reticulum (SER), which assembles 
in larger spines into a structure named the spine apparatus (SA) consisting of two or 
more SER discs separated by electron-dense material (Nimchinsky et al., 2002), which 
possibly serves as Ca2+ ion, receptor protein and ion channel store (Tarrant and 
Routtenberg, 1979). The majority of mushroom-shaped spines contain SER, in contrast 
to only about 20% of the thin spines (Spacek and Harris, 1997). Since large spines are 
more likely to contain SER, their calcium concentrations can be regulated more tightly.  
 
Polyribosomes and components of the endosomal-lysosomal pathway have also been 
found in spines, indicating that protein synthesis and degradation can occur locally 
(Steward and Schuman, 2001). Mitochondria are rarely found within spines in mature 
neurons but are essential for the formation and maintenance of spines and synapses 
(Li et al., 2004). 
1.2.6 The cytoskeleton 
The cellular morphology is stabilized by a dynamic network of filamentous specialized 
protein structures, which also facilitates the directed transport within the cell. Actin 
filaments, intermediate filaments and microtubuli interact in this meshwork. Actin 
filaments and microtubuli are built from F-actin and Tubulin subunits respectively. Actin 
filaments have especially important stabilizing functions below the plasma membrane 
and in membrane bulges like lamellopodia, microvilli, dendritic spines and during the 
dendritogenesis. Filamentous (F)-actin is enriched in dendritic spines (Kaech et al., 
1997;Wyszynski et al., 1997;Cohen et al., 1985;Matus et al., 1982), while microtubules 
are abundant only in the dendritic shaft and only few microtubule components have 
been detected in larger CA3 spines (Sorra and Harris, 2000;Van Rossum and Hanisch, 
1999;Caceres et al., 1983;Westrum et al., 1980).  
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Neurofilament proteins, which are neuron-specific filaments related to intermediate 
filaments in other tissues, have also been detected in spines, but their function is poorly 
characterized (Walsh and Kuruc, 1992). The dynamic assembly and disassembly of the 
actin cytoskeleton in dendritic spines is highly regulated as described below. 
 
Luo et al. (1996) were the first to suggest the significance of the actin cytoskeleton in 
dendritic spine formation. A disruption of the actin cytoskeleton, with the actin 
depolymerizing agent latrunculin A, during spine morphogenesis results in the global 
disassembly of synaptic structural elements (Zhang and Benson, 2001;Allison et al., 
2000). 
1.2.7   The actin cytoskeleton in dendritic spines and the neuronal nucleus 
The importance of the actin cytoskeleton for spine morphology has been stressed 
above. A stringent regulation of the actin cytoskeleton is required for dendritic spine 
structural plasticity (Honkura et al., 2008;Cingolani and Goda, 2008) and while actin is 
one of the most abundant proteins in neurons as well as in muscle cells, it is very 
differently regulated in both cell types. Actin filaments, also known as microfilaments, 
are assembled from actin and a number of actin binding proteins. The actin protein is 
organized into two-stranded helical polymers with a diameter of 5 to 9 nm which can 
form linear bundles or fine meshworks. Although actin filaments are abundant 
throughout the cell, they are concentrated beneath the plasma membrane and in 
membrane protrusions. Most neuronal microfilaments are less than 1 µm in length. 
 
Actin is present in a pool of soluble globular G-actin and filamentous F-actin polymers 
(Halpain, 2000;Rao and Craig, 2000). G-actin polymerizes fast in vitro, therefore G-
actin binding proteins like thymosin ȕ4  sequester G-actin in vivo (Safer and Nachmias, 
1994;Safer et al., 1990), and suppress its polymerization.  The ȕ- and Ȗ-actin isoforms, 
which are selectively targeted to spines, are ubiquitously expressed and abundant in 
nervous tissue. The functional significance of the different genetic isotypes of actin is 
not clear because the genes are highly conserved in their intron-exon structure and in 
their sequence.  
 
The actin filaments confer the characteristic spine morphology: In the spine neck and 
the core of the spine head F-actin forms longitudinal bundles, while it is arranged into a 
fine meshwork in the spine periphery (Landis and Reese, 1983;Fifkova and Delay, 
1982;Matus et al., 1982). 
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The actin network is constantly rearranged and only 5% of the total actin in spines is 
stable, while most of it turns over within 2 min (Star et al., 2002). This constant turnover 
involves the treadmilling of existing filaments which have structural polarity, with 
polymerization on the fast growing “barbed” ends and depolymerisation at the “pointed” 
ends (Pollard and Borisy, 2003;Pantaloni et al., 2001;Woodrum et al., 1975). The fast 
growing ends are predominantly oriented towards the spine surface. The highest 
degree of actin dynamics is observed at the contact site to the presynaptic bouton, 
indicating a relation between the actin dynamics and synaptic transmission (Roelandse 
et al., 2003). 
1.2.8 Synapse and dendritic spine morphogenesis 
The molecular mechanisms that control the formation and elimination, motility and 
stability, size and shape of dendritic spines are still under investigation (Ethell and 
Pasquale, 2005). However, data from many experiments suggest that new spines can 
form by different mechanisms: de novo from a filopodium newly forming from a dendrite 
which then finds a presynaptic partner and subsequently evolves into a spine (Harris 
and Kater, 1994), or by constant outgrowth of spines directly, of which a few become 
stabilized by a presynaptic partner (Nimchinsky et al., 2002). New spines and 
functional synapses form, and non-activated synapses retract constantly (De Roo et 
al., 2008a;Nägerl et al., 2007). 
 
Due to their high motility and flexibility it has been proposed that dendritic filopodia are 
involved in contacting new appropriate binding partners and then develop into spines. 
Filopodia form transient contacts with excitatory axons, some of which get stabilized 
and persist (Lohmann and Bonhoeffer, 2008). After that, filopodia can be 
morphologically and functionally transformed into spines (De Roo et al., 2008a;Zuo et 
al., 2005;Trachtenberg et al., 2002;Marrs et al., 2001;Maletic-Savatic et al., 1999). 
Meanwhile filopodia can also facilitate the establishment of synapses on the dendritic 
shaft (Fiala et al., 1998).  
 
Finally, new protrusions also can appear directly as spines which typically have a long 
neck and small heads (Trachtenberg et al., 2002;Engert and Bonhoeffer, 1999). They 
are distinguished from filopodia by their head and severly reduced motility, but initially 
do not seem to have a PSD (De Roo et al., 2008b;Nägerl et al., 2007;Knott et al., 
2006).  
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1.2.9 Synapse maturation 
The stabilization of a synapse is likely facilitated and regulated by neural activity 
(Ehrlich et al., 2007). Hippocampal synapses undergo structural changes in size and 
shape after long-term potentiation in vitro and experience in vivo (Harvey and Svoboda, 
2007;Holtmaat et al., 2006;Matsuzaki et al., 2004). This remodelling of spine size and 
morphology and synaptic strengh is rendered possible by reorganization of the actin 
cytoskeleton and differential recruitment of receptors and ion channels to the 
postsynaptic membrane. 
 
An increase in spine volume goes hand in hand with reorganization of the actin 
cytoskeleton from several actin pools in the spine (Honkura et al., 2008). Following 
induction of plasticity several proteins in the PSD are activated, among them the 
Ca2+/calmodulin-dependent kinase (CaMK) II which is activated through 
phosphorylation (Steiner et al., 2008). Rho GTPases such as Rac1 and Cdc42 appear 
to play central roles in spine remodelling and are regulated by several different 
signaling complexes including protein kinases such as CaMKK and CaMKI in a 
complex with GTPase exchange factor ARHGEF7 (ȕPIX) (Saneyoshi et al., 2008). An 
increase in spine volume correlates also with accumulation of additional AMPA 
receptors (Zito et al., 2009). 
1.3 A screen for differentially regulated genes in early stages of Alzheimer’s 
disease 
In an endeavour to identify new drug potential drug targets for Alzheimer’s disease, 
human cortical brain samples of different Braak stages were screened for genes that 
are differentially regulated in early stages of the disease (von der Kammer, 2009). 
Human brain samples from several ‘brain banks’ were analysed for their quality in 
respect to mRNA and protein degradation. Brain samples from the Netherlands Brain 
Bank (NBB) were found to be superior in these respects to samples from other sources 
(von der Kammer, personal communication). Histologically the individuals were 
grouped into different Braak stages and reflected the full range between Braak 0 and 
Braak 65.  These human brain tissue specimen from clinically and neuropathologically 
well characterized and age-matched individuals in frontal and inferior temporal cortex 
were analysed with real-time quantitative PCR (qRT-PCR) using gene-specific 
oligonucleotides.  
 
                                               
5 compare 1.1.6 Post-mortem diagnostic, page 21 
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In total, five different donors with Braak stage 0, seven different donors with Braak 
stage 1, five different donors with Braak stage 2, four different donors with Braak stage 
3, three different donors with Braak stage 4, six different donors with Braak stage 5 and 
four different donors with Braak stage 6 have been analysed. All values were 
normalized to Cyclophilin B values, a highly abundant ’housekeeping’ gene. 
 
 
The levels of PPM1E mRNA stuck out from the mass of analysed genes for their 
quantitative correlation with AD progression as determined by Braak staging (Figure 
1.3 A-a). Between samples of non-demented individuals staged in the lowest Braak 
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Figure 1.3 A: mRNA levels of (a) PPM1E, (b) ARHGEF6 and (c) PPM1F in human 
brain tissue samples from individuals corresponding to different Braak stages. 
mRNA levels of frontal (left) and temporal (right) cortex measured by quantitative RT-
PCR analysis. Normalized to Cylophilin B levels. au: arbitrary units. Horizontal lines 
represent the median. Statistical analysis with Mann-Whitney-U-test, 95 % confidence 
interval.  
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stage 0 and samples representing Braak stage 2 a significant increase in mRNA levels 
of PPM1E in frontal as well as inferior temporal cortex is detected. The PPM1E mRNA 
levels already show a slight increase by trend in Braak 1 compared with Braak 0, 
indicating that the upregulation of PPM1E starts early in the disease. As observed for 
the majority of analysed genes the PPM1E mRNA levels drop in later Braak stages. 
 
The mRNA levels of the guanosine exchange factor ARHGEF6 (ĮPIX) are changing in 
a similar pattern throughout the disease stages (Figure 1.3 A-b). Interestingly, 
ARHGEF6 has been proposed to be a binding partner of PPM1E (Koh et al., 2002). 
ARHGEF6 levels increase in Braak 1 and 2 compared with Braak 0 controls. 
Meanwhile no changes were detected in the mRNA levels between Braak stages of the 
closest PPM1E homolog PPM1F (Figure 1.3 A-c).  
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Figure 1.3 B: mRNA levels of  (a)  PAK1 and (b)  CaMKIIĮ in  human brain tissue 
samples from individuals corresponding to different Braak stages. mRNA levels 
of frontal (left) and temporal (right) cortex measured by quantitative RT-PCR analysis. 
Normalized to Cylophilin B levels. au: arbitrary units. Horizontal lines represent the 
median. Statistical analysis with Mann-Whitney-U-test, 95 % confidence interval. 
 
The strong upregulation of PPM1E mRNA levels indicates that PPM1E might play a 
role during the initial development of the disease (von der Kammer, 2008). However, 
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the screen was not able to reveal whether this effect is supportive for disease 
progression or an adaptive cellular answer to slow cellular and brain damage.  
 
Interestingly, the mRNA levels of the proposed effector kinases of PPM1E, PAK1 and 
CaMKIIĮ, are not strongly regulated in Braak 0 to 3 and slightly reduced in later stages 
(Figure 1.3 B;von der Kammer, 2009). PAK1 mRNA levels are slightly upregulated by 
trend in Braak 2, however this effect is not significant (Figure 1.3 B-a). The expression 
of the third proposed PPM1E target kinase, CaMKIV, was not analysed in this screen 
(von der Kammer, 2009). 
1.4 The protein phosphatase 1E - PPM1E  
The protein phosphatase 1E (PPM1E) was identified in 2001 as ‘Ca2+/calmodulin 
dependent kinase phosphatase with nuclear localization’ (CaMKP-N) as a homolog of 
PPM1F (CaMKP; POPX2) and is now also known as ‘partner of pix’ (POPX) 1. PPM1E 
was shown to be a negative regulator of of Ca2+/calmodulin dependent kinases (CaMK) 
II and IV as well as of p21-activated kinase (PAK) 1 (Kitani et al., 2006;Takeuchi et al., 
2004;Koh et al., 2002;Takeuchi et al., 2001). It  belongs  to  the  PPM  family  of  
phosphatases, which are Mn2+/Mg2+ - dependent and contains a PP2C-like 
phosphatase domain. The closest homolog, PPM1F, shares many structural and 
functional features with PPM1E and both are assumed to dephosphorylate CaMKII/IV 
and PAK1. PPM1E has long carboxy- and amino-terminal-stretches which are not 
present in PPM1F (Figure 1.4; Appendix A 1). More distant homologs for PPM1E are 
PPM1K and PPM1L, which are mitochondrial and endoplasmatic reticular localized 
Mn2+/Mg2+ - dependent phosphatases respectively (Saito et al., 2008;Joshi et al., 
2007). 
 
Comparatively little research regarding PPM1E has been released to the public, 
therefore this section can give a fairly complete overview over the state of the art with 
respect to the phosphatase. In recent years some large-scale expression screens for 
cancer-affected tissue, among others, also came up with data about PPM1E. These 
will be excluded from the following literature review due to minor relevance to the 
project (compare for example Bianchini et al., 2007). 
1.4.1 A general introduction of phosphatases 
Phosphatases are important regulators of protein activity throughout the cellular 
interactome. Around 30 % of all human proteins are divalently linked to phosphate 
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(Cohen, 2000) and in a strictly guarded interplay these phosphorylations are regulated 
by protein kinases and phosphatases. Kinases covalently link a phosphate residue 
cleaved from adenosine triphosphate (ATP) to a specific amino acid residue and 
phosphatases catalyze the reversed reaction. While the human genome encodes 600 
predicted kinases, only 200 phosphatases were predicted (Cohen, 2001). These 
numbers however equal when all possible combinations of holoenzymes are taken into 
account (Bollen and Beullens, 2002). 
 
The amino acids serine, threonine and tyrosine are phosphorylated at their oxygen 
residue in mammalian proteins, and histidine can be phosphorylated at its nitrogen 
residue. The group of O-phosphatases are further subdivided into protein tyrosine 
phosphatases (PTPs), which also include a group of dual specific phosphatases, and 
serine/threonine phosphatases (Klumpp and Krieglstein, 2002). The latter can be 
grouped according to phylogenetic criteria into phosphoprotein phosphatases (PPP) 
and metal-dependent protein phosphatases (PPM). The serine/threonine phosphatases 
are further subdivided according to their biochemical properties: PP1 is inhibited by 
heat-resistant inhibitor proteins and dephosphorylates the ȕ-subunit of the 
phosphorylase-kinase, while PP2 is not inhibited by these inhibitors and prefers the Į-
subunit. PP2A is auto-activated spontaneously, while PP2B is Ca2+- and PP2C is 
Mg2+/Mn2+-dependent (McGowan and Cohen, 1988). The PP2C phosphatases belong 
to the PPM family of phosphatases and are monomeric enzymes without known 
regulatory subunits (Barford et al., 1998;Barford, 1996;McGowan and Cohen, 1988). 
They share six conserved motives and are further distinguished into two groups by the 
amino acid sequence RXXME/QD or KXXXNED, which are designated ‘motif I’  
(Komaki et al., 2003). PPM1E and PPM1F belong with PP2CĮ, PP2Cȕ, FIN13/PP2CȖ, 
PP2Cį, PP2Cİ and Wip1 to the first group of PP2C phosphatases, PP2Cȗ und 
NERPP-2 to the latter. 
 
Although a structural model derived with X-ray crystallographic methods from PP2CĮ 
exists (Das et al., 1996), the catalytic mechanism of PP2C phosphatases is still not 
entirely clear (Jackson et al., 2003). The catalytically active, amino terminal domain of 
PP2CĮ consists of six Į-helices and eleven ȕ-sheets. In the catalytic center two Mn2+ 
ions are coordinated by four conserved aspartates, one glutamate and six water 
molecules (Barford et al., 1998;Das et al., 1996). This catalytic site is conserved in 
PPM1E and the Mn2+ and Mg2+ dependence of its catalytic activity has been 
demonstrated in vitro (Takeuchi et al., 2001). PPM1E activity is stronger correlated with 
the presence of Mn2+  than with that of Mg2+ ions. Additionally PPM1E and PPM1F 
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activity are stimulated by the presence of poly-cations like poly-L-lysine, probably 
depending on the polyglutamate stretch in the amino-terminal part of the two proteins 
(Tada et al., 2006;Takeuchi et al., 2001). 
1.4.2 The structure of the PPM1E gene and the PPM1E protein 
The PPM1E gene is located in chromosomal region 17q23.2 between bp 54188231 
and 54417319 and codes for a ‘protein phosphatase, Mg2+/Mn2+ dependent, 1E’. It is 
also known as CaMKP-N, POPX1, DKFZp781F1422, KIAA1072 and PP2CH. 
 
The full-length PPM1E protein has a length of 755 amino acids and a calculated 
molecular weight of 84 kDa (for schematic view see Figure 1.4). The PPM1E protein is 
characterized by an amino-terminal domain of unknown function which contains 
characteristic repeats of glutamate and proline, a cluster of glutamate residues, and a 
cluster of proline residues (Appendix A 1). This domain is followed by a binding motif 
for the guanine nucleotide exchange factor ARHGEF (PIX) and a characteristic 
catalytic domain which is conserved in PPM1E and PPM1F (PPM1E/1F homology 
domain (E/Fhd)). The E/Fhd section comprises a PP2C-like phosphatase domain (Koh 
et al., 2002).  
 
 
Figure 1.4: Domain structure of human phosphatase PPM1E, its truncated 
version PPM1E(1-557) and PPM1F. Postulated truncation site in PPM1E indicated 
by arrowhead. Region required for ARHGEF binding is indicated (Koh et al., 2002). 
PP2C-like: PP2C-like phosphatase domain. N: nuclear localization signal. 
PPM1E/1F homology domain (E/Fhd) between aa 190 – 490 (PPM1E variants) and 
125 - 415 (PPM1F). Domain structures derived from Koh (2002), Takeuchi (2004) 
and Kitani (2006). 
 
The homology between PPM1E and PPM1F is extended from the shared PP2C-like 
phosphatase domain towards the amino-terminal domain, suggesting that this domain 
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is required for recognition of shared substrates (Figure 1.4; Appendix A 1). The E/Fhd 
section is 59 % identical and 75 % conserved between PPM1E and PPM1F and was 
determined to comprise  amino acid positions 200 to 490 of hPPM1E (Kitani et al., 
2006). The catalytic domain is followed by a carboxy-terminal domain containing two 
nuclear localization signals (NLS) (Takeuchi et al., 2004).  
 
The two carboxy-terminal NLS in PPM1E are located downstream from a cleavage site 
proposed to be at proline 557 in the human PPM1E sequence (Kitani et al., 
2006;Takeuchi et al., 2004). Mass spectrometric analysis of rat PPM1E revealed that 
the protein runs at two apparent masses of 120 and 88 kDa in gelelectrophoresis. 
These correspond to the actual masses of an 83.4 kDa full length and a 61.1 kDa 
truncated form of PPM1E (Kitani et al., 2006). Rat PPM1E(1–554), truncated at the 
carboxyl side of proline 554 in rat PPM1E or in its vicinity, was estimated to be most 
likely the truncated form of PPM1E (Kitani et al., 2006). This corresponds to PPM1E(1-
557) in the human PPM1E sequence which is encoded by NM_0149066.   
1.4.3 Cellular localization and tissue specificity of PPM1E  
Northern blot analysis revealed that PPM1E is enriched in brain tissue and testis, and 
very weakly expressed in heart, kidney and liver, while PPM1F is ubiquitously 
expressed in all examined tissues (Kitani et al., 2003;Takeuchi et al., 2001). 
Immunoblot analysis even detected expression of PPM1E exclusively in brain and 
none in testis or any other tested tissue (Kitani et al., 2006). 
 
Endogenous PPM1E is expressed specifically in neurons and is enriched in the 
nucleus of day-in-vitro (DIV) 6, dissociated primary hippocampal neurons (Kitani et al., 
2006), while it is mainly located in the cytoplasm in most neurons of the central nervous 
system, except for few large neurons of the facial and the mesencephalic trigeminal 
nuclei (Kitani et al., 2006). 
 
PPM1E(1–554) contains - due to its C-terminal truncation - no NLS and is localized 
exclusively in the cytoplasm of COS-7 cells which encode ectopically for PPM1E(1-
554) (Kitani et al., 2006). However it was shown by western blot analysis of cellular 
fractionates of rat brain, that truncated PPM1E is endogenously also present in the 
nucleus of cells, indicating that truncation of PPM1E can also occur in the nucleus 
(Kitani et al., 2006). The full length form of PPM1E was found in the nucleus as well as 
                                               
6 NCBI (National Center for Biotechnology Information) GenBank accession number 
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in the cytoplasm.  Of all analysed cellular fractions only the microsomal fraction did not 
contain PPM1E and PPM1E(1-554). Whether the proteolytic cleavage of PPM1E is 
mediated by a protease or in an autoproteolytic manner is currently unclear.  
 
Moreover, the interrelation between protein truncation, localization and functional 
regulation of the phosphatase is largely unknown (Kitani et al., 2006;Takeuchi et al., 
2004). It was hypothesized that PPM1E is the nuclear equivalent for cytosolic PPM1F 
in CaMK regulation, and nuclear CaMKIV and CaMKKĮ while PPM1F regulates 
CaMKI, CaMKII and CaMKKȕ (Kitani et al., 2003). CaMKI is localized in the cytosol but 
CaMKIV in the nucleus (Nakamura et al., 1995;Jensen et al., 1991)  in rat CNS. This 
hypothesis would however not explain the cytosolic localization of PPM1E in neurons in 
most rat brain neuronal populations. Strong immunostaining of PPM1E was also 
observed at the synapse (Kitani et al., 2006).  
1.4.4 Upstream effectors and regulators of the PPM1E gene 
While no upstream regulators of the PPM1E protein have been identified so far, it is 
known that the PPM1E gene, which has 7 exons and 1 transcript (Dorkeld et al., 1999), 
is located in and regulated with the 17q23 amplicon (Pärssinen et al., 2007). The 
“tripartite motif-containing protein 37”  (TRIM37) gene resides on the complementary 
strand and the PPM1E 3’UTR sequence overlaps with exon 25 of TRIM37 (Hämäläinen 
et al., 2006). TRIM37 has important functions in developmental patterning and 
oncogenesis. Transcribed from the opposite strands, TRIM37b and PPM1E could act 
as cis-encoded antisense transcripts and downregulate each other's expression 
(Hämäläinen et al., 2006).  
1.4.5 Proposed PPM1E effector kinases and binding partners  
Three target kinases were proposed to be dephosphorylated by PPM1E: PAK1, 
CaMKII and CaMKIV. The CaMKs and PAKs are not homologous in their overall 
primary or domain structures and the phosphorylated threonine residues which are 
dephosphorylated by PPM1E are not in similar contexts with respect to the primary 
sequence of the proteins (sequence alignments not shown). 
 
Human PPM1E (hPPM1E) was described to form a complex with PAK1 and the ‘Rho 
guanine nucleotide exchange factor 6’ (ARHGEF6; ĮPIX), and to antagonize PAK1 
activation by Cdc42 (cell division cycle 42) (Koh et al., 2002). PPM1E thereby inhibits 
actin stress fiber breakdown and morphological changes driven by Cdc42. Additionally 
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co-expression of PPM1E and PAK1 in COS-7 kidney-derived cells decreases PAK1 
phosphorylation, indicating that this effect is mediated directly by PAK1 
dephosphorylation. The binding site for ARHGEFs has been proposed to lie within the 
amino-terminal domain in PPM1E (Figure 1; Appendix A 1) (Koh et al., 2002). 
 
Additionally, the rat and zebrafish homologues of PPM1E (rPPM1E and zPPM1E), 
designated as brain-specifically expressed ‘CaM kinase phosphatase N’ (CaMKP-N) 
and zCaMKP-N, were described to dephosphorylate specifically CaMKII and CaMKIV  
(Nimura et al., 2010;Nimura et al., 2007;Kitani et al., 2006;Takeuchi et al., 
2004;Takeuchi et al., 2001). Recombinantly expressed rPPM1E and zPPM1E 
dephosphorylate full length CaMKIV and a synthetic phosphopeptide mimicking the 
phosphorylation site of CaMKII in vitro (Nimura et al., 2007;Kitani et al., 2003;Takeuchi 
et al., 2001). No mode of interaction between PPM1E and the CaMKs has been 
proposed so far. However, the homologous phosphatase PPM1F and a recombinant 
fusion protein, containing the amino-terminal part of PPM1F and the catalytic domain of 
PP2CĮ, exhibited comparable substrate activity towards CaM kinases in vitro, while 
PP2CĮ did not (Tada et al., 2006). This indicates that activity on CaMK involves the 
amino-terminal part of the shared E/Fhd domain (Figure 1.4). Additionally the direct 
interation between CaMKII and multiple sites in PPM1F was proposed (Harvey et al., 
2004). 
 
1.4.5.1 Characterization of CaMKs and their effects on the actin cytoskeleton 
The CaMK family kinases, including CaMKI, CaMKII, CaMKIV, and CaMK kinase 
(CaMKK), react to increases in intracellular Ca2+-levels by association with the Ca2+-
binding protein calmodulin (Wayman et al., 2008). The CaMKs are activated by the 
binding of the Ca2+/calmodulin complex as well as by phosphorylation. The activated 
CaM kinases are known to be deactivated through dephosphorylation by ubiquitous 
multifunctional protein phosphatases such as protein phosphatases 1, 2A and 2C. 
 
Structure of Ca2+/calmodulin-dependent kinases II and IV (CaMKII/IV) 
CaMKII is a highly abundant serine/threonine kinase in the postsynaptic density of 
glutamatergic synapses (Colbran and Brown, 2004;Kennedy, 2000). Given its high 
abundance in dendritic spines CaMKII might have additional structural functions 
(Jourdain et al., 2003;Pratt et al., 2003;Shen et al., 1998). CaMKII is required for 
structural changes that are associated with LTP induction and can enhance the efficacy 
of synaptic transmission (reviewed in Lisman et al., 2002).  
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The CaMKII comprises 28 similar isoforms that are derived from Į, ȕ, Ȗ and į genes 
(Lisman et al., 2002). The major isoforms of CaMKII that are expressed in brain are 
CaMKIIĮ and CaMKIIȕ. These assemble in stochastic combinations into dodecameric 
heteromeric holoenzymes (Rosenberg et al., 2005). Each isoform consists of a catalytic 
kinase domain, an autoinhibitory regulatory domain (RD), a variable segment and a 
self-association domain (AD) (Figure 1.5). The catalytic domain contains the ATP-, 
substrate- and anchoring protein-binding sites and catalyses the phosphotransferase 
reaction. The autoinhibitory domain inhibits the catalytic activity by binding to the 
substrate binding site with a pseudosubstrate region. Binding of Ca2+/calmodulin to a 
region that overlaps with the substrate binding region inhibits binding of the inhibitory 
domain and facilitates autophosphorylation at Thr286 (CaMKII Į) / Thr287 (CaMKIIȕ). 
CaMKIV, also referred to as CaMK-GR, is structurally homolog to CaMKII but lacks a 
carboxyterminal association domain (Figure 1.5).  
 
 
Figure 1.5: Domain structure of the PPM1E target kinases CaMKIIĮ, CaMKIV and 
PAK1. RD: regulatory domain with calmodulin binding site. AD: association domain. PBD: 
p21 binding domain. AID: autoinhibitory domain. Small segments in PAK1: PXXP motiv. 
Larger carboxy-terminal segment in PAK1: second part of kinase domain. Domain 
structures derived from: CaMK: (Soderling and Stull, 2001); PAK1: various publications 
(compare text). 
 
Localization and function of Ca2+/calmodulin-dependent kinase II (CaMKII) 
The ȕ isoform of CaMKII binds to F-actin and is thereby responsible for the localization 
of CaMKII heterooligomers into dendritic spines (Jourdain et al., 2003;Pratt et al., 
2003;Shen et al., 1998). Elevation of Ca2+ levels through NMDA receptors induce a 
reversible translocation of CaMKII from F-actin to the postsynaptic density, where 
CaMKII binding to the NR2B subunit of NMDA receptors prolongs the CaMKII kinase 
activity (Bayer et al., 2001;Shen et al., 2000;Shen and Meyer, 1999). Experimental 
enhancement of CaMKII signaling induces spine formation and increases synapse 
number (Jourdain et al., 2003;Bienvenu et al., 2000;Allen et al., 1998).  
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A number of substrates have been identified for CaMKII, including NMDA and AMPA 
receptors, scaffolding proteins like MAP2, tau and the PSD-95 family (Colbran and 
Brown, 2004;Mauceri et al., 2004;Yoshimura et al., 2000;Shen et al., 1998). CaMKII 
phosphorylates also the RacGEF kalirin-7 at threonine 95 and they form a signaling 
complex with PSD95 and AMPA-type glutamate receptors (Xie et al., 2007) (Figure 
1.6). In primary hippocampal culture it has been shown that kalirin-7 recruitment to the 
synapse induces formation of a multiprotein complex consisting of AF-6/afadin, the 
Rho-family GTPase Rac1 and PAK which regulates spine head size (Xie et al., 2008). 
CaMKII mediated regulation of actin polymerization via this pathway has been 
proposed (Saneyoshi et al., 2010) (Figure 1.6). 
 
 
CaMKII additionally phosphorylates and thereby inhibits SynGAP, which normally 
inactivates the Rho-family GTPase Ras by stimulating Ras-GTP hydrolysis (Carlisle et 
al., 2008;Oh et al., 2002;Chen et al., 1998) (Figure 1.6). Ras acts as a GTPase on Rac 
and its inhibition results in decreased turnover of GTP to GDP bound to Rac1.  
 
Thus the kalirin-7- as well as the SynGAP-mediated effects of CaMKII culminate on 
Rac1: Rac1-GTP binds to and activates PAK1 and PAK3, which subsequently activate 
the serine-threonine kinase LIM kinase 1 (LIMK-1) by phosphorylation at threonine 508 
 
 
Figure 1.6: Nuclear and spine signaling pathways which regulate the actin 
cytosceleton, adapted from Saneyoshi (2010) and Kitani (2003). PPM1E has been 
included based on the results from Kitani et al. (2006) and Koh et al. (2002). Red 
arrows and numbers indicate a differential gene regulation in Braak stages (von der 
Kammer, 2009). Spine and nucleus sizes not to scale. 
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(Figure 1.6). This residue is in the activation loop within the LIM kinase domain (Ohashi 
et al., 2000;Edwards et al., 1999;Maekawa et al., 1999;Yang et al., 1998b). 
Subsequently LIMK-1 phosphorylates and thereby inactivates the actin depolymerising 
proteins ADF and cofilin and thereby reduces filament turnover and cell motility. 
  
Localization and function of Ca2+/calmodulin-dependent kinase IV (CaMKIV) 
The related Ca2+/calmodulin-dependent kinase CaMKIV is predominantly located in 
the nucleus (Nakamura et al., 1995;Jensen et al., 1991), and its nuclear transport is 
facilitated by importin Į (Kotera et al., 2005). CaMKIV is fully activated by CaMKK-
mediated phosphorylation at threonine 196.  CaMKIV directly activates LIMK-1 through 
phosphorylation at threonine 508 and thereby enables the induction of neurite 
outgrowth (Takemura et al., 2009) (Figure 1.6). Previous studies showed that 
knockdown or inhibition but also overexpression of LIMK-1 suppress neurite outgrowth 
and that these effects involve the phosphorylation of cofilin (Endo et al., 2007;Tursun et 
al., 2005;Rosso et al., 2004;Endo et al., 2003). LIMK-1 is also shown to localize to both 
nucleus and cytoplasm: The PDZ domain of LIMK-1 contains two leucine-rich nuclear 
export signals, which support preferentially cytoplasmic localization of LIMK-1 (Yang 
and Mizuno, 1999;Yang et al., 1998a), while the kinase domain contains a nuclear 
localization sequence (Yang and Mizuno, 1999). This way, CaMKIV activation in the 
nucleus can presumably translate to regulation of the cytoplasmic actin cytoskeleton.  
 
A second function of activated CaMKIV is the phosphorylation of transcription factor 
CREB (cAMP response element-binding protein) at serine 133 (Silva et al., 1998a;Silva 
et al., 1998b;Bito et al., 1996a;Bito et al., 1996b;Nakamura et al., 1995;Matthews et al., 
1994;Jensen et al., 1991), which then interacts with the transcription coactivator CBP 
(CREB-binding protein), resulting in the activation of CRE (cAMP response element)-
mediated transcription through the recruitment of CBP to the promoter of CREB target 
genes (Impey et al., 2002;Chawla et al., 1998;Chrivia et al., 1993). CaMKIV mediated 
CREB activation also regulates dendritic growth (Redmond et al., 2002). 
 
1.4.5.2 Characterization of PAK1 and its effects on the actin cytoskeleton 
Six PAK isoforms have been identified, PAK1 to PAK6 (Abo et al., 1998;Sells and 
Chernoff, 1997;Lim et al., 1996;Manser et al., 1994), and are distinguished based on 
their domain architecture and regulatory mechanisms into group I (PAK1-3) and group 
II (PAK4-6) PAKs (Bokoch, 2003;Jaffer and Chernoff, 2002;Dan et al., 2001). In this 
study the group I PAKs are of special interest because they are structurally highly 
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conserved and PAK1 is an effector of PPM1E (Koh et al., 2002) and CaMKII as 
described above.  
 
Structure of PAK1 
PAK1 is maintained in an inactive, dimeric complex which is autoinhibited in trans 
(Parrini et al., 2002). It contains an amino-terminal regulatory domain and a highly 
conserved C-terminal catalytic kinase domain (Figure 1.5). The regulatory domain 
consists of a ‘Cdc42 and Rac interactive binding’ (CRIB) domain - also referred to as 
PBD (p21 binding domain), the ARHGEF binding motif and an autoinhibitory switch 
domain (AID) (Eswaran et al., 2008;Lei et al., 2000). In the homodimer of PAK1 one 
kinase domain binds to the AID domain in the second PAK1 (Parrini et al., 2002). The 
binding between AID and the kinase domain can be reversed by Cdc42 or Rac binding 
(Lei et al., 2000;Morreale et al., 2000;Zhao et al., 1998). Upon termination of 
autoinhibition PAK1 is autophosphorylated at several positions, among them threonine 
423, and thereby fully activated (Gatti et al., 1999;Zenke et al., 1999;Yu et al., 1998). 
After activation through Cdc42, substrate binding and structural rearrangement PAK1 is 
active as a monomer. 
 
PAK1 additionally contains five proline-rich motives (PXXP) which are distributed over 
the length of the regulatory domain and bind to SH3 (src homology 3) domains in Nck, 
Grb2 and ARHGEF. Four of these motives bind to Nck (Bokoch et al., 1996) and Grb2 
(Puto et al., 2003), and one binds with high specificity to ARHGEF (also referred to as 
PIX). Nck and Grb2 are adaptor proteins which recruit PAK1 to the membrane after 
induction by growth receptors. ARHGEF is an exchange factor for the Rho family 
GTPases (Zhang et al., 2003), and a proposed cofactor for PPM1E action on PAK1 
(Koh et al., 2002).  
 
Function of PAK1 
PAKs have various functions in regulation of the actin cytoscleton at different celluar 
sites, but also in hormone signaling, apoptosis, gene transcription and cell cycle 
progression (Eswaran et al., 2008). Relevant to the pathway which is analysed in this 
study is mainly the PAK1-mediated phosphorylation of LIMK-1 (Ahmed et al., 
2008;Edwards et al., 1999). As described above, the activation of LIMK-1 stabilizes F-
actin through the subsequent inactivation of the F-actin-severing protein Cofilin (Figure 
1.6).  
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1.4.5.3 The PPM1E binding protein ARHGEF  
The PAK1 and PPM1E binding protein ARHGEF is a guanine nucleotide exchange 
factor (GEF) and was identified in 1997 as SH3 domain-containing protein and has two 
isoforms: ARHGEF6, also known as ĮPIX and p90-Cool-2, and ARHGEF7, also known 
as ȕPIX and p50/p85-Cool-1. Several splice variants exist for ARHGEF7, but so far 
only one has been identified for ARHGEF6 (Rhee et al., 2004;Kim et al., 2001;Kim et 
al., 2000). ARHGEF7 is a well established PAK1-interacting partner and it was shown 
that ARHGEF6 functions cooperatively with PAK3 in spine morphogenesis (Zhang et 
al., 2005;Zegers et al., 2003).  
  
Structure of ARHGEFs 
ARHGEF6 and 7 have similar domain structures except for an N-terminal ‘calponin 
homology’ (CH) domain which is only present in ARHGEF6 and is required for ȕ-parvin 
binding and membrane localization (Rosenberger et al., 2003). C-terminally from that a 
SH3 domain, required for PAK and Cbl-b binding, is followed by ‘Dbl homology’ (DH) 
and ‘pleckstrin homology’ (PH) domains, which are required in interplay with the SH3 
domain for calpain 4 binding (Figure 1.7).  The amino-terminal SH3 domain in 
ARHGEF binds a conserved proline-rich 22 residue motif in PAK1/2/3 (Manser et al., 
1998). At the C-terminal end a ‘GIT1 binding domain’ (GBD) and a ‘coiled-coil’ (CC) 
follow.  
 
 
 
Figure 1.7: Domain structure of ARHGEF6. CH: calponin homology (not present 
in ARHGEF7). SH3: src homology 3.  DH: dbl homology. PH: pleckstrin homology. 
GBD: Git-1 binding domain. CC: coiled coil. PPM1E binding region indicated (Koh et 
al., 2002). Domain structures derived from: Rosenberger et al., 2003;Koh et al., 
2001;Kim et al., 2001. 
 
ARHGEF7 is recruited to synaptic regions in hippocampal neurons by binding to the 
adaptor GIT1 (G-protein-coupled receptor kinase interacting target 1) (Zhang et al., 
2003;Manser et al., 1998).  GIT1 can activate PAK in a RhoGTPase independent 
manner by indirect binding to PAK together with ARHGEF (Loo et al., 2004). The CC 
domain at the very C-terminal end of ARHGEF is required for homo- and 
heterodimerisation of ARHGEFs (Koh et al., 2001;Kim et al., 2001). The presence of 
monomeric forms seems to be crucial for the GEF activity of ARHGEF6 towards Cdc42 
and Rac1 (Feng et al., 2004). While monomers exhibit activity towards both Rho 
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GTPases, for the dimers only an activity towards Cdc42 could be demonstrated. 
PPM1E binding sites have been identified in the carboxy-terminal domain of ARHGEF 
and are conserved in ARHGEF6 and 7 (Figure 1.7; Appendix A 5) (Koh et al., 2002). 
 
Function of ARHGEFs 
ARHGEF recruits PAK to the cell membrane and is involved in PAK activation. 
ARHGEF6 is a strong activator of PAK, wheras ARHGEF7 splice variants have 
contradictory effects on PAK: The p50-Cool-1 splice variant inhibits Rac/Cdc42 
stimulated PAK activity while p85-Cool-1 has a permisse effect on Rac/Cdc42 
stimulated PAK activity (Feng et al., 2002). ARHGEFs also act as adaptor proteins or 
GEFs for GIT and Paxillin in the translocation of focal complexes and in cell adhesion 
processes (Rosenberger et al., 2005). Hence ARHGEFs are in more ways than one 
important regulators of the actin cytoscleton. 
1.4.6 Phenotypes induced by PPM1E 
Although PPM1E targets on the molecular and cellular levels have been proposed, only 
very little insight into PPM1E-mediated phenotypes on the whole-organism level or in 
relevant cellular models has been gained to date. Additionally, no genetic disorders 
have been associated with PPM1E yet.  
 
The only example of a phenotype associated with PPM1E is provided by the knock-
down of the phosphatase during zebrafish embryogenesis (Nimura et al., 2007).  Here 
the number of embryos with morphological and cellular abnormalities and apoptosis 
was significantly increased. The authors discuss that this could be attributed to 
impaired CaMKIV signaling, because the kinase is known to be important also for the 
regulation of apoptotic events (Walters et al., 2002;Sée et al., 2001;Wayman et al., 
2000;McGinnis et al., 1998). However the results relating CaMKIV to apoptosis are 
contradictory, assigning CaMKIV pro- as well as anti-apoptotic properties (Nimura et 
al., 2007). 
1.5 Model systems and intentions of this study  
A transcriptional profiling of human temporal and frontal cortex in different Braak stages 
has revealed that the protein phosphatase 1E (PPM1E) is significantly up-regulated on 
the mRNA level with an early-onset already at Braak stage one. This and the affiliation 
of PPM1E with a major pathway regulating the actin cytoskeleton in neurons suggested 
a potential causative role in the early development of Alzheimer’s disease.   
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1.5.1 Animal and cellular models for Alzheimer’s disease 
One major difficulty in AD research is the identification of the correct animal or cellular 
model for each question. Current mouse models for AD are based on early-onset AD 
(EOAD) mutations and ApoE4, which is a risk factor for sporadic AD. They replicate 
aspects of human AD, but none individually displays all AD hallmarks. Strains have 
been crossed to combine pathologies but whether and how these pathways interact on 
the molecular and cellular level to cause AD remains uncertain (Adalbert et al., 2007). 
Although other primates develop similar disease pathology with amyloid plaques, their 
plaques have different molecular compositions and the full Alzheimer’s disease 
phenotype with cognitive defects is exclusively found in humans (Rosen et al., 2009).  
 
Dissociated primary neuronal cultures 
Due to the association of PPM1E with the above described CaMK/PAK pathway and 
actin cytoskeleton regulation, a model was sought after which would provide a straight-
forward analysis of effects on the cytoskeleton and would at the same time be close to 
the circumstances in the brain. One culture model for analysis of neuronal and spine 
morphology ex vivo are differentiated, dissociated cortical or hippocampal primary 
neurons. These permit visualization of dendritic spines by standard light or confocal 
microscopic techniques.  
 
A relative comparability of the PPM1E effects in Homo sapiens and Rattus norvegicus 
is likely, because the inter-species homologies are considerable for PPM1E and its 
binding partner ARHGEF6: Rat and human PPM1E protein sequences are 88.6% 
identical (Appendix A 3). Within the PPM1E/1F homology domain (E/Fhd) the rat and 
human PPM1E proteins are 99% identical. As described above, it has been proposed 
that effects on CaMKs are mediated by this domain. The variability between human 
and rat PPM1E is greatest in the C-terminally truncated part of the PPM1E protein 
which contains 62% of all non-identical aa. However, the two nuclear localization 
signal-containing stretches in the C-terminal part of PPM1E are 77 and 74% identical 
between human and rat PPM1E.The ARHGEF binding site is conserved in human and 
rat PPM1E (Koh et al., 2002). 
 
Rat and human ARHGEF6 are 98 % conserved with 82 % absolute sequence identity 
(Appendix A 4). The CH, DH, PH, GBD and DD domains as well as the SH3 domain, 
required for PAK binding, and amino acids 578 to 719 (human ARHGEF6), required for 
PPM1E binding, are conserved in the rat and human sequence and all ARHGEF7 
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splice variants (Appendix A 5). Moreover, also the putative target kinases CaMKII, 
CaMKIV and PAK1 do have rat homologues and the pathways are conserved in Homo 
sapiens and Rattus norvegicus. 
1.5.2 Intentions of this study 
The first objective of this study was to clarify whether the increase in PPM1E mRNA 
levels is an adaptive, protective answer of the brain, or whether the increased levels of 
PPM1E might support disease progression. For this purpose, effects of PPM1E on 
dendritic arborisation and dendritic spine morphogenesis were investigated to reveal 
whether PPM1E influences the neuronal actin cytoskeleton. Through PPM1E 
overexpression in dissociated primary neuronal culture this study shows that the 
phosphatase has a neurodegenerative effect: Dendritic mushroom spine density and 
dendritic arborization were significantly reduced. Knock-down of endogenous PPM1E 
meanwhile rather has a positive influence on dendritic spine morphogenesis or 
homeostasis, whereas it negatively influenced the complexity of the neuritic arbor. 
 
A second objective was to clarify whether the PPM1E effects in the employed model 
system are attributable to a direct interaction with CaMKII, CaMKIV or PAK1. This 
study shows that increased PPM1E levels had an influence rather on the expression 
levels than on the phosphorylation state of the kinases. 
 
Since PPM1E is relatively poorly characterized, further emphasis was placed on the 
elucidation of PPM1E localization. Amendatory to previously published results, which 
showed a nuclear localization of PPM1E in primary culture (Kitani et al., 2006), this 
study demonstrates that PPM1E changes localization depending on the developmental 
stage of the culture and that it is associated with sites of high metabolic activity in 
dendrites. 
 
An early-onset dysregulation of PPM1E in Alzheimer’s disease could negatively affect 
the dendrite and dendritic spine morphogenesis. Inhibiting PPM1E in an early stage of 
disease may delay or at best even prevent the progression of cognitive decline. 
PPM1E might therefore provide a promising new drug target for neurodegenerative 
diseases and especially for AD. 
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2 MATERIAL AND METHODS 
2.1 Material 
2.1.1 Chemicals and consumables 
Unless otherwise mentioned, all chemicals were either purchased from Sigma-Aldrich 
(Steinheim, Germany), Merck (Darmstadt, Germany) or Invitrogen (Karlsruhe, 
Germany). Unless otherwise mentioned all consumables for cell culture were obtained 
from VWR (Darmstadt, Germany). Polyacrylamid electrophoresis gels and equipment 
were obtained from Invitrogen. Phosphate buffer (PB) was obtained from AppliChem 
(10x PBS buffer powder, #A0965,9010) for biochemical and from PAA (Dulbecco’s 
PBS (1x), Pasching Austria, #H15-002) for cell culture applications. 
2.1.2 Biological material  
For description of primary rat neuronal cell culture and eukaryotic cell lines and their 
cultivation see 2.2.5 Influence of PPM1E in cell lines and primary neuronal culture 
(page 68). For E.coli competent bacterial strains see 2.2.1 General genetic, molecular 
biological and biochemical methods (page 58) and 2.2.2 His-hPPM1E protein 
expression, purification and in vitro activity determination (page 62). For Sf9 cell strains 
see 2.2.2 His-hPPM1E protein expression, purification and in vitro activity 
determination (page 62). 
2.1.3 Animals 
Timed-pregnant Wistar rats were purchased from University Medical Center Hamburg-
Eppendorf (Hamburg, Germany) directly before preparation.  
 
Wild type fruit flies were obtained from the Bloomington Stock Center (Drosophila 
melanogaster, w1118) and maintained at 25°C and 65% relative humidity on a 12h/12h 
day/night cycle. The animals were reared in 175 ml breeding vials (Greiner Bio-One, 
Solingen, Germany) on an approximately 2 cm thick layer of commercial Nekton-
Drosophila-food concentrate (Günter Enderle Nekton-Produkte, Pforzheim, Germany) 
with tap water and vinegar added. 
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2.1.4 Oligonucleotides 
All synthetic oligonucleotides were synthesized externally (Metabion, Martinsried, 
Germany). 
 
2.1.4.1 Oligonucleotides for polymerase chain reaction (PCR)  
Primer 
ID oligonucleotide primary sequence 
included 
restric-
tion site 
hPPM1E   
#10 5’-GCG GCC GCT TAT TCT ATT TTA TAG CTC CAA GG-3’ NotI 
#22 
5’-CTC GAG GGA TCC TTA TTC TAT TTT ATA GCT CCA 
AGG-3’ 
XhoI / 
BamHI 
#23 
5’-CCA GAA TTC ATG CAT CAT CAT CAT CAT CAC AGC-
3’ 
EcoRI 
#21 
5’-CAT ATG ATG CAC CAC CAC CAC CAC CAC GCC GGC 
TGC ATC CCT GAG-3’ 
NdeI 
#9 
5’-GAA TTC ATG GAA CAA AAA CTT ATT TCT GAA GAA 
GAT CTG GCC GGC TGC ATC CCT GAG-3’ 
EcoRI 
#01  5’-GGA TCC ATG GCC GGC TGC ATC CCT GAG G-3’ BamHI 
#02  
5’-GAA TTC TTA TTC TAT TTT ATA GCT CCA AGG AAG 
ATC TGG-3’ 
EcoRI 
hARHGEF6 
#30 
5’-AAG CTT TTA CTT GTC ATC GTC GTC CTT GTA GTC 
TGG AAG AAT TGA GGT CTT GC-3’ 
HindIII 
#03 5’-GAA TTC ATG AAT CCA GAA GAA CAA ATC G-3’ EcoRI 
#04  5’-CTC GAG TTA TGG AAG AAT TGA GGT CTT GC-3’ XhoI 
#28 
5’-CTC GAG TTA CAG ATC TTC TTC AGA AAT AAG TTT 
TTG TTC TGG AAG AAT TGA GGT CTT GC 
XhoI 
rat PPM1E 
#05  
5’-GAA TTC ATG GAA CAA AAA CTT ATT TCT GAA GAA 
GAT CTG GCG GGC TGC ATC CCT GAG G-3’ 
EcoRI 
#06  
 
5’- AAG CTT TTA AAT TTT ATA GTC CCA GGG AAG GTC 
TGG GC-3’ 
HindIII 
Table 2.1 – part 1: Oligonucleotides used in polymerase chain reaction (PCR) for 
cloning of different constructs used in this study. 
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Primer 
ID oligonucleotide primary sequence 
included 
restric-
tion site 
rat ARHGEF6 
#07  5’-GAA TTC ATG AAT CCA GAA GAA CGC GT-3’ EcoRI 
#08 
5’-GGA TCC TTA CTT GTC ATC GTC GTC CTT GTA GTC 
CTG GAG AAT CGA GGT CTT G-3’ 
BamHI 
hPPM1E(1-557) 
#31 5’-CTC GAG TTA GCT AGT TCT ATC AGT GAA TGA A-3’ XhoI 
 
hPPM1E mutational primers (mismatching nucleotides in bold letters) 
#11  
5’-CCA TGC CAT CAA AAA CAT GGC GAG GAA AAT GGA GGA CAA 
AC-3’ 
#12  
5’-GTT TGT CCT CCA TTT TCC TCG CCA TGT TTT TGA TGG CAT 
GG-3’ 
#19 5’-GTG ATG CTG GGT CAA GTA ATA ACA TCA CGG TTA TTG-3’ 
#20 5’-CAA TAA CCG TGA TGT TAT TAC TTG ACC CAG CAT CAC-3’ 
Table 2.1 – part 2: Oligonucleotides used in polymerase chain reaction (PCR) for 
cloning of different constructs used in this study. 
 
2.1.4.2 Oligonucleotides for real-time PCR 
 
Primers complementary to rat genes 
Cyclophilin B 
5’-TAG ACT GTG GCA AGA TCG AAG TG-3’  
5’-CAG CTG TTT AGA GGG ATG AGG TC-3’ 
PPM1E 
5’-GTT CTG GAT GGG ACT GAA GA-3’ 
5’-CAA GTG GTC AGA CAC AAC CTT-3’ 
PAK1 
5’-GCA CTA TGA TTTG GAG CTG GCA-3’ 
5’-GGA TCG ATA GAA CCG GTC CTT C-3’ 
Table 2.2 – part 1: Oligonucleotides used in quantitative real-time PCR (qRT-PCR) for 
the amplification of different genes.  
MATERIAL AND METHODS - 2.1 Material 
 
51 
 
 
Primers complementary to rat genes 
PAK3 
5’-GAC TGA CGT GGT CAC AGA AAC CT-3’ 
5’-TCC AAA GCT TGG AGG CAC TC-3’ 
LIMK-1 
5’-CAA GGA CAA GCG GCT GAA CTT CA-3’ 
5’-GAC CCT CTG ACT CCA CGG GTA C-3’ 
Drebrin1 
5’-TCC AGA AAT CGA CAT CAC CTG C-3’ 
5’-TAC TAA TCA CCA CCC TCG AA-3’ 
Primers complementary to human genes 
PPM1E 
5’-GTT CTG GAT GGG ACC GAA GA-3’ 
5’-CAG GTG GTC GGA CAC AAC TTT-3’ 
Cyclophilin B 
5’-ACT GAA GCA CTA CGG GCC TG-3’ 
5’-AGC CGT TGG TGT CTT TGC C-3’  
14-3-3 ȕĮ1 
 
5’-ACT CCC AGC AGG CTT ACC AG-3’ 
5’-GGC TAC AGG CCT TTT CAG GA-3’ 
14-3-3 ȗį2 
 
5’-TTG TAG GAG CCC GTA GGT CAT C-3’ 
5’-TCA GCA CCT TCC GTC TTT TGT-3’ 
ARHGEF6  
5’-GGC AAA TCT TCC AGA CTA TGG C-3’ 
5’-CAG CTG GAT CAT TGG GCA G-3’ 
ARHGEF7  
5’-GTT TTC ACT GGC CTC ACT CAG A-3’ 
5’-ATT TGG CCC CTC AAG CAA T-3’ 
CaMKIIĮ   
5’-TGG ACC GCA TGC CTT TTT AT-3’ 
5’-CCA ACC TGA CCC TTC TCA CAA -3’ 
Cofilin 1 
5’-CCC TGG ATT TTC CTT CTC CC-3’ 
5’-TGC TTC AGC CCA AGA GGA AT-3’ 
Cofilin 2b 
5’-TTG CAG TTC TGT GAG GCT TGA-3’ 
5’-ATC CGT GCT GCC ATA TCA CTA A-3’ 
Drebrin  
5’-TCC AGA GAT CGA CAT CAC ATG C-3’ 
5’-CGC TAA TCA CCA CCC TCG AA-3’ 
LIMK-1  
5’-CAA GGA CAA GAG GCT CAA CTT CA-3’ 
5’-CAC TCT CTG GCT CCA TGG GTA C-3’ 
MAP2  
5’-CCT AGA TTC CAT AGC CCT TGG AT-3’ 
5’-GTG GTG GCT GGA AGG TAA TCA-3’ 
Table 2.2 – part 2: Oligonucleotides used in quantitative real-time PCR (qRT-PCR) for 
the amplification of different genes. 1 tyrosine 3- /tryptophan 5-monooxygenase 
activating protein, beta/alpha polypeptide; 2 tyrosine 3-/tryptophan 5 -monooxygenase 
activation protein, zeta/delta polypeptide;  
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Primers complementary to human genes 
MARK2  
5’-GGA TGT GTG GAG CCT AGG AGT TAT-3’ 
5’-GGT TCT GTC CAT CAA AAG GCA-3’ 
PAK2  
5’-GGC CAA ACC GTT ATC TAG CTT GA-3’ 
5’-TAT GAG GCC ACA GCA GTG ATG T-3’ 
PAK4  
5’-CAT GAA TGT CCG AAG AGT GGC-3’ 
5’-GAA AAG AGG AGG CTG TCC AGG-3’ 
PAK6  
5’-CTC CCA AGT CAG GCT GAA TGA-3’ 
5’-TGG ATG ACA CCC TGA GCA TG-3’ 
PAK1  
5’-TTCCATTTGCAGAGAGCTTGG-3’ 
5’-TGATACCCTGCCAGCTGTGAG-3’ 
 
PAK3  
5’-ACT CCA GAG CTC CAG AAT CCT G-3’ 
5’-TCG CCT ATC CAC ATC CAT CTC-3’ 
PAK5  
5’-TTG CAT CGT CCC CCT CAT-3’ 
5’-CTA GCT TTG CCA CCT ACA CGA A-3’ 
PPM1F 
5’-GAA GGG TTT ATC TGC GTT CGT CT-3’ 
5’-TTT CTG GCA TCT TGG GAC TTG T-3’ 
PSD-95 
5’-CTT GGT CTG GAC TGA ATT GCC-3’ 
5’-AAT AAG AAG GGG TGG GAG GGA-3’ 
Rac1  
5’-CAC CAG TGA GTT AGC AGC ACG T-3’ 
5’-TCT CCG CAA AAG CTG GTC A-3’ 
Synaptophysin  
 
5’-GAG CTT CCA GAT GGG TTT TGT T-3’ 
5’-TCT TCT CAG GCC ACT TCC GT-3’ 
Primer complementary to AAV woodchuck postregulatory element 
(WPRE) 
WPRE 3 
5’-CTA TGT TGC TCC TTT TAC GCT ATG-3’ 
5’-TCA TAA AGA GAC AGC AAC CAG GAT -3’ 
Table 2.2 – part 3: Oligonucleotides used in quantitative real-time PCR (qRT-PCR) for 
the amplification of different genes. 3. primer sequence kindly provided by Dr. Rolf 
Sprengel (Max Planck institute for medical research, Heidelberg, Germany). 
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2.1.4.3 Oligonucleotides for construction of shRNA constructs 
shRNA constructs containing sequences complementary to the rat PPM1E gene 
5’-GAT CCC CCA TCA CTG TTATTG TGG TAT TCA AGA GAT ACC 
ACA ATA ACA GTG ATG TTT TTG GAA A-3’ 
rshRNA4 
5’-AGC TTT TCC AAA AAC ATC ACT GTT ATT GTG GTA TCT  CTT 
GAA TAC CAC AAT AAC AGT GAT GGG G-3’ 
5’-GAT CCC CCA TCA CTG TTA TTG TGG TAT TCA AGA GAT ACC 
ACA ATA ACA GTG ATG TTT TTG GAA A-3’ 
rshRNA6 
5’-AGC TTT TCC AAA AAC ATC ACT GTT ATT GTG GTA TCT CTT 
GAA TAC CAC AAT AAC AGT GAT GGG G-3’ 
shRNA constructs containing sequences complementary to the human PPM1E gene 
5’- GAT CCC CCA TCA CGG TTA TTG TGG TAT TCA AGA GAT ACC 
ACA ATA ACC GTG ATG TTT TTG GAA A-3’ 
hshRNA4 
5’-AGC TTT TCC AAA AAC ATC ACG GTT ATT GTG GTA TCT CTT 
GAA TAC CAC AAT AAC CGT GAT GGG G-3’ 
5’-GAT CCC CAT ATA ATT GCC CTT CCT TTT TCA AGA GAA AAG 
GAA GGG CAA TTA TAT TTT TTG GAA A-3’ 
hshRNA7 
5’-AGC TTT TCC AAA AAA TAT AAT TGC CCT TCC TTT TCT CTT 
GAA AAA GGA AGG GCA ATT ATA TGG G-3’ 
scrambled shRNA construct*  
5’- GAT CCC CCC GCG ACT CGC CGT CTG CGT TCA AGA GAC GCA 
GAC GGC GAG TCG CGG TTT TTG GAA A -3’ 
scram 
5’- AGC TTT TCC AAA AA CCG CGA CTC GCC GTC TGC GTC TCT 
TGA ACG CAG ACG GCG AGT CGC GGG GG -3’ 
Table 2.3: Oligonucleotides for construction of shRNA constructs. The 5’ and 3’ single-
stranded overhang of each aligned pair of oligonucleotides are complementary to BglII 
and HindIII restricted sites respectively. Sequences which are complementary to 
PPM1E sequences or scrambled are underlined. *(Vlachos et al., 2009). 
 
2.1.4.4 Oligonucleotides for sequencing  
hPPM1E  
hP_bp600_forward  5’-GGA GAT TGA GAC AGT GAA ATT GGC-3’ 
hP_bp1200_forward  5’-CTG TCG GTT TCC AGA GCT ATT GG-3’ 
hP_bp1800_forward  5’-GGT CCT GGT GCA CCA AAG AAA GC-3’ 
hP_bp200_reverse  5’-CTG GGC GAG TTT CGC GGA C-3’ 
Table 2.4 – part 1: Oligonucleotides for sequencing of PPM1E and ARHGEF6 
constructs. Other constructs were sequenced with standard external T7, SP6 and CMV 
primers provided by the sequencing service (Qiagen, Hilden, Germany). 
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hPPM1E  
hP_bp800_reverse  5’-CTC ATA ATA AAG CTG GGG TC-3’ 
hP_bp1100_forward  5’-GCT TAA GAT GTG GGA CCA CA-3’ 
hP_bp420_forward  5’-CGG TTG AGG GTG AGG AGG-3’ 
hP_bp1350_reverse  5’-AGT GGA GGC AGA ATC TGC-3’ 
hARHGEF6  
hA_bp0_forward 5’-ATG AAT CCA GAA GAA CAA ATC G-3’ 
hA_bp598_forward  5’-GAA CAG GCT GGT TCC CCA G-3’ 
hA_bp1197_forward 5’-CTG AAA GCA ATC GTA GCA TTC-3’ 
hA_bp1801_forward 5’-CTA GGT TAT AAA GAG AGG ATG-3’ 
Table 2.4 – part 2: Oligonucleotides for sequencing of PPM1E and ARHGEF6 
constructs. Other constructs were sequenced with standard external T7, SP6 and CMV 
primers provided by the sequencing service (Qiagen, Hilden, Germany). 
2.1.5 Vectors 
Vectors Origin Expression promoter (host) 
pCR-BluntII-
TOPO Invitrogen, #K2800-20 SP6 (E.coli) 
pET24a  Novagen,  #69749-3 T7 (E.coli) 
pFastBac1 Invitrogen , #10360-014 (Bac-to-Bac® Vector Kit) Polyhedron (Sf9) 
pFB-Neo-CMV Stratagene,  #217561, modified
2 
(Miller, 1997) CMV (mammalian) 
pFB-Neo-CMV-
TO pFB-Neo-CMV, modified
3 CMV under control of Tet repressor (mammalian) 
pUAST  (Brand and Perrimon, 1993) GAL UAS (D.  melanogaster) 
pAAV-6P-SEWB (Kügler et al., 2003)  synapsin (mammalian neurons) 
pcDNA3+ Invitrogen, # V790-20  
pSuper.basic OligoEngine, #VEC-PBS-0001/0002 H1 (mammalian) 
Helper plasmids Origin Viral product 
pDP1rs PlasmidFactory
1, #PF401 
(Grimm et al., 2003) AAV (serotype 1) 
pDP2rs PlasmidFactory
1, #PF402 
(Grimm et al., 2003) AAV (serotype 2) 
pVPack VSV-G 
Stratagene, #217567 (DuBridge 
et al., 1987)  
 
Moloney Mouse Leukemia 
Virus (MMLV) – based 
(vesicular stomatitis virus G 
protein) virus 
Table 2.5: DNA vectors which have been used in this study. 1 produced under licence 
of the German Cancer Research Center, DKFZ; 2 modified by A. Ebneth, Evotec 
Neurosciences GmbH, 2004 (exchange of T7 for CMV promoter); 3 modified by A. 
Ebneth, Evotec Neurosciences GmbH, 2004 (pFB-Neo-CMV with inclusion of tetR 
binding site). 
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2.1.6 Plasmids, as generated in this study 
Construct under 
control of promoter 
Cloned into 
vector 
Host for 
expression  
pFB-Neo-CMV 
pFB-Neo-CMV-
TO 
mammalian cell lines 
pUAST D.melanogaster 
Myc_hPPM1E 
pAAV mammalian neuron 
pET24a E.coli 
His_hPPM1E 
pFastBacTM1 Sf9 
Myc_hPPM1E(1-557) pFB-Neo-CMV mammalian cell lines 
Myc_rPPM1E pFB-Neo-CMV mammalian cell lines 
Myc_hARHGEF6 pUAST D.melanogaster 
Flag_hARHGEF6 pAAV mammalian neuron 
pFB-Neo-CMV CHO-K1 
Myc_hPPM1E (R241A) 
pAAV mammalian neuron 
pFB-Neo-CMV CHO-K1 
Myc_hPPM1E (D273A) 
pAAV mammalian neuron 
pFB-Neo-CMV CHO-K1 
Myc_hPPM1E (H275A)                            
pAAV mammalian neuron 
pFB-Neo-CMV CHO-K1 
Myc_hPPM1E (G276D) 
pAAV mammalian neuron 
pFB-Neo-CMV CHO-K1 
Myc_hPPM1E (D479N) 
pAAV mammalian neuron 
Table 2.6: Plasmids generated for this study. pCR-Blunt-TOPO constructs, which were 
only used as intermediates in the cloning procedure are not listed. 
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2.1.7 Antibodies and markers 
Primary antibodies 
Antigen / clone Manufacturer Orderno. Host 
phospho-c-Jun N-terminal kinase 
(JNK) (Thr183/Thr185) NEB 4668S  rabbit 
CaMKIIĮ (phospho T286) (22B1)  abcam ab2724 mouse 
CaMKIIĮ / ȕ abcam ab19223 rabbit 
CaMKIIĮ (6G9) abcam ab2725 mouse 
CaMKIIȕ  abcam  ab34703 rabbit 
CaMKII (phospo T286(Į)/T287(ȕ)) abcam ab32678 rabbit 
CaMKIV  abcam ab3557 rabbit 
CaMKIV (phospho T196+T200)  abcam ab59424 rabbit 
cyclophilin B abcam ab16045 rabbit 
EAAC1 (EAAT3) Zymed 32-1000 mouse 
Flag-tag (clone M2) Sigma F1804 mouse 
GAD 67 Millipore  MAB5406 mouse 
GAD 67 Chemicon MAB5406 mouse 
GAPDH (14C10) Cell Signalling 2118 rabbit 
GFAP Chemicon MAB360 mouse 
GFP Invitrogen A6455 rabbit 
GM130 (Golgi)  
BD 
Transduct. 
Laboratories 
610822 mouse 
KDEL (10C3)  Stressgen SPA-827 mouse 
MAP2 (clone HM-2) Sigma-Aldrich M9942 mouse 
MAP2  Millipore Ab5622 rabbit 
Myc-tag MBL  562 rabbit 
NeuN (clone A60) Chemicon MAB377 mouse 
PAK1 Chemicon AB3844 rabbit 
PAK1/2/3 [phosphoThr423] Biosource 44-942G rabbit 
PAK1/2/3 [phosphoThr423] Rockland 600-401-413 rabbit 
PAK1/2/3 [phosphoThr423]  Sigma P 7746 rabbit 
Table 2.7 – part 1: Antibodies and markers used in this study. Antibodies were diluted 
for immunoblotting and immunolabeling of formaldehyde fixated specimens as 
recommended by the manufacturer if not otherwise stated. 
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Primary antibodies 
Antigen / clone Manufacturer Orderno. Host 
PSD-95 (6G9-1C9)  abcam ab2723 mouse 
Synaptophysin Santa Cruz Biotechnology sc-17750 mouse 
Į Tubulin  Dianova DLN 15412 rabbit 
Markers 
AlexaFluor488R phalloidin Invitrogen A12379  
4`-6-diamino-2-phenylindole  
(DAPI) (5 mM) Sigma D9564  
DRAQ5 Cell Signaling 4084S  
Secondary anti-isotypic antibodies 
anti-mouse AlexaFluor® 647 Invitrogen A21236 goat 
anti-rabbit AlexaFluor® 488 Invitrogen A11034 goat 
anti-rabbit AlexaFluor® 555 Invitrogen A21429 goat 
anti-mouse IgG-HRP Santa Cruz Biotechnology sc-2031 goat 
anti-rabbit IgG-HRP Santa Cruz Biotechnology sc-2030 goat 
Table 2.7 – part 2: Antibodies and markers used in this study. Antibodies were diluted 
for immunoblotting and immunolabeling of formaldehyde fixated specimens as 
recommended by the manufacturer if not otherwise stated. 
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2.2 Methods 
2.2.1 General genetic, molecular biological and biochemical methods 
2.2.1.1 Tools for in silico genetic comparisons 
Homology searches have been performed with resources of the NCBI (National 
Institute for Biotechnology Information, Rockville Pike, USA) using BLAST-N and 
BLAST-P algorithms (Altschul et al., 1997). Homology searches between human 
PPM1E (NM_014906) and ARHGEF6 (NM_004840) genes and the Drosophila 
genome have been performed with flybase (flybase.bio.indiana.edu) resources using 
BLAST-P algorithms (flybase.org/blast).  
 
Homologies were displayed by alignment with ClustalW2 software (Larkin et al., 
2007;Thompson et al., 1997). In the alignments (compare Appendix), “*” indicates 
residues that are identical in all sequences in the alignment; “:” indicates conserved 
substitutions within the groups of 1. small, hydrophobic and aromatic (without tyrosine) 
amino acids (aa), 2. acidic aa or 3. hydroxyl, amine, amide and basic aa. “." Indicates 
semi-conserved substitutions between amino acids with similar shapes. 
 
Searches for conserved domains have been performed with the Conserved domain 
database (CDD), a NCBI database of protein domains, families and functional sites 
(Marchler-Bauer et al., 2009). 
 
2.2.1.2 Human and rat PPM1E and ARHGEF6 expression plasmid construction 
The cDNA clones for hPPM1E and hARHGEF6 were purchased from Origene 
(Rockville, USA) and the German Resource Center for Genomic Research (rzpd; 
Berlin, Germany). Human PPM1E and ARHGEF6 were amplified by polymerase-chain-
reaction (PCR), as described below, from human cDNA clone TC128041 (Origene, 
GeneID: NM_014906.3) and human UltimateTM full length ORF expression clone 
IOH26187 (RZPD, GeneID: NM_004840) with the primer pairs #01 / #02 and #03 / #04 
respectively.  
 
rPPM1E and rARHGEF6 were amplified from rat primary hippocampal culture cDNA by 
means of PCR with the primer pairs #05 / #06 and #07 / #08 respectively. Neuronal 
mRNA was isolated from primary cell culture with RNeasy Plus Mini and QIAshredder 
kits (Qiagen, 74134 and 79656) as described further in 2.2.5.8 Quantitative real-time 
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PCR from isolated mRNA and transcribed into cDNA with Sensiscript II Reverse 
Transcriptase (205213, Qiagen) as described by the manufacturer.  
All four constructs were ligated blunt into pCR-BluntII-TOPO as described in 2.2.1.3 
General DNA construct amplification and subcloning between vectors. 
 
2.2.1.3 General DNA construct amplification and subcloning between vectors 
All DNA constructs were amplified with 25 units/ml Pfu Ultra DNA polymerase 
(Stratagene, #600670-51) in a thermal cycler (MJ Research) with 1-4 µM forward and 
reverse primer concentration, 200 µM dNTPs (Amersham Pharmacia Biotec, #27-2094) 
and with or without 5 % dimethyl sulfoxide (DMSO). Optimal temperature cycling 
parameters were adapted according to the primer pair and the amplified construct: The 
optimal annealing temperature lay usually 5°C below the predicted melting temperature 
of the primer pair, the length of amplification cycles at 72°C was 1 min per 500 
basepairs of the construct, the denaturing temperature was 95°C. The temperature 
cycle was repeated 18 to 35 times avoiding longer reaction times than 6 hours. In some 
cases the DNA yield was raised through increasing the primer specificity by gradually 
lowering the annealing temperature in steps of 0.5°C in 8-12 cycles before carrying out 
10-23 cycles at the optimal calculated annealing temperature. 
 
Subcloning procedures for specific applications by means of restriction enzymes or of 
PCR into different expression plasmids (compare Tables 2.5 – Vectors, and 2.6 – 
Plasmids as generated in this study) and under addition of different affinity tags are 
described in the respective paragraph.  
 
In all cases plasmid DNA was amplified in XL-1 blue competent E.coli cells 
(Stratagene, #200249) in lysogeny broth medium (5 g/l NaCl, 10 g/l tryptone and 5 g/l 
yeast extract) with 50 µg/ml kanamycine or 100 µg/ml ampicilline depending on the 
resistance gene carried by the vector. After 16 hours vigorously shaking at 37°C, the 
plasmids were purified with the QIAprep® Spin Miniprep or QIAfilter Plasmid Midi Kit 
(Qiagen #27106 and 12245). In cases where a change of buffer was necessary the 
PCR products were purified with the QIAquick PCR Purification Kit (Qiagen, #28106). 
DNA fragments were separated according to their size by agarose gelelectrophoresis 
and subsequent excision from gels. The excised fragments were purified with the 
QIAquick Gel Extraction Kit (Qiagen, #28706). 
 
Constructs which were amplified by PCR were ligated blunt into pCR-BluntII-TOPO 
using the Zero Blunt® TOPO PCR Cloning Kit for sub-cloning according to the 
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manufacturer’s advice (Invitrogen, #K2830-20). The constructs pCR-BluntII-TOPO / 
hPPM1E, / hARHGEF6 and / rPPM1E, among others, were constructed like this for 
further subcloning procedures. All constructs were confirmed by restriction digest with 2 
to 3 appropriate restriction enzymes (Fermentas) and subsequent determination of 
fragment sizes on 1-2% agarose gelelectrophoresis in TAE buffer (AppliChem, TAE 
Puffer 50x, #A1691,5000CT). Suitable restriction sites were identified with NEBcutter 
V2.0 (Vincze et al., 2003). Constructs which were amplified by PCR were sequenced 
externally for verification (Qiagen sequencing service; compare Table 2.4 
Oligonucleotides for sequencing of PPM1E and ARHGEF6 constructs). Constructs 
were subcloned through digest with restriction enzymes as specified in the respective 
paragraph according to manufacturer’s protocol and ligated with T4 DNA Ligase 
(Fermentas, #EL0011) into the respective expression vector as recommended by the 
manufacturer. 
 
2.2.1.4 Site-directed mutagenesis of hPPM1E and plasmid construction 
pAAV / Myc-hPPM1E(R241A) and (D479N) mutants were constructed by a PCR 
overlap extension method (Ho et al., 1989) from pCR-BluntII-TOPO / hPPM1E with the 
gene primer pair #09 / #10 and the following mismatching primer pairs: (R241A): #11 / 
#12; (D479N): #19 / #20. Primer pairs for site-directed mutagenesis were designed 
using PrimerX© software (Lapid C., copyright 2003). PCR products were subcloned as 
described in 2.2.5 Influence of PPM1E in cell lines and primary neuronal culture (page 
68). 
 
2.2.1.5 shRNA design and plasmid construction 
Short hairpin oligonucleotides were designed using siDESIGN software (Thermo 
Scientific) and the human (h) and rat (r) PPM1E sequences (NM_014906 and 
NM_198773 respectively) (Table 2.3 Oligonucleotides for construction of shRNA 
constructs). The antisense part of the sequences corresponds to sections in the coding 
sequence of rat or human PPM1E. The short hairpin RNAs (shRNAs) were expressed 
under control of the polymerase-III H1 gene promoter.  
 
DNA encoding for short hairpin constructs was annealed from synthetic 
oligonucleotides and cloned as BglII / HindIII fragments into pSuper.basic 
(OligoEngine, USA). For expression of shRNAs, the transcriptional control units from 
pSuper.basic, containing the H1 promoter followed by the DNA encoding for the short 
hairpin constructs, were inserted as XbaI / XhoI fragments into pAAV-6P-SEWB 
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leaving the coding region and promoter for the EGFP gene intact (Shevtsova et al., 
2005;Kügler et al., 2003).   
 
2.2.1.6 Quantitative and qualitative immunoblotting 
Cell culture lysates or protein solutions for immunoblotting were obtained as described 
in the respective paragraphs. Protein concentrations were determined with the BCA 
Protein Assay Kit (Thermo Scientific, #23225) using bovine serum albumin as 
standard. Equal amounts of protein (15–25 µg) from each cell culture lysate were 
dissolved in a mixture of sample and reducing sodium dodecylsulfate (SDS)- 
polyacrylamide gel electrophoresis (PAGE) buffer and heated at 70°C for 10 min as 
described by the manufacturer (Invitrogen, NuPAGE LDS sample buffer #NP0007 and 
reducing agent #NP0004).  
 
The proteins were separated by SDS-PAGE on 10 % or 4-12 %-acrylamide gels 
(Invitrogen, NuPAGE Bis-Tris acrylamide gels), and transferred to PVDF membranes in 
transfer buffer containing 25 mM Tris, 200 mM glycine, 0.02% SDS and 20% methanol 
at 350 mA for 90 min. 
 
For qualitative immunoblotting samples were separated by SDS-PAGE gels, and 
transferred to standard PVDF membranes (GE Healthcare, #RPN303F). Membranes 
were blocked in 10 % (w/v) milk powder in TBS-T (10mM Tris, 150 mM NaCl, 0.05 % 
Tween 20, pH 7.5). All further steps containing antibodies were carried out in 2.5 % 
(w/v) milk powder in TBS-T. 
 
For quantitative immunoblotting five step 1:2 dilution series of each sample were 
separated by SDS-PAGE and transferred to ImmobilonTM-FL PVDF membranes 
(Millipore, #IPFL10100). Membranes were blocked with Sea blockTM blocking buffer 
(Pierce).  All further steps containing antibodies were carried out in Sea blockTM 
blocking buffer. 
 
All blots were incubated in primary and secondary antibodies for 1 hour each at room 
temperature and washed three times in TBS-T in between antibody incubations and 
before detection.  
 
Qualitative immunoblots were detected with horseradish-peroxidase-labeled anti-
isotypic antibodies and an ECL western blotting detection system according to 
manufacturer’s instructions (GE Healthcare, #RPN2132) on chemiluminescence film 
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(GE Healthcare, #28906837). Films were developed with an automatic film processor 
(Amersham Hyperprocessor, GE Healthcare). 
 
On quantitative immunoblots the bound primary antibodies were detected with 
fluorescently labeled QdotR-conjugated anti-isotypic antibody (Invitrogen) and 
visualized on the FMBIOR II Fluorescent Image Scanning Unit (Ornberg et al., 2005). 
Analysis of fluorescence intensity was performed with ImageJ 1.38x (Abràmoff et al., 
2004). Pictures were inverted and pixel intensities of the respective protein bands were 
measured. Values of the sample dilution series that are in the dynamic range of the 
fluorescence scan are averaged. Reported values were normalized to anti-Cyclophilin 
B or anti-Į-Tubulin staining. 
2.2.2 His-hPPM1E protein expression, purification and in vitro activity 
determination  
2.2.2.1 Plasmid construction for and expression of His-hPPM1E protein in E.coli 
pET24a / His-hPPM1E was constructed by PCR from pCR-BluntII-TOPO / hPPM1E 
with the primers #21 and #22. The PCR product was cloned as NdeI / XhoI fragment 
into pET24a (Novagen, #69749-3).  His-hPPM1E was expressed in E. coli, BL21DE3 
(Stratagene, #200131) or BL21-CodonPlus® -RIL and -RP(DE3) (Stratagene, #230245 
and #230255) competent cells under control of the bacterial T7 promoter. E.coli was 
grown in 20 g/l tryptone, 10 g/l yeast extract, 5 g/l NaCl, 1 % Glucose, 20 mM K2HPO4 
and 4 mM MgSO4. Expression was induced with 0.5 mM Isopropyl-ȕ-D-
thiogalactopyranosid (IPTG) at OD600nm=0.6 for 4 to 24 hours at 25 or 37°C. Cells were 
harvested by centrifugation at 17 000 g, suspended in 10 mM Tris-Cl pH 7.0, 150 mM 
NaCl with a general protease inhibitor mix (Complete, Roche, 11697498001) and 
disrupted by sonic oscillation. These and all following steps are performed on ice. A 
pinch of each DNase (Sigma, #D5025-150KU) and RNase (Sigma, #R4875-500MG) 
were added for 30 min on ice and cell debris was removed by centrifugation. 
 
2.2.2.2 Plasmid construction for and expression of His-hPPM1E protein in Sf9 
insect cells 
His_PPM1E was expressed in the Spodoptera frugiperda cell line Sf9 under control of 
the polyhedrin promoter (Vaughn et al., 1977) (Cell Culture Service). The His_hPPM1E 
coding sequence was introduced into a baculovirus, AcNPV, using the Bac-To-
BacBaculovirus Expression System with pFastBac 1 according to manufacturer’s 
instructions with minor modifications (Gibco-BRL/Life Technologies, Gaithersburg, MD, 
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USA). pFastBac1 / His_hPPM1E was constructed by PCR from pCR-BluntII-TOPO / 
hPPM1E with the primers #23 and #22. The PCR product was cloned EcoRI / XhoI into 
pFastBac1.  
 
Sf9 cells infected with the recombinant baculovirus were grown adherent at 27°C in 
TC100 medium (GIBCO, 13055-025) supplemented with 10% FCS, 1% sodium 
pyruvate (Sigma, S8636) and 0.83x Yeastolate (GIBCO, #18200-048). For protein 
expression 1x1010 cells in 1 l suspension culture with supplemented TC100 and 0.2 % 
pluronic F-68 (Sigma, # P5556), 10 U /ml penicillin, 10 mg/ml streptavidin (PAA, # P11-
010) and 10 µg/ml gentamicin (Gibco, # 15710-049) were infected at multiplicity of 
infection (MOI) 5 to 8 in 2 l disposable PETG flasks (Nalgene, #4112-2000). After 72 
hours the cells for protein production were harvested and disrupted as described in 
2.2.2.1 Plasmid construction for and expression of His-hPPM1E protein in E.coli.   
 
2.2.2.3 His-hPPM1E protein purification and detection 
The His-tagged hPPM1E was purified using Ni-NTA chromatography with a 5 ml 
HisTrap™ HP column (GE Healthcare, #71-5027-68 AF) according to the 
manufacturer’s instructions in 10 mM Tris-Cl pH 7.0, 150 mM NaCl using an 
ÄKTAprime™ plus system (GE Healthcare). His-PPM1E was eluted from the column 
with 150 mM imidazole (Fluka, #56750). After removal of imidazole by dialysis to 10 
mM Tris-Cl pH 7.0, 150 mM NaCl in pleated dialysis tubing with a molecular weight cut 
off (MWCO) of 10 kDa (Pierce, #68100) the protein was concentrated to 1 mg/ml in 
Centriprep® centrifugal filters with MWCO of 10 kDa (Millipore, #4321) and 
subsequently stored with general protease inhibitor mix (Complete, Roche, 
11697498001) in 4°C for several weeks. 
 
Protein purifications were analyzed by SDS-PAGE and subsequent immunoblotting as 
described in 2.2.1.6 Quantitative and qualitative immunoblotting, or by subsequent 
general protein stain with Coomassie solution (0.78 g/l copper sulphate, 0.5 g/l serva 
blue R, 0.5 g/l crocein scarlet, 25 % 2-propanol, 10 % glacial acetic acid) for 1 h. 
Excess dye was removed in 18 % 2-propanol / 9 % glacial acetic acid. 
 
2.2.2.4 His-hPPM1E phosphatase activity assay 
His-hPPM1E activity was tested in two biochemical activity assays based on 
dephosphorylation of a phosphorylated peptide. A malachite green based assay 
detected subsequently released anorganic phosphate, while a polarization based 
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assay detected antibody binding to a tetramethyl-6-carboxyrhodamine dye (TAMRA)-
labeled phosphorylated peptide. 
 
In the malachite green based assay the PPM1E substrate peptide YGGMHRQEpTVDC 
(pT: phosphorylated threonine) containing the sequence around the 
autophosphorylation site of rat CaMKIIĮ(281-289), and assay conditions are based on 
a PPM1E activity assay by (Takeuchi et al., 2001) with minor modifications. The 
phosphopeptides YGGMHRQEpTVDC and a shortened version MHRQEpTVDC were 
synthesized externally (Metabion, Germany). Reaction buffer consisted of 50 mM Tris-
HCl pH 7.5, 2.5 mM MnCl, 2.5 mM MgCl2, 0.125 mM EDTA, 0.0125 % Tween20 and 
12.5 µg/ml poly-L-lysine with 40 µM phosphopeptide. Dephosphorylation was started 
by the addition of purified His_PPM1E at 30 °C to a reaction volume of 50 µl and 
stopped by the addition of malachite green solutions according to manufacturer’s 
instructions (R&D systems, #DY996). The release of inorganic phosphate was 
determined by the malachite green method of (Baykov et al., 1988) by measurement of 
absorbance at 620 nm on a Saphire2 plate reader (Tecan, Switzerland) in 96 to 384 
well plate format. 
 
In the polarization based assay dephosphorylation of 10 nM TAMRA-labeled peptide 
TAMRA-MpTPpYV was started by the addition of purified His-PPM1E under conditions 
as described above. An antibody raised against the phosphorylated c-Jun N-terminal 
kinase (JNK) and which binds to the phosphorylated assay peptide, was added in 1:20 
dilution with 10 mM hydrogen peroxide to stop the reaction. Changes in fluorescence 
polarization are detected based on changes in abundance of large TAMRA-antibody 
complexes with a fluorescence correlation spectroscopy (FCS) reader (Evotec AG). 
The unspecific PPM1E inhibitor 1-Amino-8-naphtol-2,4-disulfonic acid was added as 
control (Calbiochem, 208775) (Sueyoshi et al., 2007). 
2.2.3 PPM1E Antibody production and characterization 
2.2.3.1 Anti-PPM1E and anti-ARHGEF6 antibody production 
Rabbit polyclonal antibodies reactive to polypeptides corresponding to parts of the 
human PPM1E or ARHGEF6 sequence have been produced externally by 
immunization of rabbits with a synthetic peptide (Davids Biotechnologie, Regensburg, 
Germany).  
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Antibody 
synthetic peptide used for 
immunization 
Peptide 
ID 
Working 
concentration 
ĮPPM1E(AGC) AGCIPEEKTYRRFLELFL I 0.2-0.8 µg/ml1 
ĮPPM1E(GAA) GAATAAAAPGHSAVPPPPP II  
ĮPPM1E(KLA) KLARSVFSKLHEIC III  
ĮPPM1E(ENS) ENSFQGGQEDGGDDKENHGECK IV 4 µg/ml2 
ĮARHGEF6(LLA) LLAVNKATEDQLSERPCGR V  
ĮARHGEF6(SRR) SRRDLEKLVRRLLKQTDE  VI  
Table 2.8: Sequences of the synthetic peptides used for immunization of rabbits and 
subsequent antibody isolation. 1 dilution for immunoblotting with qualitative and 
quantitative detection respectively. 2 dilution for immunolabeling of cell culture after 
formaldehyde fixation. 
 
The amino acid sequences for anti-PPM1E immunization peptides nos. I (AGC), III 
(KLA) and IV (ENS) are conserved in human and rat PPM1E sequences (Appendix A 
3). The peptide sequence II is specific for human PPM1E. The amino acid sequence 
for anti-ARHGEF6 immunization peptide nos. V (LLA) is conserved in human and rat, 
while the sequence IV (SRR) is specific for human ARHGEF6 (Appendix A 4). 
Rabbits immunized with these peptides developed PPM1E-specific antibodies with 
different affinities and specificities. Antibodies were purified externally based on their 
affinity to the immunization peptides (Davids Biotechnologie, Regensburg, Germany). 
 
2.2.3.2 Anti-PPM1E and anti-ARHGEF6 antibody characterization for immunoblot 
applications 
Antibodies were tested on human frontal cortex samples (Netherlands Brain Bank) for 
their specificity in western blot applications.  Protein samples and subsequent 
immunoblots were prepared as described in 2.2.1.6 Quantitative and qualitative 
immunoblotting. 25 µg total protein per lane were detected with different concentrations 
of the respective antibodies. For specificity and signal intensity optimized antibody 
concentrations were then tested on several additional cell extracts and compared with 
signals of anti-affinity-tag antibodies in cell extracts of stable H4_Myc_PPM1E and 
H4_ARHGEF6_Flag cell lines. 
 
2.2.3.3 Anti-PPM1E antibody characterization for immunofluorescence 
applications 
The antibodies were tested on formaldehyde fixated primary neuronal culture and rat 
and human cryocut brain slices of frontal and temporal cortex. Antibody concentrations 
between 0.2 and 4 µg/ml were incubated for 1 hour at room temperature or 4°C over 
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night. Unspecific non-epitopic antibody binding was ruled out by blocking the epitope-
binding site by pre-incubation of the antibody with 10 µg/ml of the respective 
immunization peptide. Binding was subsequently detected with anti-isotypic fluorophore 
conjugated Alexa antibodies (Invitrogen) as described in 2.2.5 Influence of PPM1E in 
cell lines and primary neuronal culture (page 68). Samples were embedded in 
Fluoromount-G (Southern Biotech) and imaged using an inverse Olympus iX81 
fluorescence microscope. Specific PPM1E staining pattern and background intensity 
were assessed. 
2.2.4 Effects of PPM1E expression in Drosophila melanogaster 
2.2.4.1 Cloning of pUAST injection vectors 
pUAST is designed to direct GAL4-dependent transcription of a gene of choice in 
D.melanogaster. The respective sequence is subcloned into a polylinker situated 
downstream of five tandemly arrayed, optimized GAL4 binding sites, and upstream of 
the SV40 small t intron and polyadenylation site. Human PPM1E and ARHGEF6 were 
amplified by PCR from pCR-BluntII-TOPO / hPPM1E and / hARHGEF6. The used 
primer pairs, #09 / #22 and #03 / #28 respectively, included a N-terminal and C-
terminal Myc-tag respectively. The genes were cloned as EcoRI / XhoI fragments into 
pUAST.  
 
2.2.4.2 Establishment of transgenic D.melanogaster strains and fly rearing 
w1118 flies were employed as wild-type controls. The following fly lines were provided by 
the Bloomington Stock Center: wildtype control w1118, double balancer [w*; nocSco/CyO; 
Sb1/TM3] and GAL4 driver P{GawB}elavC155. Driver line P was kindly provided by Dr. 
Doris Kretzschmar (OHSU School of Medicine, Portland, USA). GAL4 in the driver lines 
is expressed in the eye under control of the glass multiple reporter (gmr) promoter 
(Freeman, 1996) or the neuron-specific elav promoter. As wildtype control the w1118 fly 
stock and GAL4-driver lines crossed to w1118 were used.  
 
P-element mediated germline transformation of w1118 flies was performed as described 
(Rubin and Spradling, 1982;Spradling and Rubin, 1982). Transgenes were created by 
injection of pUAST, containing the desired gene PPM1E or ARHGEF6, into w1118 
embryos. This led to random and stable integration of the gene on chromosome X, 2 or 
3. Injection was carried out by Vanedis Drosophila Injection Service (Norway). For the 
establishment of stable fly lines, hatched transgenic flies were crossed to the double 
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balancer line and kept as stock as [w1118; gene of interest/CyO] or [w1118; +/+; gene of 
interest/Tm3] (“+”: wildtype chromosome).  
 
Drosophila cultures were maintained on a 12–12 h light–dark cycle on standard corn 
meal yeast agar medium (160 g/l agar-agar, 0.044 % sugar beet molasses, 0.08 % 
malt extract, 0.08 % corn semolina, 0.018 % brewer's yeast, 0.01 % soy flour and 90 
g/l methyl 4-hydroxybenzoate) at 25 °C in an environmental chamber (Mytrom, 
WB120K). All ingredients were purchased in public stores, except for methyl 4-
hydroxybenzoate (nipagin, Sigma-Aldrich, #H3647). Cultures were transferred to a new 
vial every three to four days to avoid overcrowding.  
 
For each transgene at least one strong and weak expressing cross to P{GawB}elavC155 
and P{w; gmr-GAL4} was analyzed on western blot  and for alterations in its eye and 
central nervous system respectively by visualization under the light microscope, 
surveillance of potential motor deficits and determination of the mean life span. Fly 
eyes in P{w; gmr-GAL4} were visualized directly without fixation and immunolabeling in 
a Zeiss Stemi 2000-C microscope after anesthetization with CO2.  The Lifespan of 
P{GawB}elavC155 crosses was evaluated in 70 flies per cross, the flies were collected 
within 16 hours after hatching, kept in groups of up to 25 individuals and their survival 
was evaluated thrice weekly after anesthetization with CO2. 
 
2.2.4.3 Immunoblot analyses of fly extracts 
Ten flies were shock-frozen in liquid nitrogen. For analysis of gmr-GAL4 crosses the 
heads were separated from the torso by application of shock to the deep-frozen flies. 
The heads were transferred to 4°C ready-made RIPA buffer (0.5% deoxycholate, 0.1% 
SDS, 1% NP40 and 5 mM EDTA in PBS; Sigma, #R0278) including a cocktail of 
general protease inhibitors (Complete, Roche, #11697498001). They were 
homogenized with 10 blows in a 200 µl all glass tissue grinder (Wheaton, Neo-lab, #9-
0906) and incubated on ice for 30 min. For analysis of Elav-GAL4 crosses whole flies 
were homogenized in the same manner. Soluble and insoluble fractions were 
separated by centrifugation at 16 000 g at 4 °C for 10 min. The supernatant was 
analyzed by SDS-PAGE and subsequent immunoblotting as described in 2.2.1.6 
Quantitative and qualitative immunoblotting. 
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2.2.5 Influence of PPM1E in cell lines and primary neuronal culture 
All cell culture reagents and media were obtained from PAA (Pasching, Austria), Sigma 
Aldrich (St. Louis, MO, USA) or Invitrogen (Karlsruhe, Germany). Culture plates in 75 
and 175 cm2 and 6-, 24- and 96-well plates with growth areas of 0.9, 1.9 and 9.6 cm2 
per well respectively and culture dishes with 15 cm diameter were purchased from 
greiner bio-one (Kremsmünster, Austria).  
 
2.2.5.1 Plasmid construction 
All plasmids for expression of recombinant proteins or shRNAs in neuronal cells were 
modified from pAAV-6P-SEWB. For expression of ARHGEF6_Flag the gene was 
amplified with Flag-tag from pCR-BluntII-TOPO / hARHGEF6 with primer pair #03 / #30 
and cloned as EcoRI / HindIII fragment into pAAV-6P-SEWB. The EcoRI / NotI 
digested Myc_PPM1E_mutant inserts, constructed as described in 2.2.1.4 Site-directed 
mutagenesis of hPPM1E and plasmid construction, and an EcoRI / NotI Myc_PPM1E 
PCR fragment from PCR on pCR-BluntII-TOPO / hPPM1E with the following primer 
pair #09 / #10, were ligated to the EcoRI restricted site of an EcoRI / BsrGI digested 
pAAV-6P-SEWB. Single-strand DNA was complementarized with the DNA polymerase 
klenow fragment (Fermentas, #EP0051) and ligated blunt to gain a circular construct. 
Myc_PPM1E, Myc_PPM1E mutants and ARHGEF6_Flag were expressed under 
control of the human synapsin promoter. Control plasmid: pAAV-6P-SEWB, expression 
of EGFP (Table 2.5 DNA vectors which have been used in this study).  
 
For expression in mammalian cell lines Myc_PPM1E or Myc_PPM1E mutants  and 
ARGEF6_Flag were subcloned as EcoRI / NotI  and EcoRI / HindIII fragments 
respectively from the respective pAAV-6P-SEWB construct into pFB-Neo-CMV and 
pFB-Neo-CMV-TO. Myc_hPPM1E(1-557) was amplified with Myc-tag from pCR-
BluntII-TOPO / hPPM1E with the primer pair #09 / #31 and cloned as EcoRI / XhoI 
fragment into pFB-Neo-CMV. The genes of interest were expressed under control of 
the mammalian CMV promoter with and without Tet repression respectively. Control 
plasmid: pFB-Neo-CMV-EGFP, expression of EGFP (Table 2.5 DNA vectors which 
have been used in this study). 
 
2.2.5.2 Cultivation of immortalized cell lines 
All cell lines were obtained from the American Type Tissue Culture Collection (ATCC, 
Molsheim, France). Cultures were grown at 37°C in humidified atmosphere in 75 to 175 
cm2 cell culture dishes and as specified in Table 2.9. Cells in culture were split twice 
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weekly, with cell numbers as specified in Table 2.9. Cell numbers were determined with 
an automated CasyR cell counting system (Innovatis, TT-2GB-1357). For long-time 
conservation 5*106 cells were stored in 95 % FCS (GIBCO) and 10 % DMSO in liquid 
nitrogen.  
 
Cell line Origin Morphology Growth medium1 CO2 conc. 
CHO-K110/ 
CHO-TRex8 
Cricetulus griseus 
(hamster, Chinese), 
ovary 
epithelial-
like  
minimum 
essential 
medium (MEM, 
Gibco, 31095-
029) 
5 % 
HEK 293 GP5, 
11 / HEK 293 
T176 
Homo sapiens, 
embryonic kidney epithelial  
DMEM (Sigma, 
D5796) 8 % 
H4 Homo sapiens brain (neuroglioma) epithelial 
DMEM (Sigma, 
D5796) 8 % 
RBL-1  
Rattus norvegicus, 
peripheral blood 
(leukemia) 
lymphoblast 
DMEM F-12 
(Sigma, 
D8437)3, 
1xMEM NEAA 
(PAA, #M11-
003) 
5 % 
Pc-122 
Rattus norvegicus 
adrenal gland 
(pheochromocytoma) 
polygonal, 
neuronal-
like 
RPMI 1640 
(Sigma, 
#R8758), 5 % 
horse serum 
5 % 
Neuroscreen-
17 Pc-12 subclone 
polygonal, 
neuronal-
like 
RPMI 1650 
(GIBCO9), 
25mM HEPES, 
5 % horse 
serum, 2 mM L-
Glutamine 
(Sigma, 
#G6784) 
5 % 
ST14A4  
 
embryonic 
day 14 rat striatal 
primordia, derived by 
retroviral 
transduction 
polygonal, 
fibroblast-
like 
DMEM high 
glucose with 
NaPyruvat 
(PAA, #E15-
011), 2 mM L-
Glutamine 
(Sigma, 
#G6784) 
5 % 
Table 2.9: Cell lines cultivated in this study.1 supplemented with 10 % fetal bovine 
serum (FBS, GIBCO) and 10 U » ml penicillin and 10 mg » ml streptomycin 
(Penicillin/Streptomycin (100 x), PAA, # P11-010); 2  (Levi et al., 1985;Green et al., 
1976); 3 supplemented with 15 % instead of 10% fetal bovine serum (FBS, GIBCO); 4 
(Ehrlich et al., 2001); 5 packaging cell line for VSV-G production; 6 packaging cell line 
for AAV production; 7 Culture plates for Neuroscreen-1 cultivation are coated with 10x 
PBS diluted collagen solution (Sigma, #C8919); 8 supplemented with 5 ȝg/ml 
blasticidin; 9 not in stock anymore; 10 (Kao and Puck, 1968) ; 11 (Graham et al., 1977). 
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All cell lines were cultured with 10 U » ml penicillin and 10 mg » ml streptomycin 
(Penicillin/Streptomycin (100 x), PAA, # P11-010), except for transfection or 
transduction purposes or directly after thawing of new culture stocks. 
 
2.2.5.3 Transient transfection and establishment of stable transgenic cell lines 
For transient transfection, plasmid lipofectamine 2000 particles were allowed to form 
for 20 minutes in a mixture of  100 µl OptiMEM (Gibco, #31985-047), 1-4 µl 
lipofectamine 2000 reagent (Invitrogen, #11668-027) and 1 µg pFB-Neo-CMV or pFB-
Neo-CMV-TO vector containing the gene of interest. The transfection mixture was 
added to 1.9 cm2 confluent cells in 400 µl of their respective culture medium. 24 hours 
after transfection of pFB-Neo-CMV-TO constructs, expression was induced by addition 
of 1 ȝg/ml tetracycline.  
 
For construction of a stable cell line, HEK 293 GP cells were incubated with 
transfection mixture as described above with minor modifications: 9.6 cm2 confluent 
cells in 2 ml culture medium were transfected by addition of 500 µl OptiMEM, 10 µl 
lipofectamine 2000, 2 µg pFB-Neo-CMV and 2 µg pVPack VSV-G helper plasmid. After 
48 hours the virus-containing supernatant was mixed with 10 µg/ ml DEAE-Dextran 
hydrochloride (Sigma, #D9885). 1 ml mixture was added to 9.6 cm2 confluent cell 
culture of the respective cell line and supplemented with an equal amount of the 
respective culture medium after 3 hours. After 24 hours 400 µg / ml G418 antibiotic 
was added for selection. For establishment of monoclonal cultures 1 cell / well was 
seeded in a 96 well plate in growth medium with G418 antibiotic for selection and 
amplified subsequently. 
 
2.2.5.4 Immunolabeling and -blotting of monolayer culture of immortalized cell 
lines 
For standard immunolabeling monolayer cells were fixed 4 to 24 hours after 
transfection or induction of construct expression with 4% formaldehyde (FA) in PB for 
20 minutes at room temperature (RT) or in ice-cold methanol for 16 hours in -20 °C. 
Afterwards the cells were washed in PB and permeabilized and blocked in 0.5% Triton 
X-100 and 5 % normal goat serum in PB buffer for 30 min, then incubated with the 
primary antibodies for 1 hour in PB. After three washes in PB, antibody binding was 
detected for 1 hour with anti-isotypic fluorophore conjugated antibodies Alexa-488, 
Alexa-555 or Alexa-647 in a mixture with other desired autofluorescent or fluorophore-
labeled markers (Table 2.7 – Antibodies and markers). For F-actin staining with 
AlexaFluor488R labeled phalloidin the incubation time was extended to 2 hours. Cells 
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were then rinsed in PB and embedded in Aqua PolyMount (Polysciences Europe, 
#18606-20) on glass slides. Quantitative analysis of the number of transfected or 
infected cells was performed using an Olympus IX81 fluorescence microscope. Twenty 
fields per coverslip per experiment (n=3) were analyzed. Data were expressed as 
mean % of total cells per experiment ± standard error of the mean. 
 
For standard immunoblotting cells were washed with PB buffer and scraped off the 
culture dish or dissociated from the underground by trypsination (PAA, #L11-004) and 
solved in ready-made RIPA buffer (Sigma, #R0278) and a mix of general protease 
inhibitors (Roche, #11697498001). In cases where the preservation of the protein 
phosphorylation was necessary, the cells were directly lysed in above described buffer 
with a mix of phosphatase inhibitors (PhosStop, Roche, #04906845001) without a prior 
washing step in PB. Further sample preparation and immunoblotting was carried out as 
described in 2.2.1.6 Quantitative and qualitative immunoblotting. 
 
2.2.5.5 Primary hippocampal neuronal culture 
Primary rat hippocampal cultures were prepared from 17-day-old (E17) embryos of 
timed-pregnant Wistar rats as described previously  (Wei et al., 2008;Zheng et al., 
2002), with minor modification. In brief, the pregnant rats were anaesthetized with CO2 
(up to 80 %, 10 min) and then decapitated. The hippocampi (hc) or cortices (co) from 
the pup brain were then dissected in Hanks’s balanced salt solution (HBSS) 
supplemented with 2 mM kynurenic acid, 10 mM hepes, 20 mM MgCl2 and 0.6% 
glucose and digested with 20 units / ml papain (Fluka, #76216) in HBSS. The hc or co 
were washed with plating medium (MEM, 10 % ml FCS, 10 units / ml penicillin and 10 
mg / ml streptomycin (Penicillin/Streptomycin (100 x), PAA, # P11-010) and 1% 
Glutamax), mechanically triturated and plated on either 96-well plates (4*104 hc cells 
per well for survival » death assay), 24-well plates (7.5*104 hc or 5*105 co cells per well 
for biochemical analysis) or 13-mm round glass coverslips  (VWR, #ECN 631-1578 or 
Marienfeld, #0111530) (7.5*104 hc or 5*105 co cells per coverslip for 
immunohistochemical staining and morphological analyses). VWR coverslips were 
etched in 65 % nitric acid for 24 h before usage. Plates and coverslips were coated 
with 0.1 mg/ml poly-L-lysine and 1 µg/ml laminine. The cultures were grown at 37 °C in 
a  5  % CO2 humidified atmosphere in Neurobasal medium supplemented with B27, 2 
mM L-glutamine, 10 units » ml penicillin and 10 mg » ml streptomycin for 21 days. The 
medium was replaced 3 hours after plating and subsequently given half-changes twice 
weekly. Glial cell growth and mitosis was not inhibited to support the establishment of 
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good neuronal network (Figure 2.1). Neurons were transfected or infected on day in 
vitro (DIV) 7. 
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Figure 2.1: Development of glial cells (labelled with anti-GFAP antibody) and 
neurons (labelled with anti-NeuN antibody) in primary hippocampal culture on 
day-in-vitro (DIV) 8 and 21. GFAP: glial fibrillary protein. NeuN: neuron specific 
nuclear antigen. Merge: overlay of GFAP (green) and NeuN (red) stains. Scale bar: 
200 µm. 
 
2.2.5.6 AAV vector production 
AAV vector production was carried out in HEK 293 T17 cells and following a previously 
described calcium phosphate transfection protocol (Grimm et al., 1998). rAAVs were 
produced with serotype 1 and 2 packaging proteins both of which efficiently infect 
neuronal cells (Grimm et al., 2003) . PPM1E is expressed under control of the neuron-
specific promoter for human synapsin (hSYN) which induces exclusively neuronal 
expression (Kügler et al., 2003) .  
For preparative large-scale productions, 1.5*107 cells were seeded in each of ten 15-
cm culture dishes and after adherence transfected with 21 µg DNA. AAV vector and 
each of the helper plasmids pDP1 and pDP2 were transfected in equimolar amounts. 
Medium was changed after 24 hours and cells were incubated for 72 hours after 
infection and then scraped off the culture dish in 2.5 ml PB per 15 cm culture dish. 
Cells were pelleted, frozen and then thawed in 0.85 ml 50 mM Tris-Cl pH 8.0, 150 mM 
NaCl per 15 cm plate. Vector particles from large preparations were purified and 
concentrated by iodixanol density centrifugation as described by others with minor 
modifications (Zolotukhin et al., 1999). In brief, 0.85 µl cell lysate was incubated with 40 
units benzonase nuclease (Novagen, # 70746) and 0.6 % Na-deoxycholate for 30 min 
at 37°C, NaCl concentration was raised to 1 M and the suspension incubated 30 min at 
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56°C and frozen in dry ice. After complete freezing the pellet was thawn at 37°C, 
centrifuged at 7000 rpm for 30 min at 4°C and purified on an 3 ml 54% - 3 ml 30% - 3 
ml 20% - 6 ml 5% iodixanol (OptiPrep® density gradient medium, Sigma, #D1556) / PB 
gradient, the 5% fraction containing 1 M NaCl. Tubes were sealed and centrifuged in a 
Type 1250 rotor (Sorvall Discovery 90SE Ultrazentrifuge) at 271 000 g for 90 min at 12 
°C. 2.5 ml from the border between the 54% and the 30% gradient step were aspirated 
with a syringe equipped with a 0.9 x 70 mm needle (Sterican), washed in 25 ml PB and 
concentrated in Amicon Ultra 15 Centrifugal Filter Devices (Millipore). The 
concentrated virus was filtered sterile through 0.45 µm filter (Millex-HV Syringe-Drive 
Filter (4 mm)) and stored at -80°C. 
 
The number of DNA containing viral particles was estimated by real-time PCR with 
primers against the cis-acting woodchuck postregulatory regulatory element WPRE 
element in the viral DNA (Table 2.2 - Oligonucleotides used in quantitative real-time 
PCR).   
 
2.2.5.7 Infection of neurons and subsequent analyses 
1.9 cm2 medium-density primary neurons were infected with 3*108 DNA containing 
particles purified recombinant adeno-associated virus (rAAV) per ml on day in-vitro 
(DIV) 7 (compare (Grimm et al., 2003)). DIV 21 cells were lysed with self- or ready-
made lysis buffer ((3% SDS, 20 mM Tris-Cl, pH 7.5, 10 mM EGTA, 2.5 mM MgCl2) or 
RIPA (Sigma, #R0278)), containing a mix of general protease inhibitors (Roche, 
#11697498001). In cases where the preservation of the protein phosphorylation was 
necessary, the cells were directly lysed in above described buffer with PhosStop 
phosphatase inhibitor (Roche, #04906845001) and 10 µM CaMKP-Inhibitor 
(Calbiochem, #208775; (Sueyoshi et al., 2007)). Samples were analyzed in SDS-PAGE 
and immunoblotting as described in 2.2.1.6 Quantitative and qualitative 
immunoblotting. 
 
2.2.5.8 Quantitative real-time PCR from isolated mRNA 
mRNA was isolated from immortalized cell lines or primary cell culture with RNeasy 
Plus Mini and QIAshredder or 96 well TurboCapture mRNA kits (Qiagen, #74134, 
#79656 and #72251) and transcribed into cDNA with T20 primers and Sensiscript II 
Reverse Transcriptase (Qiagen, #205213) as described by the manufacturer. General 
precautions to avoid RNase contamination, the usage of RNase free materials, 
cleaning with RNase decontamination solution (ZAP, Ambion, #9780) and breathing 
away from the samples were taken. Quantitative real-time PCR (qRT-PCR) was 
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performed with Sybr Green stain (Roche, #04707516001) on a LightCycler 480 
(Roche). The PCR parameters were 95°C, 10 min then [95°C, 5 s (ramp rate (rr) 
4.4°C/s) Æ 56°C, 5 s (rr 2.2°C/s) Æ 72°C, 5 s (rr 4.4°C/s)] for 50 cycles, then for 
melting curve determination 95°C, 1 s (rr 4.4°C/2) Æ 65°C, 15 s (rr 2.2°C/s) Æ 95°C 
continuous (rr 0.06°C). Melting curves were performed to document single product 
formation and additionally the product size was confirmed on a microfluidics-based 
platform (Agilent, 2100 Electrophoresis BioanalyzerR). In a typical run, samples were 
analyzed in triplicate for each primer pair (Table 2.2 – Oligonucleotides used in 
quantitative real-time PCR). Standard curves for each primer pair were derived from 
total brain cDNA dilution series with defined concentrations between 2 ng to 4 pg/µl. 
Total brain cDNA was polymerized as described above from total brain rat or human 
RNA purchased from Clontech (France). Samples were amplified with candidate gene 
and “housekeeping gene” cyclophilin B primers in separate reactions. The parameter 
Ct was derived for each cDNA sample and primer pair. Ct is an expression of 
amplification kinetics referring to the cycle at which log-phase amplification reaches the 
pre-determined threshold. Gene expression was expressed relative compared to 
cyclophilin B expression. 
 
2.2.5.9 Transfection, immunostaining and imaging of primary neurons 
Primary neurons growing on glass coverslips were transfected with pAAV-6-SEWB 
derived constructs on day-in-vitro (DIV) 7 and fixed on DIV21. The culture medium was 
changed to Neurobasal without additives and the conditioned culture supernatant was 
stored at 37 °C. Plasmid-Lipofectamine 2000 (Invitrogen, #11668-027) complexes were 
allowed to form for 20 minutes before application of 1 µg DNA in Neurobasal without 
additives to 1.9 cm2 neuronal culture. After 1 hour the medium was changed to 
Neurobasal with 0.5 µM APV (Tocris), 5 % FCS, 10 units » ml penicillin and 10 mg » ml 
streptomycin (Penicillin/Streptomycin (100 x), PAA, # P11-010). After an additional 
hour the cells were washed with culture medium Neurobasal supplemented with B27, 2 
mM L-glutamine, 10 units » ml penicillin and 10 mg » ml streptomycin, half of the volume 
was then replaced with the stored conditioned culture supernatant. All constructs 
coding for a protein were co-transfected in equal DNA volumes with EGFP expressing 
pAAV-6P-SEWB. To control for unspecific transfection effects a non-coding plasmid 
(pcDNA3+) was always co-transfected so that the total plasmid DNA summed up to 1 
µg DNA per 1.9 cm2 culture. EGFP was co-transfected to visualize the transfected 
neurons. All constructs coding for shRNAs contained the EGFP gene as well (see 
2.2.1.5 shRNA design and plasmid construction).   
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Cells were fixed on DIV 21 with 4 % formaldehyde, 4 % sucrose in PB for 10 min at 
room temperature (RT). Samples were permeabilized with 0.1 % Triton® X-100 and 
blocked with 5 % normal goat serum in PB.  Cells were stained with primary antibodies 
in PB for 1 hour at RT with the antibodies specified in Table 2.7 (Antibodies and 
markers). Detection with secondary antibodies was similarly performed for 45 minutes 
at RT, using anti-isotypic fluorophore conjugated antibodies Alexa-488, Alexa-555 or 
Alexa-647 in a mixture with other desired autofluorescent or fluorophore-labeled 
markers (Table 2.7 – Antibodies and markers). For F-actin staining with 
AlexaFluor488®-labeled phalloidin the incubation time was extended to 2 hours. 
Samples were embedded in Fluoromount-G (Southern Biotech).  
 
For spine analysis samples were imaged using an inverse Leica SP2 microscope 
equipped with a 63x oil-immersion objective and connected to a Leica TCS SP2 AOBS 
confocal laser scanning setup. Z-stacks with 0.2 µm intervals, image resolution of 2048 
x 2048 and 2x zoom were recorded. For general morphological analyses samples were 
imaged with an Olympus IX81 fluorescence microscope. For neurite outgrowth analysis 
samples were imaged with a 20x water-immersion objective in an Opera high content 
screening system (Perkin Elmer, #OP-QEHS-01) 
 
2.2.5.10 Analysis of dendritic spines 
To quantify the number and qualify the morphology of dendritic spines, one- or two-
channel images were acquired using the same acquisition settings. Three dimensional 
stacks were built and spines along two secondary dendrites per neuron analyzed with 
Neuron Studio 0.9.44 software (Rodriguez et al., 2008). Results of the internal spine 
analysis tool were corrected manually. The spines were assigned to the group of 
mushroom, stubby or thin spines based on their head-to-neck size ratio (Peters and 
Kaiserman-Abramof, 1970). A total of 60 secondary dendrites from 30 neurons from 
three independent experiments were quantified for each transfection condition. For 
each dendrite an 80 to 200 µm segment was analyzed. In total more than 900 spines 
were counted for each analyzed condition.  
 
2.2.5.11 Neurite analysis 
The arborisation of neurons was evaluated in transfected 96well primary neuronal 
culture. 17 random pictures from GFP and DRAQ5 autofluorescence per well were 
taken with a 20x water-immersion objective and automatically evaluated with the 
NeuriteOutgrowth script from Acapella image analysis software (Perkin Elmer). A total 
of 17 pictures from 8 wells in one 96well plate for 3 independent experiments were 
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analyzed for each culture condition. In total over 300 transfected neurons were 
evaluated for each condition. Parameters were the following: maximal neurite width: 5 
pixels (p); minimal neurite length: 10. Evaluated are the number of roots, i.e.segments 
having their origin in the neuron itself, and the total neurite length, i.e. the total length of 
the neurite structure in one neuron. 
 
2.2.5.12 Statistical analysis 
Statistical analyses were performed with R 2.10.1 (R foundation for statistical 
computing) and Prism 3.02 (GraphPad, La Jolla, CA, USA). Bars in figures indicate 
minima and maxima, boxes the 25 and 75% percentile with the median value. 
Statistical analyses of two groups were performed using two-tailed Mann Whitney U-
test or Wilcoxon matched pairs test and 95% confidence intervals.  
 
Correlation tests between parameters were performed by linear regression and 
estimation of the goodness of the fit from the coefficient of determination R2. The latter 
is a global effectiveness measure for the fit. To test the coefficient of determination R2 
statistically, it is tested against the R2=0 hypothesis which would indicate that there is 
no correlation between parameters. If R2 is significantly different from 0 then the 
parameters are assumed to correlate. 
2.2.6 Expression and localization of PPM1E in human, rat and mouse brain 
2.2.6.1 Cryosections, fixation and immunofluorescence of human and rat brain 
samples 
Human, age-matched brain samples from healthy and Alzheimer’s disease (AD)-
affected donors were obtained deep-frozen from the Netherlands Brain Bank (NBB). 
Total rat brains were dissected from adult female Wistar rats. The rats were 
anaesthetized with CO2 (up to 80 %, 10 min) and then decapitated.  
 
Approximately 50 mg samples, separated from the deep-frozen human cortical brain 
specimen, or total deep-frozen adult rat brain hemispheres were embedded in O.C.T. 
Tissue-TekR compound medium (Sakura Finetek, The Netherlands) on dry ice. 14 µm 
cryosections were taken at 17 °C with a cryo-microtome (Leica CM3050 S) and 
mounted sequentially on glass slides (Superfrost Plus, Thermo Scientific, 
#J1800AMNZ) and stored in -80 °C.  
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For immunolabeling glass slides were dried 30 min at room temperature, washed three 
times in PB buffer and blocked 30 min in humid atmosphere in 10 % normal goat 
serum and 0.2 % Triton X-100 in PB buffer. Primary antibody was incubated over night 
at 4 °C. Then the glass slides were washed three times in 0.1 % Triton X-100 in PB, 
blocked in 3 % BSA / PB for 30 min and incubated with the secondary antibody 1:600 
in 1 % BSA / PB for 2 h. Glass slides were washed in PB buffer twice before staining of 
neutral triglycerides and lipids with 1 % sudan black (Roth, #0292.1) in 70 % ethanol 
for 2.5 min and embedding in Fluoromount G (Southern Biotech). 
 
2.2.6.2 Lysis of human and rat brain samples, SDS-PAGE and Immunoblot 
quantification 
Approximately 50 mg human and rat brain samples were obtained as described above 
(2.2.6.1 Cryosections, fixation and immunofluorescence of human and rat brain 
samples), transferred to 4 °C ready-made RIPA lysis buffer (Sigma, #R0278), 
containing protease inhibitor Complete (Roche), and homogenized with 10 blows in a 7 
ml all glass dounce tissue grinder (Kimble Chase). After 30 minutes incubation on ice, 
the protein lysate was separated from cell debris by centrifugation at 16 000 g. 
Measurement of protein concentration and subsequent SDS-PAGE and western 
blotting were carried out as described in 2.2.1.6 Quantitative and qualitative 
immunoblotting. 
 
     
 
RESULTS - 3.1 Characterization of tools for this study 
 
78 
 
3 RESULTS 
3.1 Characterization of tools for this study 
This section will introduce tools which were essential for this study, and therefore 
needed careful characterization because they had not been discussed extensively in 
the literature before. Among them is the selection of primary sequences for rat and 
human PPM1E, the analysis of the specificity of anti-PPM1E antibodies, which were 
characterized during the cause of this study, and the difficulties in the selection of 
suitable cell lines for investigation of PPM1E effects. The last paragraph will introduce 
the human brain samples, which are investigated in this study and which were 
analysed previously regarding their PPM1E mRNA levels (von der Kammer, 2009). 
Potential correlations between PPM1E mRNA levels in human brain samples and post-
mortem delay time7 and other parameters will be critically reassessed.  
3.1.1 Polymorphisms in the PPM1E sequence 
Expression of the human PPM1E protein has been induced for different purposes in 
different cell lines and in primary neuronal culture during the course of this study. A 
critical first step was to determine the ‘correct’ PPM1E sequence from online database 
searches. 
 
BlastP searches for human DNA sequences homologous to the PPM1E sequence, as 
derived from previous publications  (Takeuchi et al., 2004;Koh et al., 2002;Takeuchi et 
al., 2001), revealed three slightly different PPM1E variants: homo sapiens mRNA for 
KIAA1072 protein (AB0289958, 759 amino acids (aa)), homo sapiens PP2CH mRNA 
(AF2602699, 766 aa) and homo sapiens protein phosphatase 1E (PP2C domain 
containing) (PPM1E) (NM_01490610, 755 aa) (Appendix A 2). The sequences of the 
encoded proteins differed in the number of glutamate-proline repeats within the amino-
terminal part of the protein (11 in sequences AB028995 and AF260269, 10 in 
sequence NM_014906), in a 9 aa insertion (PLSERITPR) encoded only by the 
sequence AF260269, and in a valine at position 385 (NM_014906) /  389 (AB028995), 
which is replaced by an isoleucine (position 396) in AF260269. The sequence 
NM_014906 was used for all experiments discussed in this study. It was the most 
                                               
7 post-mortem delay time (PMT): time between death of the donor and deep-freezing of the brain 
8 NCBI (National Center for Biotechnology Information) GenBank accession number 
9 NCBI GenBank accession number 
10 NCBI GenBank accession number 
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commonly sequenced transcript, as judged from the number of expressed sequence 
tags (ESTs) in the NCBI database, and it was used in prior studies of PPM1E 
(Takeuchi et al., 2004;Koh et al., 2002;Takeuchi et al., 2001) (KIAA1072 of the Kazusa 
cDNA library = NM_014906).  
 
The sequence of the PPM1E homolog in Rattus norvegicus was required in this study 
for the design and functional testing of short hairpin (sh) RNA constructs which were 
used to down-regulate rat PPM1E expression in rat primary neuronal cell culture. 
‘Rattus norvegicus protein phosphatase 1E (PP2C domain containing)’ (Ppm1e; 
NM_19877311, 750 aa), was amplified from mRNA isolated from the rat primary 
neuronal culture used in this study with terminally binding PCR primers. Others have 
characterized the PPM1E sequence ‘Rattus norvegicus mRNA for calmodulin-
dependent protein kinase phosphatase N’ (AB08172912, 750 aa) which is 100% 
identical to NM_198773 (Kitani et al., 2006).  
3.1.2 Specificity of polyclonal anti-PPM1E antibodies 
Since no commercial anti-PPM1E antibodies were available, polyclonal PPM1E 
antibodies were generated and purified by a service provider on behalf of this study. 
The polyclonal anti-PPM1E antibodies were generated by immunization of rabbits with 
synthetic peptides corresponding to the PPM1E sequence (Appendix A 3). Four 
peptides were used for immunization of two rabbits each. The purified polyclonal 
antibodies were characterized for immunoblotting and immunolabeling of formaldehyde 
fixed tissue and cell cultures in this study. The immunization with peptides I (AGC) and 
IV (ENS) resulted in the most specific polyclonal antibodies for these applications 
respectively. These specific anti-PPM1E antibodies are referred to as anti-
PPM1E(AGC) and anti-PPM1E(ENS) according to the first three amino acids in the 
respective immunization peptide. Their sequences are conserved in human and rat 
PPM1E (Appendix A 3).  
 
3.1.2.1 Anti-PPM1E(AGC) detects rat and human PPM1E specifically in 
immunoblotting 
The specificity and suitable concentrations of all antibodies were initially tested in 
antibody dilution series on immunoblotted human cortical brain sample homogenates 
(data not shown). In this study concentrations of 0.2 to 0.8 µg / ml anti-PPM1E(AGC) 
                                               
11 NCBI GenBank accession number 
12 NCBI GenBank accession number 
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antibody were used for PPM1E detection in qualitative and quantitative immunoblotting 
respectively.   
The antibodies were then tested for immunoblotting applications on day-in-vitro (DIV) 
21 rat primary neuronal cell lysates from wildtype cultures and cultures in which 
Myc_PPM1E expression was induced by infection with recombinant adeno-associated 
viruses (rAAV) on DIV 7 (Figure 3.1). The antibody anti-PPM1E(AGC) revealed two 
specific bands at apparent masses around 120 and 80 kDa in Myc_PPM1E 
overexpressing cultures. The 120 kDa band is very weak and therefore only visible 
after longer exposure times of the light-sensitive film to the ECL-detected immunoblot 
(Figure 3.1: “1 min exposure”). The antibody specificity was controlled with an anti-
Myc_tag antibody, which detected proteins with the same apparent molecular weights 
as anti-PPM1E(AGC) (Figure 3.1: “Myc”). 
 
Kitani et al. (2006) 
predicted the truncation 
site of rat PPM1E to be 
located at proline 554. 
This site is homologous 
to proline 557 in the 
human PPM1E isoform 
(Appendix A 3, 
arrowhead). Rat PPM1E 
and PPM1E(1-554) run 
at 120 and 80 kDa in 
SDS-PAGE. These 
correspond to actual 
masses of 87.7 and 65.3 
kDa respectively as 
demonstrated by mass 
spectrometric analysis (Kitani et al., 2006).  The authors did not speculate on a 
possible explanation for this unusual running behaviour in SDS-PAGE. 
Human PPM1E  and PPM1E(1-557) have predicted molecular weights of 84.0 and 61.4 
kDa, but run also at apparent molecular weights of approximately 120 and 80 kDa 
(Figure 3.1)  (Kitani et al., 2006;Takeuchi et al., 2001). In the wildtype primary 
hippocampal culture truncated PPM1E(1-554) is the predominant PPM1E species 
(Figure 3.1). However, extended anti-PPM1E(AGC) antibody detection revealed full-
length as well as PPM1E(1-554) expression in these cultures (compare Figure 3.11). 
 
Figure 3.1: Specific detection of Myc_PPM1E with anti-
PPM1E(AGC) (“AGC”) and anti-Myc-tag (“Myc”) 
antibodies. Wildtype and rAAV / Myc_PPM1E-infected 
dissociated primary rat hippocampal culture. Infection on 
DIV 7, analysis on DIV 21. Detection with anti-
PPM1E(AGC) or anti-Myc-tag and anti-Į-Tubulin antibody; 
10 s (left) and 1 min (right) exposure of light-sensitive film 
to the same ECL-detected blot. trunc. PPM1E: truncated 
PPM1E (human PPM1E(1-557) or rat PPM1E(1-554)). 
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3.1.2.2 Anti-PPM1E(ENS) detects PPM1E specifically in formaldehyde fixated 
specimen 
Additionally the specificity proper concentration of polyclonal anti-PPM1E antibodies 
was tested in immunolabeling of formaldehyde (FA)-fixed, dissociated primary 
hippocampal culture and brain tissues (Figures 3.2 and 3.3 for anti-PPM1E(ENS); not 
shown for other polyclonal antibodies).  
 
PPM1E detection with anti-PPM1E(ENS) in dissociated primary hippocampal 
culture 
 Primary hippocampal cell cultures were transfected on day-in-vitro (DIV) 7 with EGFP 
and Myc_PPM1E and analyzed on DIV 21 (Figure 3.2). The antibody anti-
PPM1E(ENS) (4 µg/ml) revealed a characteristic fragmented staining pattern in the 
dendrites of primary neurons which were transfected with Myc_PPM1E or 
untransfected (Figure 3.2 A). The fragmented detection was comparable with that of an 
anti-Myc_tag antibody of the same hippocampal culture batch (Figure 3.2 B).  
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Figure 3.2: Myc_PPM1E expression in EGFP- and Myc-PPM1E-co-expressing and 
untransfected primary hippocampal neurons. Transfection on DIV 7, analysis on 
DIV 21. EGFP autofluorescence (left) and (A) anti-PPM1E(ENS) or (B) anti-Myc-tag 
stain; and merge of both: EGFP green, anti-Myc-tag or anti-PPM1E(ENS) red. Scale 
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bar: 50 µm. 
 
Moreover, in young DIV 3 hippocampal neurons the primarily dendritic and somatic, 
non-nuclear staining pattern is comparable with one that has been shown previously by 
Kitani et al. (2006) (Figure 3.17 A). 
 
The above described fragmented expression pattern of PPM1E was present in some 
but not all investigated cultures (compare Figures 3.2 and 3.17). The trigger for this 
fragmentation could not be identified in this study and occurred from time to time, 
depending on the culture batch, although due caution was taken to standardize the 
culture, fixation and immunolabeling procedures.  
 
PPM1E detection with anti-PPM1E(ENS) in human cortical brain samples 
In human frontal cortex tissue the antibody anti-PPM1E(ENS) detected PPM1E 
expression in neuronal nucleus and enriched in cytoplasm as indicated by NeuN co-
labeling (Figure 3.3 A). A cytoplasmic enrichment of PPM1E has been shown before 
(Kitani et al., 2006).  
 
A  
 
             
 NeuN                                   anti-PPM1E(ENS)              merge  
B                                              anti-PPM1E(ENS)  
  NeuN                              preincubated with peptide IV                               merge 
 
Figure 3.3: Specificity of PPM1E(ENS) antibody in detection of endogenous 
PPM1E expression in human frontal cortex. Detection with anti-NeuN (left) and 
anti-PPM1E(ENS) (middle) antibodies. Merge of NeuN (red) and anti-PPM1E(ENS) 
(green) detection (right). (A) Arrowhead indicates an example of a PPM1E(ENS)-
positive, but NeuN-negative cell. (B) Preincubation with the corresponding 
immunization peptide blocks the anti-PPM1E(ENS) binding to the specimen. Scale 
bars: 50 µm 
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The anti-NeuN antibody specifically recognizes the DNA-binding, neuron-specific 
protein NeuN, which is present in the nucleus and cytoplasm. Occasionally cells can be 
found which are anti-PPM1E(ENS), but not anti-NeuN positive (Figure 3.3 A, 
arrowhead). Some neurons fail to be recognized by anti-NeuN: retinal cells, Cajal-
Retzius cells, Purkinje cells, inferior olivary and dentate nucleus neurons, and 
sympathetic ganglion cells (Wolf et al., 1996;Mullen et al., 1992).  Additionally anti-
PPM1E(ENS) detected a diffuse stain which is visible as globular structures in higher 
magnification in between neuronal cell bodies13 (Figure 3.3 A). This diffuse stain and 
the soma detection of PPM1E could be blocked with the corresponding peptide 
ENSFQGGQEDGGDDKENHGECK (Figure 3.3 B).  
3.1.3 Endogenous and ectopic expression of PPM1E in different cell lines 
Cell lines which express rat or human PPM1E would be a valuable tool to test the 
down-regulation of PPM1E by RNA interference and to evaluate PPM1E effects in a 
simple model system. Therefore a number of cell lines were tested for endogenous, 
immunoblot-detectable expression of PPM1E (Figure 3.4). 
 
A PPM1E protein expression in different cell lines 
 
B PPM1E mRNA in H4  
 
Figure 3.4: Endogenous and ectopic expression of PPM1E in different cell lines. 
(A) PPM1E is expressed in 1. wildtype H4, and after transfection (2, 5) or transduction 
(3, 8, 11, 12) with Myc_PPM1E (2, 3, 5, 8, 11) or His_PPM1E (12) constructs in H4, 
HEK and Sf9 cell lines in different PPM1E to PPM1E(1-557) ratios. In other cell lines 
with human or rat origin no PPM1E expression could be detected (4: HEK 293 GP; 6: 
RBL; 7: PC12; 9: NeuroscreenTM-1; 10: ST14A). 15 µg total protein per lane; 
immunoblot detection with anti-PPM1E(AGC). trunc. PPM1E: truncated PPM1E 
(PPM1E(1-557)). (B) PPM1E mRNA levels in H4 (wt) and H4_Myc_PPM1E (PPM1E) 
cell lines, normalized to Cyclophilin B levels. qRT-PCR analysis. au: arbitrary units; 
wt: wildtype. 
 
However most analyzed cell lines did not express PPM1E in immunoblot-detectable 
amounts: Neither non-neuronal cell lines of human origin, namely human embryonic 
                                               
13 for further investigation see paragraph 3.2.2.5 Co-localization of PPM1E with EAAC1 but not GAD67 in human 
cortical neurons 
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kidney cells (HEK 293 GP), nor cell lines of rat origin with neuron-like morphology like 
PC12 and NeuroscreenTM-1, or without neuron-like morphology like lymphoblast- (RBL-
1) and fibroblast-resembling (ST14A) cells (Figure 3.4 A). The Spodoptera frugiperda-
derived cell line Sf9 also did not – and was not expected to – express PPM1E. 
 
A low endogenous PPM1E expression was however found in the human neuroglioma 
cell line H4 (Figure 3.4 A (1)). Quantitative real-time (qRT) PCR of H4 cells confirmed 
low levels of PPM1E mRNA (Figure 3.4 B). A H4 cell line, stably expressing 
Myc_PPM1E was established (H4_Myc_PPM1E), which revealed a fifty times increase 
in PPM1E expression (Figure 3.4 A (1, 3), B). 
 
Ectopic expression of human PPM1E in H4, HEK or Sf9 cells by transfection or 
transduction resulted in expression of PPM1E in different ratios of truncated and full-
length form (Figure 3.4 A (2, 3, 5, 8, 11, 12)). Obviously the mechanism of PPM1E 
truncation is neither restricted to neuronal, nor to mammalian cells. In H4 cells only 
PPM1E(1-557) is detected (Figure 3.4 A (1-3, 8, 11)), whereas in transiently 
Myc_PPM1E expressing HEK and Sf9 cells both forms, PPM1E and PPM1E(1-557), 
are present (Figure 3.4 A (5,12)). The truncated PPM1E(1-557) is in all analyzed 
samples the predominant PPM1E species.  
 
In Sf9 cells in which expression of PPM1E is induced by a baculovirus which encodes 
human PPM1E, a third, shortened form appears, which has a molecular weight of 
approximately 60 kDa (Figure 3.4 A (12)). This has been observed before in attempts 
to express PPM1E in Sf9 cells (Takeuchi et al., 2001).  
 
No rat cell line with a sufficiently high endogenous PPM1E expression to test shRNA 
constructs was identified, therefore transient overexpression of PPM1E in HEK cells 
was used for this purpose as described below14. 
3.1.4 Characterization of human brain samples  
Human frontal and temporal cortex samples in different Braak stages were obtained 
from the Netherlands Brain Bank (NBB; Amsterdam, The Netherlands). The mRNA and 
protein quality of the brain samples was controlled previously (von der Kammer, 2009) 
and the donors are age-matched between 63 and 91 years.  PPM1E mRNA levels 
                                               
14 compare 3.3.5 Down-regulation of PPM1E with RNA interference affects spines and dendritic arborization, page 125 
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were determined by means of quantitative real-time PCR (qRT-PCR) for frontal and 
temporal cortex before (von der Kammer, 2009) (Figure 1.3 A-a and Table 3.1). 
NBB 
ID 
PMT 
[min] 
Brain 
mass pH CSF sex age 
Braak 
stage 
Diag-
nosis 
PPM1E mRNA 
in frontal / 
temporal 
cortex1 
PPM1E 
protein 
in frontal 
cortex 
IB2 
PPM1E 
protein 
in frontal 
cortex 
IHC3 
93-105 420 1405 6.75 m 80 0 NDC 9.50 / 11.18 0.65 yes 
93-110 525 1346 6.11 m 73 0 NDC 12.03 / 6.87 0.61 yes 
00-090 465 1560 6.46 m 70 0 NDC 10.40 / 11.41   
01-004 515 1169 6.4 f 64 0 NDC 1.76 / 2.97 0.58 yes 
00-067 45 1267 -- m 73 0 NDC 12.46 / 9.46 0.86 yes 
94-124 330 967 6.60 m 63 1 CVE 28.47 / 24.11   
00-032 390 1047 7.02 f 78 1 NDC 26.23 / 19.43   
01-005 1185 1149 6.21 f 77 1 NDC 46.47 / 27.75 0.97 yes 
01-006 345 1088 6.49 f 91 1 NDC 7.33 / 11.03 0.98  
01-016 505 1138 7.19 m 77 1 NDC 10.41 / 6.44 0.83  
00-137 435 1031 7.00 f 92 1 NDC 3.77 / 4.15   
00-142 330 1280 6.6 f 82 1 NDC 9.26 / 10.99 1.07  
96-044 350 1101 7.00 f 90 2 NDC 64.68 / 48.12 1.37 yes 
00-030 426 1468 6.66 m 82 2 NDC 28.39 / 21.79 0.86  
01-094 330 1220 6.76 m 86 2 NDC 42.59 / 19.81   
01-139 815 1249 6.3 f 73 2 NDC 29.88 / 18.87 0.97  
96-075 345 1449 7.31 m 76 2 Dsicc 18.09 / 26.24   
96-051 290 1256 6.65 f 71 3 NDC 43.73 / 15.48 0.96 yes 
00-070 285 1150 6.54 m 80 3 Dsicc 20.80 / 24.05 0.82  
01-030 540 1199 6.54 f 85 3 Dsicc 17.63 / 25.29 0.76  
03-006 320 1106 6.51 f 91 3 NDC 17.09 / 39.54 0.98  
92-088 415 1378 6.55 m 83 4 AD 14.06 / 19.04 0.89 yes 
01-039 300 1213 6.49 m 88 4 AD 12.80 / 38.41 0.81  
00-104 360 1377 6.38 m 86 4 AD 4.73 / 8.42 0.97  
Table 3.1: Human brain samples, which were classified as Braak 0 to 4, and 
analyzed for PPM1E mRNA levels previously (von der Kammer, 2008). 1 PPM1E 
mRNA normalized against cyclophilin B mRNA, determined by qRT-PCR  [arbitrary 
units] (von der Kammer, 2009). 2 PPM1E(1-557) protein levels normalized against Į-
Tubulin (for details see section 3.2.1, page 88 ff). 3 for details see section 3.22, page 
94ff. NBB: Netherlands Brain Bank. PMT: post-mortem delay time between death of 
donor and freezing of brain. NDC: non-demented control. CVE: control with vascular 
encephalopathy. Dsicc: dementia with senile involutive cortical changes. IB: PPM1E 
protein expression analyzed by immunoblotting of human frontal cortical brain samples 
in the present study. IHC: PPM1E protein expression analyzed by immunolabeling of 
FA-fixated human cortical brain samples.  
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To test against possible process-inherent effects on the degradation-sensitive mRNA, a 
possible correlation between post-mortem delay time (PMT) - the period between death 
of the brain donor and the deep-freezing of the brain - and mRNA levels of PPM1E was 
assessed. No significant correlation between either frontal or temporal mRNA 
expression and the PMT was found (Figure 3.5 A). Tested against the R2=0 hypothesis 
(no correlation), the probability for a correlation with the post-mortem time is p= 0.95 
and p=0.38 for temporal and frontal PPM1E expression respectively, hence no 
significant correlation was found (95 % confidence interval).  
 
Moreover, no correlation was found between other potentially relevant parameters for 
mRNA stability, which were documented for the brain samples (Table 3.1), and either 
frontal or temporal PPM1E mRNA levels, neither for age of the donor, nor for pH in 
cerebrospinal fluid (CSF), nor for the brain mass (Figure 3.5 B-D).  
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Figure 3.5: Linear regression between PPM1E mRNA levels and relevant 
properties of the analyzed human brain samples depicted in Table 3.1. Correlation 
with (A) post-mortem delay time; (B) age of donor; (C) pH in cerebrospinal fluid and (D) 
brain mass. Linear regression analysis for frontal and temporal cortex respectively: R2 = 
0.0394 / 0.0002 (PMT); 0.0003 / 0.1370 (age of donor); 0.0126 / 0.0100 (pH CSF); 
0.0445 / 0.0446 (brain mass). All parameter pairs were tested against R2 = 0, and were 
not significantly correlated. au: arbitrary units. *PPM1E mRNA normalized to cylcophilin 
B mRNA levels. 
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The brain samples were therefore, and due to previous histological and biochemical 
analysis (von der Kammer, 2009), regarded as sufficiently well preserved in respect to 
protein and mRNA quality. The microscopic integrity of the tissues was good as 
determined previously during Braak staging analysis by the NBB. 
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3.2 Characteristic truncation and localization of the PPM1E phosphatase 
3.2.1 PPM1E truncation and expression levels 
The human PPM1E protein exists in a full-length form with a length of 755 aa and a 
form which is truncated after proline 557 (PPM1E(1-557)). This truncation site was 
proposed on the basis of mass spectrometric data for the rat PPM1E isoform, which 
indicated that the phosphatases is truncated carboxyterminally from the homologous 
proline at position 554 in rat PPM1E(554). No regulatory or mechanistic insights into 
the mechanism of truncation exist yet. Therefore the expression of PPM1E and 
PPM1E(1-557) in different tissues was investigated further. 
 
3.2.1.1 PPM1E expression in H4 neuroglioma cells 
 Kitani et al. (2006) predicted the truncation site of rat PPM1E to be located at proline 
554. Therefore this study tested whether the homologous truncated protein 
PPM1E(557) would exhibit a comparable running behaviour than truncated full length 
PPM1E in ectopically expressing cells. 
Human neuroglioma H4 cell lines stably expressing the full-length Myc_PPM1E or the 
truncated Myc_PPM1E(1-557) were established. In accordance with predictions from 
Kitani et al. (2006) for the rat PPM1E (CaMKP-N) homolog, one specific PPM1E band 
at an apparent mass of approximately 80 kDa was detected in either cellular lysate 
(Figure 3.6).  
 
 
Figure 3.6:  Ectopic 
PPM1E(1-557) and PPM1E 
expression in H4 cells 
results in PPM1E bands 
with similar molecular 
weights. 15 µg total protein 
per lane; immunoblot 
detection with anti-
PPM1E(AGC) and anti-Į-
Tubulin antibodies. 
 
The endogenous PPM1E expression in H4 cells is very low. However the molecular 
weight of the endogenous PPM1E is also comparable to that of the induced 
Myc_PPM1E(1-557) expression (compare Figure 3.4 A (1) and Figure 3.6). 
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3.2.1.2 PPM1E expression in human frontal cortex 
To investigate whether PPM1E protein levels are also differentially regulated in early 
Braak stages, like the mRNA levels, samples from a subset of previously analyzed 
donors were subjected to quantitative immunoblot analyses of the PPM1E protein 
levels. 
 
The analysis of PPM1E protein expression in this study was focused on brain samples 
which are classified as Braak 0 to 4. In these the PPM1E mRNA levels were 
differentially regulated and therefore they were regarded as most relevant to the cause 
of the present study. Human brain samples which represent very late Alzheimer stages 
(Braak 5 and 6, compare Figure 1.3) were not analysed. This study quantitatively 
evaluated the protein levels of PPM1E in frontal cortex from 18 donors.  
 
In human frontal cortex protein extracts from 18 donors, the full-length as well as 
PPM1E(1-557) were detected and analyzed. PPM1E(1-557) was shown to be the 
predominant PPM1E species in all analyzed samples, except sample 01-005, although 
the ratio between truncated and full-length PPM1E was subject to considerable 
changes between the donors (Figure 3.7).  
 
 
Figure 3.7: PPM1E levels in frontal human cortex samples classified into Braak 
stages 0 to 4. Qualitative Western blot detection with anti-PPM1E(AGC) and anti-Į-
Tubulin. 15 µg protein of frontal cortex per lane. The samples are labeled with the 
donor ID from the NBB (see Table 3.1 for donor characterization).  
 
The exact PPM1E protein levels were determined with quantitative immunoblots to 
investigate whether early changes of PPM1E mRNA levels are reflected in the protein 
concentration. All investigated samples were derived from human frontal cortex. 
However, due to the limited availability of brain samples not all samples could be 
matched with respect to the region in frontal cortex.  
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The overall expression of PPM1E and PPM1E(1-557) was determined from five-step 
dilution series of frontal cortex protein extracts of each of 18 donor samples (Figure 3.8 
A, example blots). Values in the dynamic range of antibody binding and detection for 
PPM1E(1-557) were averaged for each sample and normalized to equally derived 
levels of the “housekeeping” protein Į-Tubulin15 (Figure 3.8 B). Į-Tubulin is a 
component of microtubules and due to the high abundance of microtubules in 
eukaryotic cells it is a suitable protein for normalization.  
 
Approximate values were similarly derived for full-length PPM1E, however the signal 
was too low in several samples to achieve detection in the dynamic range (Figure 3.7 
and 3.8 C). Therefore no conclusive statement on the levels of full-length PPM1E 
during the development of Alzheimer’s disease can be made here. However it can be 
said, that the expression of full-length PPM1E does not appear to follow the same 
regulatory pattern through the Braak stages as PPM1E(1-557) levels (Figure 3.7). 
 
 
  
Figure 3.8: PPM1E protein levels in human frontal cortical brain samples. (A) 
Example blots with 1:2, 5-step, dilution series of brain samples; 15 µg protein per lane in 
highest dilution. Detection with anti-PPM1E(AGC) and anti-Į-Tubulin antibodies. (B) 
Mean values from the dynamic values of quantitative dilution series PPM1E(1-557), 
normalized to Į-Tubulin, and (C) values for full-length PPM1E from the highest protein 
concentration in the dilution series (15 µg protein), normalized against Į-Tubulin. 
Horizontal lines represent the median for each Braak stage cohort. 
 
                                               
15 For a more detailed description of the quantification procedure see 3.3.3.3 Immunoblot quantification of protein levels, 
page 111, and 2.2.1.6 Quantitative and qualitative immunoblotting, page 61. 
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The PPM1E(1-557) levels in Braak 1 and 2 
are considerably higher than those in 
Braak 0 samples (Figure 3.8 B). These 
differences in PPM1E(1-557) levels are 
statistically not significant, potentially due 
to the low number of samples. However, 
the changes in levels of PPM1E(1-557) 
obviously reflect the changes in 
concentration of PPM1E mRNA through 
the investigated Braak stages 0 to 4 
(Figure 3.9, compare also Figures 1.3 A-a 
and 3.8 B). The PPM1E(1-557) protein 
levels correlate linear significantly 
(p=0.045) with the PPM1E mRNA levels in frontal cortex.  
 
3.2.1.3 PPM1E expression in rat brain 
The model system for neuronal morphogenesis in this study was dissociated rat 
hippocampal culture. Therefore the PPM1E expression in adult rat was also 
investigated to verify that the expression with respect to truncation and localization was 
comparable with the expression of PPM1E in human brain tissue. The PPM1E 
expression in embryonal day 17 (E17) rat and younger embryonal stages was analyzed 
as an additional reference for the dissociated culture which is prepared from 17-days-
old embryos. Additionally embryonal day 9 and 13 were analyzed because initial 
synapse development during rat embryogenesis happens around E10 (Li and Sheng, 
2003). 
 
The PPM1E expression in adult and embryonal rat brain tissue was investigated in 
tissue homogenates from the brain regions frontal cortex, cerebellum, hippocampus 
and olfactory bulb for adult rats and embryonal day 17 (E17) (Figure 3.10 A). Due to 
their small size the E9 and E13 embryos were analyzed as whole embryos. Head and 
limbs of E13 embryos were additionally analyzed separately. 
 
 
Figure 3.9: Linear correlation between 
PPM1E mRNA levels, normalized 
against cyclophilin B, and PPM1E(1-
557) protein levels, normalized 
against Į-Tubulin. p=0.045, linear 
regression. 
 
RESULTS - 3.2 Characteristic truncation and localization of the PPM1E phosphatase 
 
92 
 
 
 
 
Figure 3.10: Levels of PPM1E 
and PPM1E(1-554) in adult and 
embryonal day E17 rat brain 
tissues. (A,  B)  Levels  of  the  
phosphatase in different 
developmental stages. co, cortex; 
ce, cerebellum; hc, hippocampus; 
ob, olfactory bulb; - without and + 
with amniotic sac; w, whole 
embryo; he, head; li, limbs. 15 µg 
protein from tissue homogenates 
per lane, immunoblot detected with 
anti-PPM1E(AGC) and anti-Į-
Tubulin antibodies. E: day during 
embryogenesis on which 
embryonal lysates are prepared. 
(C) Determination of putative 
molecular weight of undermined 
band (“?”) in A and B with the help 
of a correlation of the distances 
between the bands of the molecular 
weight marker. au: arbitrary units. 
 
The ratio between full-length and the predominant truncated form of PPM1E was 
comparable with that in Homo sapiens cortical samples (Figure 3.10 A: adult, e.g. “fc”: 
frontal cortex). The levels of expression differed considerably between the analyzed 
brain areas and ages: The PPM1E(1-554) expression was considerably lower in all four 
analyzed brain areas in E17 embryos than in adult rat, and full length PPM1E was only 
detectable in adult rat homogenates (Figure 3.10 A), potentially due to lower PPM1E 
expression levels. The expression of PPM1E(1-554) is especially high in hippocampus 
and olfactory bulb in the adult rat, whereas in E17 embryos the PPM1E expression is 
higher in the frontal cortex and the cerebellum. In E9 complete embryo homogenates 
no PPM1E or PPM1E(1-554) signal can be detected, whereas a low concentration of 
PPM1E(1-554) was present in E13 whole embryo and embryonal head homogenates 
(Figure 3.10 A). It cannot be excluded that PPM1E expression is present, but too 
diluted, because the E9 embryos measured only approximately 50 mm in diameter and 
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were therefore analyzed in whole. Also the E13 “head” sample is diluted by other 
constituent parts of the head other than the evolving brain. 
 
A previously unknown signal with a mass of approximately 200 kDa appears very 
stongly in all E9 and weaker in the E13 samples and is also present in E17 olfactory 
bulb (Figure 3.10 A – “?”). To verify that the signal in E17 olfactory bulb is no technical 
artifact the immunoblot was repeated without adjacent E9 homogenates (Figure 3.10 
B). The new anti-PPM1E(ENS) detected signal had a size of approximately 206.79 kDa 
as determined in relation to the marker bands by measuring the relative distance to the 
20 kDa band of the same marker (Figure 3.10 C). However, a 207 kDa protein or 
protein complex has not been described in the literature in conjunction with PPM1E 
and this study could not identify whether this signal a specific detection of a PPM1E 
complex.  
 
Finally it can be stated that the PPM1E expression rises considerably between the 
embryonal stages and the adult rat. 
 
3.2.1.4 PPM1E expression in rat primary hippocampal culture 
The development of PPM1E expression during the maturation of rat primary 
hippocampal culture which was prepared from E17 rat embryonal hippocampi was also 
analyzed in immunoblots. The endogenous PPM1E expression rises considerably with 
increasing culture age (Figure 3.11). No expression of PPM1E(1-554) is detected on 
day-in-vitro (DIV)  1,  and  
after that the expression 
rises and remains 
relatively constant 
between DIV 8 and 20. 
Subsequently the 
expression of PPM1E(1-
554) at least doubles 
and again remains constant between DIV 21 and 25. Post-DIV 25 cultures were not 
investigated in this study. The exact age at which PPM1E expression would undergo 
the last steep increase in expression varied slightly between cultures between DIV 20 
and 21 (data not shown). These changes in expression are conserved in full-length 
                                               
16 The exposure time of the light sensitive film to the qualitative example blot in Figure 3.10 was ten times longer for 
detection of full-length PPM1E than for detection of PPM1E(1-554) and Į-Tubulin. 
 
Figure 3.11: Endogenous PPM1E expression during 
maturation of hippocampal neuronal culture16. 
Qualitative immunoblot detected with anti-PPM1E(AGC) 
and anti-Į-Tubulin antibodies. DIV: day-in-vitro. 
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PPM1E, although its levels are considerably lower16. The ratio between PPM1E and 
PPM1E(1-554) does not change significantly during the maturation. 
3.2.2 Cellular and sub-cellular localization of endogenous PPM1E  
It was previously reported that day-in-vitro (DIV) 6 rat primary hippocampal neurons 
show a different distribution of PPM1E expression than the majority of human brain 
neurons, including those in the hippocampal CA1 region (Kitani et al., 2006). The 
PPM1E expression is neuron-specific and cytoplasmatic in most neuronal brain 
populations, but enriched in the nucleus in primary hippocampal neurons on DIV 6 
(Kitani et al., 2006). To understand why PPM1E shows different localization in these 
neurons, the sub-cellular localization of PPM1E was investigated in this study. 
 
3.2.2.1 Localization of PPM1E in human frontal cortex 
Co-detection with NeuN revealed that PPM1E is enriched in neuronal soma also in the 
human frontal cortex samples which were investigated in the present study (Figure 
3.12). This observation confirmed data from Kitani et al. (2006). The PPM1E levels in 
nuclei are considerably lower, as shown by co-labelling with the DNA binding marker 
DAPI (4',6-diamidino-2-phenylindole) (Figure 3.12, arrowheads). Additionally anti-
PPM1E(ENS) detects small globular structures in between the neurons which are 
described in further detail below17. These are visible as diffuse stain in lower 
magnification (Figure 3.12). 
 
NeuN                                 PPM1E                             merge with DAPI 
 
Figure 3.12: PPM1E is co-localized with the neuronal marker NeuN in 
human brain. Example picture from human frontal cortex, Braak 0 donor 93-
105. Merge: anti-NeuN detection red; anti-PPM1E(ENS) detection green; 
DAPI detection blue. Arrowheads indicate nuclei. Scale bar 20 µm. 
 
To analyze whether PPM1E localization does change during the development of 
Alzheimer’s disease as reflected by Braak staging, a subset of the previously described 
brain samples was analyzed. Eight donor samples were picked based on their PPM1E 
                                               
17 see paragraph  3.2.2.5 Co-localization of PPM1E with EAAC1 but not GAD67 in human cortical neurons , page 100 
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protein expression levels, to represent the whole range of expression levels (Figure 
3.13). Frontal cortical samples were co-immunolabeled with anti-PPM1E(ENS) and 
anti-NeuN antibodies and superficial cortical layers were imaged. The superficial 
cortical regions could not be entirely matched due to the restricted availability of brain 
samples. 
 
The localization of PPM1E is not changed in samples of different Braak stages (Figure 
3.13). PPM1E is consistently co-localized with NeuN in healthy brain donors as well as 
in Alzheimer’s disease patients. Higher PPM1E protein levels are not visibly reflected 
by a higher degree of PPM1E(ENS) immunolabeling in these frontal cortex specimen.   
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Occasionally very few cells in human cortex are anti-PPM1E(ENS) but not anti-NeuN 
positive (compare Figure 3.3, arrowheads). However, co-immunolabeling of 
PPM1E(ENS) and glial cells revealed that PPM1E was not present in glial cells of 
human frontal cortex (Figure 3.14). The glia cells were detected with a monoclonal 
antibody directed against GFAP (glial fibrillary acidic protein).  
 
 GFAP                                    PPM1E                                  merge 
 
Figure 3.14: No co-localization between glial cells and PPM1E(ENS) labeling. 
Detection with anti-GFAP and anti-PPM1E(ENS) antibody. merge: GFAP green, 
PPM1E(ENS) red. Scale bar 20 µm.  
 
As described previously, NeuN fails to detect some neurons. Therefore it is not unlikely 
that the cells which are NeuN negative and PPM1E positive might be neurons. 
 
3.2.2.2 Localization of PPM1E in rat hippocampus and cortex 
The investigation of PPM1E expression in rat hippocampus and frontal cortex revealed 
that PPM1E is concentrated in the neuronal soma and weakly also in the nucleus as 
derived from co-immunolabeling with NeuN protein (Figure 3.15). The NeuN protein is 
localized mainly in the nucleus of embryonic neurons and is distributed throughout the 
nucleus and cytoplasm in mature neurons. The co-localization of PPM1E and NeuN is 
conserved in frontal cortex and dendate gyrus (DG) samples. 
 
As described for human frontal cortex PPM1E is also in rat brain samples additionally 
diffusely distributed between neuronal cell bodies (see “background” stain in Figure 
3.15 B). The expression pattern in human and rat brain samples appear to be 
comparable. 
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Figure 3.15: PPM1E is co-localized with the neuronal marker NeuN in rat frontal 
cortex and hippocampal dendate gyrus. PPM1E is enriched in the cytoplasm. 
merge: PPM1E(ENS) green; NeuN red. Cortex: frontal cortex. (B) Zooms from merged 
pictures in Figure 3.15 A. Scale bar (A) 120 µm, (B) 40 µm. 
 
3.2.2.3 Localization of PPM1E during rat embryogenesis 
The distribution of PPM1E during rat embryogenesis was analyzed in immunolabeled 
cryosections. While PPM1E was readily detected with the anti-PPM1E(ENS) antibody 
in E17 specimen, the signal strength was markedly reduced in specimen of earlier days 
of embryonic development E9 and E13 (Figure 3.16, considerably longer exposure 
times for PPM1E in E9 and E13 specimen).  
 
This difference in signal strength confirms the immunoblotting results described above, 
which detected no PPM1E(1-554) or full length PPM1E in specimen taken during early 
embryogenesis on E9. However the comparison of PPM1E expression in E9 embryos 
interestingly showed a distinctly different distribution from E17 and adult rat specimen. 
PPM1E appears diffusely mainly in the cytoplasm and to a minor extend also in the 
nuclei of E9 and E13 neurons, like in the adult rat as described above, while it shows a 
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strong nuclear and diffuse cytoplasmic stain during later stages of embryonic 
development in E17 neurons. 
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 NeuN                                PPM1E                              DAPI 
 
Figure 3.16: Change in PPM1E localization during rat embryogenesis. 
Immunolabeling of cryosections of rat embryonal brain tissue with anti-
PPM1E(ENS) and anti-NeuN antibodies and DAPI. E: day in rat embryogenesis.
Scale bar 20 µm. 
 
3.2.2.4 Localization of PPM1E in rat primary neuronal culture 
The primary dissociated cultures which were investigated in this study were medium-
dense, mixed hippocampal or cortical cultures, which contain neuronal but also glial 
cells (Figure 2.1). Glial growth and mitosis was not inhibited in favour of consistent 
neuronal development: The glial cells improved the growth conditions for neurons and 
supported the establishment of a differentiated neuritic network.  
 
The hippocampal neuronal culture usually appeared healthier for a longer time than 
cortical culture of the same age18. It showed less signs of cell detachment and neurite 
death. Therefore the culturing period was restricted to 17 days-in-vitro (DIV) for cortical 
neurons, while hippocampal neurons were kept in culture for 21 to 22 days. 
 
                                               
18 Primary cortical neurons were cultivated only for the biochemical analysis of PAK phosphorylation in this study. For 
further details see 3.3.3.6 PPM1E affects PAK1 expression but not phosphorylation, page 117. 
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Immunolabeling of mixed rat hippocampal and cortical primary culture showed that 
PPM1E was consistently expressed in all neurons of the primary neuronal culture 
(Figure 3.17).  Neurons were detected with co-immunolabeling of the microtubule-
associated protein 2 (MAP2). Seldom non-neuronal cells showed also PPM1E 
expression, (Figure 3.17 B, DIV 17, green arrow). 
 
 
 
 
 
Figure 3.17: PPM1E translocates from the nucleus to the cytoplasm during 
maturation of dissociated neuronal cultures from rat hippocampus (A) and 
cortex (B). Neurons are labeled by anti-MAP2 antibody detection, nuclei are stained 
with DAPI. Red and white arrows indicate neurons in which PPM1E is enriched in the 
cytoplasm and nucleus respectively. Green arrow indicates a PPM1E(ENS)-positive 
non-neuronal cell. Scale bar 100 µm. 
 
 
A 
B 
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In accordance with the literature PPM1E was mainly located in the nucleus in young 
primary hippocampal and cortical neurons on DIV 3 (Kitani et al., 2006) (Figure 3.17: 
DIV 3). However during culture maturation the localization was gradually shifting in an 
increasing number of cells towards the cytoplasm (Figure 3.17: DIV 10 to DIV 17 / 22). 
During the maturation of cortical neurons this shift in localization occurred usually later 
than in hippocampal cultures. On DIV 17 some cortical neurons still showed nuclear 
PPM1E expression while PPM1E was translocated to the cytoplasm in almost all 
hippocampal neurons by DIV 10. 
 
The distribution of PPM1E was however different between culture batches, in that the 
ratio of nuclear to cytoplasmatic PPM1E on DIV 21 was in some cases almost 1 as 
determined by visual inspection, while in other culture batches, the cytoplasmatic 
fraction of PPM1E was much bigger than the nuclear (e.g. Figure 3.17 A). As 
discussed before additionally the dendritic expression appeared in some culture 
batches in a fragmented and in other in smooth fashion.  
 
The reported differential distribution of PPM1E in intact mature brain tissue and 
dissociated culture is thus abolished in the comparison with mature neuronal cultures.  
 
3.2.2.5 Co-localization of PPM1E with EAAC1 but not GAD67 in human cortical 
neurons 
In addition to the enrichment of PPM1E in the cytoplasm or the nucleus, it has also 
been reported that electron microscopic immunolabeling detects enrichment of the 
phosphatase at the post-synaptic density (Kitani et al., 2006). In cortical tissue, beyond 
and within the borders of the neuronal soma and in dendrites diffuse PPM1E-
containing globular structures are detected as indicated above.  
 
Interestingly, PPM1E was partly co-localized with the high affinity glutamate transporter 
EAAC1 (excitatory amino acid carrier 1) in human frontal cortex (Figure 3.18). EAAC1 
is responsible for re-uptake of the neurotransmitter glutamate from the synaptic cleft.  
EAAC1 is specific for glutamatergic, excitatory neurons and purkinje cells, specifically 
enriched in cortex, hippocampus and caudate-putamen and confined to presynaptic 
and postsynaptic elements. The co-localization of PPM1E and EAAC1 supports the 
results from Kitani et al. (2006) who stated that PPM1E is specifically present in the 
post-synaptic compartment of excitatory, asymmetric synapses. 
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A PPM1E                                 EAAC1                                 merge 
 
B
 
C
 
Figure 3.18: PPM1E is co-localized with EAAC1 in human frontal cortex. merge: 
PPM1E red, EAAC1 green. (C) Arrows indicate co-localization. Scale bar (A) 20 µm, (B) 
10 µm, (C) 4 µm. 
 
However PPM1E was not co-localized with GAD67 (glutamic acid decarboxylase 67-
kDa isoform) (Figure 3.19), which catalyzes the conversion of glutamate to GABA 
(gamma-aminobutyric acid), the principal inhibitory neurotransmitter in the brain (Fong 
et al., 2005). GAD67 is thought to be diffusely distributed through the nerve cell body of 
GABAergic inhibitory neurons and is shown to be targeted to axonal nerve terminals 
and enriched at presynaptic clusters (Kanaani et al., 1999). 
A PPM1E                                 GAD67                                 merge 
 
B
 
C
 
Figure 3.19: PPM1E is spacially close to GAD67 in human frontal cortex. Arrows 
indicate close spatial localization. merge: PPM1E red, GAD67 green. (B, C) Zooms 
are turned 90°counter-clockwise. (C) Arrows indicate close spatial localization of 
PPM1E and GAD67. Scale bar (A) 25 µm, (B) 6 µm, (C) 2.5 µm. 
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PPM1E and GAD67 signals were in some cases spatially very close, which might imply 
that the PPM1E accumulation is not restricted to excitatory synapses, but also present 
in the postsynaptic compartment of inhibitory synapses (Figure 3.19, arrows). 
 
3.2.2.6 Localization of PPM1E in dissociated primary hippocampal neurons 
The resolution of pre- and postsynaptic structures in monolayer culture is considerably 
better than in the investigated brain slices. Therefore possible co-localizations between 
PPM1E and cellular organelles and the association of PPM1E with the post-synaptic 
compartment were closer investigated in dissociated rat hippocampal neurons. 
 
No co-localization between PPM1E and golgi apparatus or ER 
PPM1E is not co-localized with elements of larger organelles like the golgi apparatus or 
the endoplasmatic reticulum (ER), even though the occasionally fragmented dendritic 
localization indicated a possible co-localization with larger cellular organelles (Figure 
3.20 and 3.21). The potential co-localization with golgi apparatus was tested by co-
immunolabeling of PPM1E and GM130, the ‘golgi matrix protein of 130 kDa’ (Figure 
3.20). PPM1E is not present in or associated with the golgi apparatus. 
 
  PPM1E                                 golgi apparatus (GM130)         
 
 merge                                   zoom of merge 
 
Figure 3.20: PPM1E is not co-localized with the golgi apparatus. Co-detection 
with anti-PPM1E(ENS) and anti-GM130. Merge: PPM1E(ENS) green; GM130 red. 
Primary hippocampal cell culture DIV 21. Scale bar 20 µm, zoom: 3.3 µm. 
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A co-localization with the endoplasmic reticulum was investigated by co-
immunolabeling of PPM1E and an antibody against the KDEL tetrapeptide (Figure 
3.21). The sequence KDEL is located at the carboxy-terminus of luminal proteins and 
serves as essential retrieval motif during the sorting of these proteins along the 
secretory pathway. PPM1E is not transported into or associated with the 
endoplasmatic-reticulum (Figure 3.21). 
 
  PPM1E                             endoplasmic reticulum (KDEL) 
 
 merge with DAPI                 zoom of merge 
 
 
Figure 3.21: PPM1E is not co-localized with the endoplasmic reticulum. Co-
detection with anti-PPM1E(ENS), anti-KDEL and DAPI. Merge: PPM1E(ENS) green; 
KDEL red; DAPI blue. Primary hippocampal cell culture DIV 21. Scale bar 12 µm, zoom 
3 µm. 
 
Close spatial localization of PPM1E and synaptophysin in primary neuronal 
culture 
The synaptic localization of PPM1E which was found in cortical brain tissue is 
conserved in primary neuronal culture. Small globular enrichment of PPM1E can be 
found opposed to synaptophysin and localized in close spatial relation to dendritic 
spines of dissociated DIV 21 hippocampal neurons (Figure 3.22). Synaptophysin is a 
characteristically enriched in presynaptic vesicles. 
 
As described above the small globular PPM1E enrichment is not restricted to the 
spines, but can also be seen in the dendritic shaft. In some cultures these globular 
structures form clusters within a dendrite, which appear like a fragmented distribution in 
lower magnification (Figure 3.22, merge, zoom 1). 
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 PPM1E                                 synaptophysin                       EGFP 
 
 merge                                    zoom 1 of merge                  zoom 2 of merge 
 
Figure 3.22: PPM1E is spatially closely correlated with synaptophysin and 
dendritic spines. Primary hippocampal cell culture DIV 21, transfected on DIV 7 with 
0.2 µg pAAV / PPM1E and / EGFP. Merge: EGFP green; synaptophysin blue, PPM1E 
red. Scale bar 45 µm, zoom 1: 9 µm, zoom 2: 3 µm.   
 
Co-localization of PPM1E with mitochondria in dendritic shaft  
Due to the globular structure of PPM1E agglomerations the co-localization with 
mitochondria was investigated. Indeed, the sites of PPM1E enrichment in dendrites 
overlap with sites of COXII (cytochrome oxidase subunit II) accumulation (Figure 3.23). 
COX catalyzes the reduction of oxygen to water in the respiratory chain and is localized 
in the inner mitochondrial membrane. 
A  F-actin                    mitochondria (COXII) PPM1E                    merge 
 
B 
zo
om
 
 F-actin                   mitochondria (COXII) PPM1E                     merge 
 
Figure 3.23: PPM1E is co-localized with the mitochondrial protein COXII and not 
enriched at sites of F-actin accumulation in DIV 21 dissociated hippocampal 
neurons. Immunolabeling with anti-PPM1E(ENS) and anti-COXII antibodies and 
phalloidin (F-actin labeling). Merge: PPM1E green; COXII blue; F-actin (phalloidin) 
red. Scale bar 50 µm, (B) zoom: 12 µm.   
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All three proposed target kinases of PPM1E are regulators of the actin cytoskeleton. 
Therefore the distribution of F-actin and PPM1E were compared. In the same culture 
the co-immunolabeling of F-actin with phalloidin showed that no accumulation of 
PPM1E at F-actin-rich sites was detected (Figure 3.23). 
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3.3 Effects of PPM1E in vitro and in primary neuronal culture 
3.3.1 Eukaryotically expressed PPM1E exhibits phosphatase activity in vitro 
The activity of PPM1E was determined previously in vitro in a cell-free system for rat 
but not for human PPM1E (Takeuchi et al., 2001). Therefore, and to enable future 
screens for PPM1E inhibitors, the activity of human PPM1E, encoded by NM_014906, 
was analyzed in an in vitro phosphatase assay.  
 
His_hPPM1E protein expression, purification and activity determination.  
The phosphatase was expressed in the Spodoptera frugiperda cell line Sf9 with an 
amino-terminal His-tag (Figure 3.4, lane 12). PPM1E was also expressed in different 
E.coli strains, but although the proteins solubility, size and truncation were identical in 
immunoblots, the protein was inactive (data not shown). His-PPM1E containing protein 
lysates were harvested from Sf9 cell culture 72 h after induction of expression. His-
PPM1E was then purified with Ni-NTA affinity chromatographic columns in 
physiological pH values and salt concentrations. The resulting purity of His_PPM1E 
was approximately 80% as judged from Coomassie-stained gel electrophoresis (data 
not shown). Subsequently tested size-exclusion chromatography led to a higher purity 
of PPM1E (compare: “Expression, purification and characterisation of PPM1E and 
PPM1F”, Bachelor’s Thesis D.Siebert, excerpt in Appendix A 8). 
 
The design of the phosphatase activity 
assay was based on an established assay 
for PPM1E (Takeuchi et al., 2001) and 
adapted to a 96-well medium-throughput 
screening format. The assay made use of a 
phosphorylated target peptide and the 
detection of phosphate released from this 
peptide.  
The peptide contains a phosphorylated 
threonine (pT) and has a length of 12 
amino acids YGGMHRQEpTVDC. These 
mimick the CaMKIIĮȕ autophosphorylation 
site around threonine 286/287. The peptide was readily dephosphorylated after 30 min 
incubation at 30°C by increasing concentrations of purified His_PPM1E as indicated by 
 
Figure 3.24: Dephosphorylation of the 
peptide YGGMHRQEpTVDC by 
increased concentrations of purified 
His_PPM1E. 
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increased amounts of inorganic phosphate (Figure 3.24). In this assay inorganic 
phosphate is detected by its binding to molybdate, which then complexes in the 
solution with malachite green. This complex has an peak absorption at 620 nm. Ideal 
peptide concentrations were determined by titration. The half maximal effective 
concentration (EC50) for PPM1E in this activity assay is 180 nM.  
 
3.3.2 PPM1F levels do not compensate for PPM1E overexpression 
The endogenous expression of the closest PPM1E homolog PPM1F was monitored in 
primary hippocampal neurons which ectopically expressed PPM1E, to detect potential 
compensatory effects in the cells. Mature DIV 17 hippocampal neurons showed no 
difference in their PPM1F expression after 10 days of ectopic PPM1E expression and a 
visibly increased PPM1E expression (Figure 3.25). Therefore the effects of ectopic 
PPM1E expression on PPM1F were not investigated further. 
  EGFP                                    PPM1E                                 PPM1F     
 
Figure 3.25: PPM1F expression is independent from PPM1E expression under 
experimental conditions. DIV 17 hippocampal neurons, transfected with 0.2 µg 
pAAV / EGFP and pAAV / PPM1E each on DIV 7. Immunolabeling with anti-
PPM1E(ENS)- and anti-PPM1F-antibodies and DAPI. Scale bar 50 µm. 
3.3.3 Dephosphorylation of downstream kinases in primary neuronal culture 
Three target kinases for the PPM1E phosphatase activity have been proposed 
(Takeuchi et al., 2001; Koh et al., 2002; Kitani et al., 2003). However, the PPM1E 
activity on PAK1 at threonine 422 has been suggested indirectly on the basis that the 
closest homolog PPM1Fdephosphorylates PAK1 in vitro, and that PPM1F and PPM1E 
both are able to inhibit PAK1 induced stress-fiber formation and Cdc42-based PAK1 
activation in HeLa19 and COS-7 cells (Koh et al., 2002). Also the dephosphorylation of 
CaMKIV and a phosphopeptide modelled after the CaMKII phosphorylation site has 
been shown in vitro (Takeuchi et al., 2001). However for none of the kinases it was 
shown that PPM1E is able to dephosphorylate them in a neuronal cellular model. In 
                                               
19 HeLa was the first human cell line and was derived from a cervical cancer from the patient Henrietta Lacks in 1951.  
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this study rat primary neuronal culture was employed as a relatively simple but 
sufficiently complex cellular model to analyze whether PPM1E actively 
dephosphorylates CaMKIV, CaMKII and PAK1. 
 
3.3.3.1 Design and expression of PPM1E activity mutants 
Design of PPM1E mutants 
Functionally inactive single-amino acid mutants of PPM1E were employed as negative 
controls, where it was possible, in the following experiments. Thereby the possibility 
that effects of PPM1E overexpression are caused by mechanisms other than the 
phosphatase activity of PPM1E was excluded.  
 
The exchanged amino acids arginine 241 and aspartate 479 are highly conserved in 
the PP2C family of phosphatases (Jackson et al., 2003;Kusuda et al., 1998) (Figure 
3.26). The mutated sites were chosen analogue to previously described single amino 
acid exchanges in the PPM1E homolog PPM1F (Tada et al., 2006). The resulting 
PPM1E mutants R241A and D479N correspond to the previously characterized PPM1F 
mutants R162A and D400N, which are inactive in vitro, and to the amino acids arginine 
33 and aspartate 282 in PP2CĮ (Figure 3.26; Appendix A 1). The PP2CĮ X-ray model 
by Das et al. (1996)  predicts that both residues are part of the active phosphatase site. 
The active site of PP2CĮ is composed of several invariant amino acids in the PP2C 
family of phosphatases, which may serve as metal-coordinating and phosphate-binding 
residues and as a general acid during catalysis. Arginine 241 (R162 in PPM1F; R33 in 
PP2CĮ) is thought to be an inorganic phosphate-binding residue and aspartate 479 
(D400 in PPM1F; D286 in PP2CĮ) may coordinate two divalent ions in the active 
center (Das et al., 1996). 
 
 
Figure 3.26: PPM1E activity mutants. Schematic view of the PPM1E protein, 
including the location of point mutations. PP2C phosphatase and E/Fhd domains 
shaded in grey, N: nuclear localization signal. ARHGEF binding site is indicated. 
Arrows indicate the location of single amino acid mutations in the PPM1E 
phosphatase. 
 
 
RESULTS - 3.3 Effects of PPM1E in vitro and in primary neuronal culture 
 
109 
 
Expression of PPM1E activity mutants 
Transient expression of PPM1E and the activity mutants in HEK cells confirmed that 
the mutants are truncated in the same manner as the active phosphatase (Figure 3.27 
B). Moreover, after transfection of dissociated hippocampal neurons PPM1E and the 
PPM1E mutants are all mainly expressed in the cytoplasm and in neurites (Figure 3.27 
A). The levels of the expressed proteins were comparable for PPM1E mutants and 
PPM1E transfected neurons. The expression of PPM1E and the mutants appeared in 
some cultures fragmented in the neurites (see Figure 3.27 A, expression of PPM1E 
and PPM1E(R241A)). However this fragmented distribution of PPM1E in the dendrites 
was not conserved in all experiments as discussed above. 
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Figure 3.27: Expression of PPM1E and the activity mutants Myc_PPM1E(R241A) 
and Myc_PPM1E(D479N). (A)  Dissociated hippocampal neurons on DIV 21, 
transfection on DIV 7. (B) Truncation of PPM1E and the activity mutants 
Myc_PPM1E(R241A) and Myc_PPM1E(D479N) in HEK cells after transfection. Scale 
bar 60 µm. 
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3.3.3.2 PPM1E overexpression in neuronal culture with rAAV  
The relative phosphorylation of CaMKII/IV and PAK1 was analyzed in rAAV_PPM1E 
infected primary neuronal cell culture and normalized to the total expression of the 
respective kinase. For this biochemical analysis primary hippocampal neurons were 
infected with recombinant adeno-associated viruses (rAAV) on DIV 7 and cellular 
lysates were analyzed on DIV 21. PPM1E or EGFP are expressed under control of the 
neuron-specific promoter for human synapsin (hSYN) which induces exclusively 
neuronal expression (Kügler et al., 2003).  The expression of EGFP-encoding rAAV 
became gradually visible 48 hours after viral infection and did reach comparable 
protein expression levels achieved by transfection as judged from visual inspection of 
EGFP autofluorescence (Figure 3.28 A). 72 hours after infection of neurons, the 
expression of the desired gene was detected in all neurons that means that the number 
of target gene expressing neurons is considerably higher than after transfection (Figure 
3.28 A). 
A 
 
   
   
   
 D
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pAAV / EGFP transfected    rAAV / EGFP infected 
 
B 
 
Figure 3.28: Efficiency of rAAV induced protein expression. (A)  Representative 
example pictures of EGFP autofluorescence, demonstrating the transfection and rAAV-
infection efficiency in medium-dense DIV 14 neuronal culture. Transfected / infected on 
DIV 7 with 0.2 µg pAAV / EGFP or 3*108 Dcvp per 1.9 cm2 culture. (B) Overexpression 
of the encoded protein in dissociated hippocampal cell culture after infection with 
respective rAAVs on DIV 7 with 3*108 or 6*108 (2x) Dcvp per 1.9 cm2 culture. Dcvp: 
DNA-containing viral particles. (A) Scale bar 200 µm. 
 
Purified viral vectors were able to induce a high overexpression of PPM1E or other 
encoded genes, in a rAAV-concentration dependent manner (Figure 3.28 B). The 
mutant PPM1E(R241A) was used as negative control for rAAV / PPM1E expression 
and also in this context the mutant was truncated in the same manner as the active 
phosphatase (Figure 3.28 B). 
 
RESULTS - 3.3 Effects of PPM1E in vitro and in primary neuronal culture 
 
111 
 
3.3.3.3 Immunoblot quantification of protein levels 
To analyse the PPM1E 
effects on the target 
kinases, five- to three-step 
dilution series of cell 
lysates were blotted on 
PVDF membranes and 
detected quantitatively with 
fluorescently labelled 
antibodies as described 
above for the detection of 
PPM1E levels in human 
brain samples (compare 
also Figure 3.29 A). This 
relatively laborious method 
was chosen because 
standard 
chemiluminscence 
detection allows only a 
snapshot of the enzymatic 
detection reaction and is 
therefore highly dependent 
on timing and exposure 
and not suitable for quantitative Western blot detection (Gassmann et al., 
2009;Dickinson and Fowler, 2002). The dynamic range, in which the signal is directly 
proportional to the amount of target is very limited. Compared to this standard detection 
the quantitative detection used in this study offers two advantages which broaden the 
dynamic range of detection: Firstly the samples are loaded in dilution series, which 
compensates for expression differences between different samples on the same blot 
and inter-experiment variation, and secondly the detection with antibodies which are 
conjugated to a fluorophor offers inherently a more stable signal than the detection 
through an enzymatic reaction. 
 
From fluorescence scans the signal intensities for CaMKII, phosphoCaMKIIĮȕ 
(threonine 286/7), CaMKIV, phospoCaMKIV (threonine 196), PAK1 and phosphoPAK 
(threonine 423) were quantified with ImageJ software. The signals were plotted with 
 
 
 
Figure 3.29: Reduction of CaMKIIĮ and ȕ 
phosphorylation in dissociated wt and PPM1E 
overexpressing cortical neuronal cell culture. (A) 
Example blots for PPM1E overexpression and CaMKII 
phosphorylation. (B) Examples for plotting of signal 
intensities  of phosphorylated CaMKII, measured with 
ImageJ.  DIV 21 neurons, infected on DIV 7. wt: 
uninfected, wildtype neurons; au: arbitrary units. 
RESULTS - 3.3 Effects of PPM1E in vitro and in primary neuronal culture 
 
112 
 
Microsoft® Office Excel® (Figure 3.29 B), and those in the dynamic range were 
averaged and normalized to similarly derived housekeeping protein levels.  
 
Exemplified, an immunoblot for the quantitative detection of PPM1E and 
phosphorylated CaMKII Į and ȕ isoforms (threonine 286 and 287 respectively) is 
shown (Figure 3.29 A). The isoform CaMKIIȕ with about 57 kDa and the isoform 
CaMKIIĮ with about 50 kDa are both detected by this phosphorylation-specific antibody 
(Figure 3.29 A, lower blot).   
 
These loaded cell extracts are derived from DIV 21 hippocampal culture infected rAAV-
EGFP or with rAAV-PPM1E and are analysed in dilution series between 15 and 0.9 µg 
per lane. Densitrometric quantification of the bands with ImageJ shows a weaker 
phosphorylation of CaMKIIĮ as well as of CaMKIIȕ in this experimental batch of 
PPM1E overexpressing cells (Figure 3.29 B).  
 
In the following analyses the characterized protein or phosphorylation level were 
normalized against equally derived values for the expression of a ‘housekeeping 
protein’, either cyclophilin B or GAPDH (glyceraldehyde 3-phosphate dehydrogenase). 
All three are highly abundant, consistently expressed proteins and thus suitable for the 
normalization. 
 
3.3.3.4 PPM1E affects CaMKIIĮ expression and potentially its phosphorylation at 
T286 
The large-scale analysis of PPM1E effects on CaMKII was focussed on the isoform 
CaMKIIĮ for simplification. However, initial experiments did not show a difference in the 
influence of PPM1E on the Į- or the ȕ-CaMKII isoform (compare immunoblot example 
in Figure 3.29).  
 
The values for CaMKIIĮ phosphorylation and expression were normalized to the levels 
of the GAPDH protein (Figure 3.30 A).  The variability between the experiments was 
high, which is a relatively common problem in the analysis of primary neuronal culture 
(Chen et al., 2008;Maximov et al., 2007). Therefore all derived values were additionally 
normalized to the wildtype values of the same culture batch. 
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A     Blot phospho-CaMKIIĮ and CaMKIIĮ 
 
 
 
B                      CaMKIIĮ  
phosphorylation & protein levels 
 
C               phospho-CaMKIIĮ /  
CaMKIIĮ protein levels 
[Excerpt from data in B] 
 
D   phospho-CaMKIIĮ & protein levels     
           with PPM1E mutant R241A 
[Partically an excerpt from data in B] 
 
 
E             mRNA levels of CaMKIIĮ  
Figure 3.30: Influence of ectopic PPM1E expression on CaMKIIĮ expression and 
phosphorylation in primary hippocampal culture. (A) Quantitative example blot, 
detected with anti-CaMKIIĮ- or -phospho CaMKIIĮ- and -GAPDH-antibody, with 5-step 
dilution series of wt and rAAV-PPM1E infected hippocampal culture (infection with 
3*108 Dcvp rAAV / PPM1E). (B) Quantitative changes in CaMKIIĮ phosphorylation and 
expression in wildtype and rAAV-PPM1E infected hippocampal culture expressed as 
% of wildtype. n=6 (C) Quantitative phospho-CaMKIIĮ / CaMKIIĮ levels. n=6 (D) 
Quantitative changes in CaMKIIĮ phosphorylation and expression in wildtype, rAAV-
PPM1E and -PPM1E(R241A) infected hippocampal culture expressed as % of wt. n=5 
(E) CaMKIIĮ mRNA levels, normalized against cyclophilin B (PPIB). n=6 from one 
experiment. Horizontal bars represent the median. Mature neurons (between DIV 17 
and DIV 21) infected on DIV 7. wt: wildtype culture. pCaMKIIĮ: CaMKIIĮ 
phosphorylated at threonine 286. Statistical test: Wilcoxon matched pairs test, 95 % 
confidence interval (no significance for any of the above experiments). 
RESULTS - 3.3 Effects of PPM1E in vitro and in primary neuronal culture 
 
114 
 
The phosphorylation of CaMKIIĮ at threonine 286, normalized to total CaMKIIĮ levels, 
showed a trend towards a reduction in PPM1E overexpressing hippocampal compared 
with wildtype culture. The median of six experiments was 21.4 % lower than that of 
wildtype (Figure 3.30 B, C). However, this was a result from a slight increase in the 
median level of CaMKIIĮ phosphorylation (8.7 %) and a considerable increase in the 
median of the total CaMKIIĮ expression (20 %) (Figure 3.30 B). The number of 
experiments which could be conducted was limited, therefore it has to be noted that no 
significant change was be determined between wildtype and ectopically PPM1E 
expressing cultures.  However, the trend towards a changes CaMKIIĮ expression in 
ectopically PPM1E expressing cultures was not present in PPM1E(R241A) expressing 
cultures (Figure 3.30 D). PPM1E(R241A) expressing hippocampal cultures show a 
similar deviation of the median, although in the opposite direction,  from the wildtype 
levels in respect to phosphorylation of CaMKIIĮ, but they do not have an effect on total 
CaMKIIĮ expression. This indicates that ectopic PPM1E expression might have an 
effect on CaMKII expression rather than on phosphorylation. 
 
Ectopically PPM1E expressing primary hippocampal cultures were also analysed for 
their CaMKIIĮ mRNA levels and interestingly they are increased by trend compared to 
wildtype (Figure 3.30 E), providing potentially a basis for the same trend on the protein 
level. 
  
Evaluation of CaMKIIĮ phosphorylation in immunolabeled primary neurons 
To get a better impression of – potentially only localized – differences in CaMKIIĮ 
phosphorylation and expressen, both parameters were initially also evaluated by 
immonolabeling of transfected cultures in which only single neurons express PPM1E in 
high levels. However, due to the density of the neuritic network, the investigation of 
CaMKII, CaMKIV and PAK and their phosphorylation in detail was not possible, 
because they are all expressed throughout the dendritic and axonal compartment 
(Figure 3.31 A), while PPM1E is only visibly expressed in dendrites. The resolution of 
single dendrites from the surrounding axons in the medium-dense cultures was not 
satisfying. Therefore the analysis was proceeded biochemically. 
 
However, in single cultures a reduction in phosphorylated CaMKIIĮ was visible in 
PPM1E transfected neurons (Figure 3.31). Although the network of pCaMKII(Thr286) 
positive neurites is very dense, the strong reduction became apparent in thicker 
secondary dendrites (Figure 3.31 B, arrows).  
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Figure 3.31: CaMKIIĮ phosphorylation is visibly reduced in secondary dendrites 
which overexpress PPM1E. Mature primary hippocampal neuronal culture, transfected 
on DIV 7 with 0.2 µg pAAV / EGFP and 0.2 µg pAAV / PPM1E per 1.9 cm2 culture. (A) 
EGFP autofluorescence, MAP2 labeling of neurons, pCaMKII(threonine 286) detection. 
Merge: EGFP green, MAP2 blue, pCaMKII(T286) red. (B) Zooms into A on two 
dendrites from a (top) untransfected control neuron and (B) transfected neuron. Merge 
and pCaMKII(T286) labeling. Same colouring as in A. Scale bar (A) 50 µm; (B) 10 µm. 
 
3.3.3.5 PPM1E affects CaMKIV expression and phosphorylation at threonine 196 
CaMKIV expression and phosphorylation was analysed with quantitative immunoblots 
as described for CaMKIIĮ above (Figure 3.32 A). All derived values were normalized to 
GAPDH and subsequently to the wildtype values of the same culture batch because 
the inter-culture variations were high. The phosphorylation of CaMKIV at threonine 196 
normalized against total CaMKIV expression, was significantly reduced in in primary 
hippocampal cultures which ectopically expressed PPM1E (32.8 %, p = 0.0313) (Figure 
3.32 B, C). This was a result of the overall levels of CaMKIV, which were slightly 
increased by trend compared with wildtype levels (10 %) and the phosphorylation of 
CaMKIV which was decreased by trend (27 %) (Figure 3.32 B).  
 
In one experiment the inactive mutant PPM1E(R241A) was tested for its effect on 
CaMKIV expression and phosphorylation. Due to problems in the manufacture of the 
rAAV-PPM1E(R241A), only the limited number of one experiment could be conducted 
and can therefore only deliver a first indication for the reliability of the previous 
experiments. 
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A     Blot phospho-CaMKIV and CaMKIV 
 
B                    CaMKIV  
phosphorylation & protein levels 
C     phospho-CaMKIV / CaMKIV protein  
levels [Excerpt from data in B] 
 
D CaMKIV phosphorylation & protein 
levels with PPM1E mutant R241A 
 
 
 
E              mRNA levels of CaMKIV 
 
Figure 3.32: Influence of ectopic PPM1E expression on CaMKIV expression and 
phosphorylation in primary hippocampal culture. (A) Quantitative example blot, 
detected with anti-CaMKIV- or anti-phospho CaMKIV- and anti-GAPDH-antibody, with 
4-step dilution series of wildtype and rAAV-PPM1E infected hippocampal culture 
(infection with 3*108 Dcvp rAAV / PPM1E). (B) Quantitative changes in CaMKIV 
phosphorylation and expression in wildtype and rAAV-PPM1E infected hippocampal 
culture expressed as % of wildtype. n=6 (C) Quantitative phospho CaMKIV / CaMKIV 
levels. n=6 (p=0.0313, 95 % confidence interval,Wilcoxon matched pairs test) (D) 
Quantitative changes in CaMKIV phosphorylation and expression in wildtype, rAAV-
PPM1E and rAAV-PPM1E(R241A) infected hippocampal culture expressed as % of 
wildtype. n=1 (E) CaMKIV mRNA levels, normalized against cyclophilin B (PPIB). n=6 
from one experiment. (p=0.0260, 95 % confidence interval, Mann-Whitney-U-test) 
Horizontal bars represent the median. Mature neurons (between DIV 17 and DIV 21) 
infected on DIV 7. wt: wildtype culture. pCaMKIV: CaMKIV phosphorylated at 
threonine 196. Statistical test: Wilcoxon matched pairs test, 95 % confidence interval 
(no significance for any of the above experiments). 
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However, the trend towards an increase of CaMKIV expression in ectopically PPM1E 
expressing cultures was not present in the PPM1E(R241A) expressing culture (Figure 
3.32 D). However the phosphorylation of CaMKIV in the ectopically PPM1E expressing 
culture differed a lot from the median of all analysed cultures. Therefore no speculation 
is can be made here with respect to the influence of PPM1E(R241A) on the 
phosphorylation of CaMKIV. 
 
Interestingly the CaMKIV levels are regulated on the mRNA level. Ectopically PPM1E 
expressing hippocampal cultures show a significant increase in CaMKIV mRNA by 47.2 
% compared with wildtype cultures (Figure 3.32 E, p=0.0260). 
 
Overall, the CaMKIV protein levels by trend do not increase as much as those of 
CaMKIIĮ after ectopic PPM1E expression, and additionally the phosphorylation is 
reduced in all experiments. Thus the predicted PPM1E target kinase CaMKIV might 
well be directly dephosphorylated by PPM1E also in primary neurons as proposed for 
other cell types before. However these experiments cannot exclude that the effect is 
only indirectly mediated by ectopic PPM1E expression. 
  
3.3.3.6 PPM1E affects PAK1 expression but not phosphorylation 
In a third approach the effect of ectopic PPM1E expression on PAK was analysed. A 
potential challenge with regard to the p21-activated kinase 1 (PAK1) was that phospho-
specific antibodies against phospho-threonine 423 of PAK1 do also detect PAK2 and 
PAK3. Therefore it is important to note that only one band was observed on the 
immunoblots. However, the rat PAK1, PAK2 and PAK3 have similar predicted 
molecular weights of 60.59, 58 and 60.72 kDa respectively. Therefore PAK2 as well as 
PAK3 could have been detected due to overlap of their bands. However, it has been 
described before that in dissociated cortical cultures PAK1 is the predominant isoform 
of group I PAK kinases (Jacobs et al., 2007). Hence in the following experiments the 
effects of PPM1E on PAK1 were investigated in cortical instead of hippocampal 
dissociated culture. 
 
All derived values were normalized to Cyclophilin B and subsequently to wildtype 
values of the same culture batch to compensate for inter-culture variations. No 
decrease in PAK phosphorylation with increased PPM1E expression was observed in 
DIV 17 primary cortical culture, which was infected with rAAV / PPM1E on DIV 7 
(Figure 3.33). Instead, the median PAK1 expression was by trend lowered (31.5 %), 
whereas the overall median phosphorylation was slightly by trend reduced (9.3 %). 
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This resulted by trend in an overall increase in the phosphorylated PAK / PAK1 ratio 
(33.6 %).  
 
A         Blot phospho-PAK and PAK1  
           
B  PAK1 phosphorylation & protein 
levels 
 
 
Figure 3.33: Influence of ectopic PPM1E expression on PAK1 expression and 
PAK phosphorylation in primary cortical culture. Infection with 3*108 Dcvp rAAV / 
PPM1E (A) by trend decreased the total expression of PAK1, by trend decreased the 
phosphorylation of PAK at threonine 423 and (C) by trend increased the ratio of pPAK 
/ PAK1 to approximately 33.6 % of wildtype level. Horizontal bars represent the 
median. DIV 17 neurons, infected on DIV 7. wt: wildtype culture. pPAK: PAK 
phosphorylated at threonine 423. n=4, from three independent neuronal cultures. 
 
Due to problems in the manufacture of the rAAV-PPM1E(R241A), only the experiments 
could not be repeated with the inactive mutant as control and can therefore only deliver 
a first indication. Although none of the described trends is significant, it is apparent that 
the ectopic PPM1E expression would influence PAK1 differently than expected, from 
previous literature data.  
3.3.4 Increased PPM1E levels reduce mushroom spine density and dendritic 
arborization 
rAAV infected neuronal cultures are unsuited for morphological analyses on single 
neurons because close to 100 % of all neurons are expressing the protein of interest, in 
this case EGFP. The neuritic network would therefore be too dense to differentiate 
between single neurons and to differentiate single spines. Therefore the neuronal 
cultures are instead transfected with the respective construct. 
 
Transfection and co-transfection efficiency in primary neuronal culture  
Most primary neurons are differentiated, post-mitotic cells which cannot be transfected 
as readily as immortalized, mitotic cell lines. However in recent years efficient methods 
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for transfection of primary neurons have been developed. In this study optimized 
protocols for lipid-mediated DNA transfection efficiently transfected around 7 % of all 
neurons in hippocampal culture. Co-transfection of two plasmids encoding different 
proteins led in all examined cultures also to the co-expression of both proteins. 
Transfected neurons showed EGFP autofluorescence after 24 hours.  
 
3.3.4.1 PPM1E has a deteriorating effect on dendritic spines 
To examine the effects of increased PPM1E levels on neurogenesis and synaptic 
plasticity, the spine number and morphology was evaluated in primary rat hippocampal 
neuronal cultures, which were transfected on DIV 7 and analyzed on DIV 21. EGFP 
was co-expressed with all constructs to visualize the dendritic spines. Three-
dimensional, confocal images of the dendrites were deconvolved from z-stacks, and 
the spine number was analyzed with NeuronStudio software with the investigator being 
blind to the transfection condition.  
 
Effects of PPM1E and PPM1E activity mutants on dendritic spine number 
Changes in the spine number between PPM1E and EGFP or PPM1E mutant 
transfected neurons were analyzed semi-automated with the NeuroStudio software and 
the investigator was blind to the transfection condition. 
 
On DIV 21, 14 days after transfection, the mushroom spine density in PPM1E 
expressing cells was severely decreased by 34 % (0.6 µg pAAV / PPM1E per 1.9 cm2 
culture), compared to control EGFP expressing neurons (Figure 3.34 A; p<0.0122). 
The mushroom spines are believed to have the greatest synaptic capacity (Ethell and 
Pasquale, 2005). PPM1E did not change the numbers of stubby or thin spines 
significantly. Meanwhile the neurons that were expressing either one of the PPM1E 
mutants (0.6 µg pAAV / PPM1E mutant per 1.9 cm2 culture) did not show a difference 
to the EGFP control neurons in any of the morphologically differentiated groups of 
spines (Figure 3.34 A-C). Thus, effects on dendritic mushroom spines observed 
between the neurons expressing PPM1E and control groups are indeed attributable to 
increased levels of PPM1E phosphatase activity.  
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A                  Mushroom spines 
 
B                     Stubby spines 
 
C                        Thin spines  
Figure 3.34:  PPM1E reduces the number of mushroom spines in hippocampal 
neurons. Ectopic expression of functionally phosphatase-inactive PPM1E mutants 
does not affect the numbers of (A) mushroom, (B) stubby or (C) thin spines on mature 
hippocampal neurons. (A) hPPM1E expressing neurons show a significant decrease 
in mushroom spine number per µm of dendrite compared to EGFP control and 
PPM1E mutant transfected neurons by 34% (p<0.0122), two-tailed Mann-Whitney U-
test. DIV 21 neurons, transfected on DIV 7 with 0.2 µg pAAV / EGFP or 0.6 µg pAAV / 
PPM1E or / PPM1E_mutant construct per 1.9 cm2 culture. n=30 neurons from 3 
independent experiments. D479N: PPM1E(D479N); R241A: PPM1E(R241A). 
 
Effects of PPM1E and inactive PPM1E mutants on spine morphology 
Also the spine length and spine head diameter were determined in the semi-automated 
detection of spines with NeuronStudio software (Figure 3.35). The median head 
diameter is unchanged in all groups of spines between PPM1E expressing and control 
neurons (Figure 3.35 A). Additionally the spine length of mushroom and thin spines is 
consistent between the control groups of EGFP and PPM1E mutant expressing 
neurons. However neurons with increased PPM1E expression show a decrease in the 
length of stubby spines by 11.8 % compared with the group of EGFP transfected 
neurons.  
 
In summary, PPM1E has a deteriorating effect on mushroom spine number and the 
group of stubby spines is shorter than spines in control groups.  
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A                         Head diameter B                       Spine length 
 
Figure 3.35: Effects of EGFP, PPM1E and PPM1E(D479) expression on the (A) 
head diameter and (B) the spine length on hippocampal neurons. Effects on 
mushroom, stubby or thin spines. Statistical test and p-values derived with two-tailed 
Mann-Whitney U-test. DIV 21 neurons, transfected on DIV 7 with 0.2 µg pAAV / EGFP 
or 0.6 µg pAAV / PPM1E or / PPM1E_mutant construct per 1.9 cm2 culture. n=30 
neurons from 3 idependent experiments. ** significance p=0.0042, reduction of stubby 
spine length by 11.8 %. 
 
3.3.4.2 PPM1E effect on dendritic spines is concentration-dependent 
To support these results, three levels of ectopic PPM1E expression were induced in 
hippocampal neurons to evaluate whether the deteriorating on mushroom spines in 
concentration-dependent. The number of spines was evaluated manually and the 
investigator was blind to the transfection conditions. 
 
Indeed the number of mushroom spines was reduced by 23%, 47% and 59% 
compared to control neurons, depending on the concentration of pAAV / PPM1E 
plasmid in the transfection (0.2, 0.6 and 0.8 µg pAAV / PPM1E per 1.9 cm2 culture 
respectively; Figure 3.36). Again the variability between cultures was high as visible 
from large deviations from the median. 
 
The neurons which were transfected with the highest concentration of PPM1E showed 
additionally a considerably increased number in filopodia-like long protrusions without 
spine head (not shown). These were not included in the evaluation. 
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3.3.4.3 Effects of PPM1E and inactive PPM1E mutants on dendritic arborization 
The putative PPM1E target kinase CaMKIV was reported to affect dendrite outgrowth 
in neurons (Takemura et al., 2009). Therefore the dendritic arborisation in PPM1E and 
PPM1E mutant expressing neurons was evaluated. The arborisation of DIV 21 neurons 
which express the PPM1E activity mutants is not affected (Figure 3.37). They show no 
difference compared with the EGFP control group.  
 
  
 
 
 D 
 
Figure 3.36: PPM1E expression decreases the number of mushroom-shaped 
spines in a concentration-dependent manner. PPM1E expressing neurons show a 
significant and concentration dependent decrease in the number of mushroom-shaped 
spines per µm dendrite compared to EGFP control neurons. DIV 21 neurons, 
transfected on DIV 7 with (A) 0.2 µg, (B) 0.6 µg and (C) 0.8 µg pAAV / PPM1E per 1.9 
cm2 culture. n=30 neurons from 3 independent experiments. Reduction of mushroom-
shaped spines compared to control (A) 23% (p=0.0178), (B) 34% (p=0.0122), (C) 59% 
(p=0.0001), two-tailed Mann-Whitney U-test. (D) example pictures from dendrites 
transfected with (D) EGFP and PPM1E. EGFP autofluorescence. Scale bar 4 µm. 
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Although it was shown that PPM1E is enriched at the postsynaptic density (Kitani et al., 
2006 and above), PPM1E is ubiquitous in the cytoplasm of mature neurons in the brain 
and in primary neuronal culture and might therefore affect additional molecules, like the 
proposed PPM1E target kinase CaMKIV. Since CaMKIV regulates neuritogenesis 
potential effects of PPM1E on neuritic arborisation were investigated.  
 
Densely seeded hippocampal primary neurons (40 000 / 0.9 cm2) were transfected with 
PPM1E on DIV 7 and analyzed on DIV 17 and DIV 21. The number of primary 
dendrites branching off from a neuronal soma (roots) and the total length of neurites 
were determined. The dendritic arborisation was evaluated in a semi-automated 
manner with the ‘Neurite’ script (Acapella). 
 
The number of roots and neurites in PPM1E overexpressing neurons is reduced by 
30.7 % and 36.7 % respectively, as described above (Figure 3.37, compare also 
independent experiments in Figure 3.38). 
 
 A  
 
EGFP                       PPM1E                     R241A                      D479N 
 
 B             Mean total neurite length  C               Mean number of roots 
Figure 3.37: PPM1E activity mutants have no influence on the arborization of 
primary hippocampal neurons. (A) Example pictures. Scale bar 60 µm. (B) Mean 
number of roots (= primary dendrites). (C) Mean total neurite length. Each dot 
represents the mean from 17 pictures from one culture well. Horizontal bars represent 
the median. Reduction compared to EGFP control after transfection of 0.1 pAAV / 
PPM1E per 0.9 cm2: Roots: 30.7%. Mean total neurite length: 36.7 %. Statistical test 
with Mann-Whitney-U-test. Transfection with  0.1 µg pAAV / EGFP and 0.3 µg of pAAV / 
PPM1E, / PPM1E(R241A) or /PPM1E(D479N) on DIV 7 per 0.9 cm2 hippocampal 
culture on DIV 7. Analysis on DIV21. n=20, from 2 independent experiments. 
 
RESULTS - 3.3 Effects of PPM1E in vitro and in primary neuronal culture 
 
124 
 
3.3.4.4 PPM1E effect on neuritic arbour is concentration-dependent 
Additionally the effects of PPM1E on the number of primary dendrites and the total 
neurite length are strengthend with increased PPM1E expression (Figure 3.38). This 
effect is dependent on the amount of transfected pAAV / PPM1E and the maturity of 
the culture. Two different culture ages were tested to analyse whether the effect is 
rather an outgrowth-inhibiting or retraction-promoting effect. Interestingly at DIV 17 no 
significant differences in the number of roots and the mean total neurite length can be 
found, wheras the neurite length appears to be slightly reduced. Analysis on DIV 21 
revealed that PPM1E expression has a concentration-dependent negative influence on 
the number of roots (Figure 3.38 A). These are reduced by 20 % and 38 % after 
transfection of 0.2 µg and 0.8 µg pAAV / PPM1E per 1.9 cm2 culture. Moreover the 
PPM1E expressing neurons also had a by 25 % and 40 % shortened neuritic arbor 
than control neurons respectively (Figure 3.38 B). 
 
  
Figure 3.38: PPM1E overexpression significantly and concentration-dependent 
reduced the number of roots and the total neurite length. Transfection with 0.1 µg 
pAAV / EGFP and 0.1 µg or 0.4 µg of pAAV / PPM1E on DIV 7 per 0.9 cm2 
hippocampal culture on DIV 7. Analysis on DIV 17 or 21. n>22, from three 
independent experiments. Each dot represents the mean from 17 pictures from one 
culture well. Horizontal bars represent the median. Reduction compared to EGFP 
control after transfection of 0.1 µg and 0.4 µg pAAV / PPM1E per 0.9 cm2: Roots: 20 % 
and 38 % (p=0.0002 and <0.0001) respectively. Mean total neurite length: 25 % and 
40 % (p=0.0007 and <0.0001) respectively. Statistical test with Mann-Whitney-U-test.   
 
PPM1E overexpression clearly decreases the branching in the neuronal arbour at DIV 
21. However, PPM1E overexpressing neurons at DIV 17 show no reduction in roots or 
neurite length (Figure 3.38), hence this effect has its onset between these culture days. 
It might be facilitated by increase of the neurite retraction mediated through PPM1E.  
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3.3.5 Down-regulation of PPM1E with RNA interference affects spines and 
dendritic arborization  
RNA interference is a powerful tool for the down-regulation of endogenous protein 
expression. However, in silico designed short hairpin RNAs (shRNA) can have 
unexpected side effects (Alvarez et al., 2006). These can be due to reactivity with other 
genes than the target gene or to overburdening of the endogenous micro RNA 
processing machinery. Therefore several shRNAs which were directed against PPM1E 
and two control shRNAs were tested for their down-regulation efficiencies and 
secondary effects on primary neurons. 
 
3.3.5.1 Validation of shRNA constructs against rat PPM1E 
The knock-down efficiencies of shRNA constructs which targeted rat PPM1E (rshRNA) 
were assessed by co-expression of rat PPM1E and shRNAs in a HEK cell line under 
control of the mammalian CMV and H1 promoters respectively, because no cell line 
was identified which expresses considerable amounts of endogenous rat PPM1E as 
described above. One scrambled shRNA sequence (scram_shRNA) (Vlachos et al., 
2009), and one shRNA directed against human PPM1E (hshRNA4) with similar 
nucleotide composition to rshRNA4 served as control constructs. All plasmid constructs 
for shRNA expression also encode the EGFP protein, hence positive transfection of a 
neuron could be concluded from EGFP autofluorescence. Scram_shRNA had no effect 
on rat PPM1E expression in HEK cells (data not shown), however this scrambled 
shRNA obviously had deteriorating effects on the vitality of transfected neurons. Very 
few transfected neurons survived until DIV 21 and those showed a weak and 
fragmented expression of the co-expressed EGFP protein (Figure 3.39 A). Therefore 
hshRNA4 was employed as negative control in the following experiments.   
 
In HEK cells the transfection efficiency was – in contract to transfection of neurons - 
high enough to enable evaluation of the rat PPM1E levels through immunoblotting 
(Figure 3.39 B). The shRNA constructs rshRNA4 and rshRNA6 were directed against 
the rat PPM1E mRNA sequence and efficiently lowered the PPM1E expression while 
the control construct hshRNA4 had no effect on PPM1E. 
 
These shRNA constructs were subsequently tested in primary neuronal culture by co-
immunolabeling of endogenous PPM1E and MAP2 (Figure 3.39 C). The shRNAs 
number 4 and 6 against rat PPM1E (rshRNA4 and rshRNA6 respectively) also visibly 
reduced the expression of rat PPM1E (rPPM1E) in primary neuronal cells while the 
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control construct hshRNA4 had no effect on ratPPM1E expression primary neuronal 
culture (Figure 3.39 C). 
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Figure 3.39: shRNA constructs down-regulate the expression of rat PPM1E. (A) 
Fragmented EGFP autofluorescence induced by co-expression of a scrambled shRNA 
construct. (B) Transient co-expression of different shRNAs with rat PPM1E in a HEK 
293 GP cell line. Scale bar 10 µm. (C) anti-human-PPM1E hshRNA4 has no effect on 
endogenous PPM1E expression in rat primary neurons, while anti-rat-PPM1E 
rshRNA4 and rshRNA6 down-regulate the endogenous PPM1E expression. (A, C) DIV 
21 neurons transfected with 0.2 µg pAAV/EGFP/shRNA per 7.5 * 104 neurons on DIV 
7. Detected with anti-PPM1E(ENS) and anti-MAP2 antibodies. Scale bar: 23 µm. 
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3.3.5.2 Effects of PPM1E down-regulation on dendritic spines 
The endogenous rat PPM1E expression was down-regulated to test which effect the 
reverse regulation of PPM1E had on the spine number. The spine length and spine 
head diameter were determined again in a semi-automated manner with NeuronStudio 
software (Figure 3.40).  
 
Along with the knockdown of PPM1E in single neurons by transfection (0.2 µg pAAV / 
GFP / rshRNA6 per 7.5*104 cells) a significant 38 % increase in stubby spine number 
from 0.37 to 0.51 spines per µm dendrite was determined (Figure 3.40 A). The 
numbers of mushroom and thin spines were not affected. Furthermore, the morphology 
of spines was affected in those neurons in which PPM1E expression was suppressed 
(Figures 3.38 B, C). The head diameter of stubby spines was significantly decreased 
by 13 % and 11 % compared to the control groups of EGFP and hshRNA4 transfected 
neurons respectively (Figure 3.40 B). The length of stubby spines was significantly 
increased by 11 % compared with the control group of EGFP transfected neurons 
(Figure 3.40 C). The length of stubby spine in neurons which express the control 
A                        Spine number B                    Spine head diameter 
 
C                       Spine length 
 
Figure 3.40:  Downregulation of PPM1E 
increases the number and length and 
decreases the head diameter of stubby 
spines in hippocampal neurons. DIV 21 
neurons, transfected on DIV 7 with 0.2 µg 
pAAV  /  EGFP,  /  EGFP  /  rshRNA6  or  /  
EGFP / hshRNA4 per 1.9 cm2 culture. (A) 
Number of spines, (B) head diameter and 
(C) spine length.   n=30 neurons from 3 
independent experiments. Two-tailed 
Mann-Whitney U-test, 95 % confidence 
interval. 
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hshRNA4 was however not comparable with that of the second control EGFP. The 
variance in both control groups was high. The morphology of mushroom and thin 
spines was not affected.  
 
The shRNA4-hPPM1E control shRNA had no influence on the spines number, head 
diameter or length compared to the EGFP transfected control group, thus the effect is 
presumably specifically attributable to loss or reduction of endogenous PPM1E 
expression. 
 
In summary, PPM1E downregulation has a positive influence on the number of stubby 
spines. The resulting group of stubby spines however has a smaller head diameter and 
increased length. 
 
3.3.5.3 Effects of PPM1E down-regulation on neuritic arborisation 
The effects of PPM1E downregulation on dendritic arborisation were investigated in a 
semi-automated manner with the ‘Neurite’ script (Acapella). Surprisingly the 
arborisation of DIV21 neurons was affected by the downregulation of PPM1E in a 
similar magnitude as by PPM1E overexpression (Figure 3.41, compare Figure 3.37). 
 
In this experiment the transfection of two shRNAs against rat PPM1E (rshRNA4 and 
rshRNA6) was compared with EGFP control and PPM1E overexpressing neurons. No 
ineffective shRNA was accompanying, instead the control of the experiment was 
constituted by two shRNAs against the rat PPM1E which would be compared. Both 
shRNA constructs had similar deteriorating effect on the neuritic arbour and reduced 
the number of roots significantly by 35.8 % and 18.7 % and the total neuritic arbour 
length by 39.1 % and 13.2 %. PPM1E overexpression reduced the number of roots in a 
similar magnitude by 24.6 % and the neuritic arbour length by 20.4 %. 
  
Although the down-regulation of PPM1E seems to have a positive influence on spine 
development, in that it increases the stubby spine number, it apparently has a negative 
influence on the stability of the neuritic arbour. 
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Figure 3.41: PPM1E overexpression as well as down-regulation reduce neuritic 
arborization. Transfection with  0.1 µg pAAV / EGFP or 0.1 µg of pAAV / PPM1E, / 
EGFP /rshRNA4 or //  EGFP / rshRNA6 on DIV 7 per 0.9 cm2 hippocampal culture on 
DIV 7. Analysis on DIV21. n=20, from 2 independent experiments. Each dot represents 
the mean from 17 pictures from one culture well. Horizontal bars represent the median. 
Reduction compared to EGFP control after transfection in PPM1E, rshRNA4 and 
rshRNA6 groups: Roots: 20.4 %, 35.8 % and 18.7 % respectively. Mean total neurite 
length: 24.6 %, 39.1 % and 13.2% respectively. Statistical test with Mann-Whitney-U-
test. 
3.3.6 Coexpression of hARHGEF6 had no effect on dendritic spines 
ARHGEFs supposedly enable negative regulation of PAK1 function through PPM1E by 
acting as a molecular linker between PAK1 and PPM1E (Koh et al., 2002). Therefore 
this study tested whether concomitant expression of PPM1E and ARHGEF6 in 
dissociated primary neurons leads to a modulation of the PPM1E induced phenotype.  
 
  
Figure 3.42: Overexpression of ARHGEF6 does not affect the number of spines 
nor does it increase the effect of PPM1E overexpression in mature hippocampal 
neurons. (A) ARHGEF6 expressing neurons show no changes in spine numbers 
compared to EGFP control. (B) PPM1E expressing neurons show a decrease in 
mushroom spine number by 22% (p=0.023) comparable with that of PPM1E alone. DIV 
21 neurons, transfected on DIV 7 with 0.2 µg pAAV / EGFP or (A) pAAV / ARHGEF6 or 
(B) / PPM1E and / ARHGEF6 per 1.9 cm2 culture. (A) n=30 neurons from 3 
independent experiments; (B) n=20 neurons from 2 independent experiments. 
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Moderate overexpression of ARHGEF6 alone from DIV 7 had no effect on the spine 
number in DIV 21 hippocampal neurons (Figure 3.42 A). Subsequently PPM1E and 
ARHGEF6 were co-expressed. Near-equimolar expression with 0.2 µg of both 
constructs per 1.9 cm2 culture resulted in a reduction in mushroom-shaped spine 
number by 22% (p=0.023) compared to 23% by induced by 0.2 µg of pAAV / hPPM1E 
alone (Figure 3.42 B).  The induced changes in spine density did therefore not differ 
from those induced by PPM1E expression alone (compare Figure 3.36 A and 3.42 B).  
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4 DISCUSSION 
The protein phosphatase PPM1E was found to be up-regulated in early Braak stages in 
a screen for genes which are differentially regulated in early Alzheimer’s disease (von 
der Kammer, 2009). PPM1E had not been correlated with neurodegenerative diseases 
before. The brain-specific phosphatase was initially identified as the closest homolog of 
the protein phosphatase PPM1F and described to be a regulator of the kinases 
CaMKII, CaMKIV and PAK1 (Koh et al., 2002;Takeuchi et al., 2001). Consequently, the 
research so far focussed on the influence of PPM1E on these kinases and related 
pathways in-vitro and in eukaryotic cell culture. This study aimed to complement these 
results by focussing on PPM1E properties in the native brain and PPM1E effects in the 
relevant model system of primary dissociated neuronal cell culture. 
4.1 Characterization of PPM1E 
4.1.1 Assessment of differential PPM1E expression is based on well-
characterized human brain samples 
The quality of human brain samples which are available for research has to be critically 
evaluated. Mainly due to a big variability in dissection and treatment protocols the 
quality of many available brain samples is low (Hulette, 2003). This is especially critical 
for mRNA analysis. Therefore the mRNA and protein quality of the samples used in this 
study has been evaluated prior to this study in a careful manner (von der Kammer, 
2009). Although the quality of the human brain samples was satisfactory, this study 
started with the re-evaluation of potential correlations between PPM1E expression and 
different factors which might have been influenced by brain preparation. Others had 
found a correlation between the post-mortem time and the mRNA levels of certain 
groups of genes (Catts et al., 2005). The lack of a correlation of the PPM1E mRNA 
level with the post-mortem time, the pH of the interstitial fluid and the donor age, 
substantiated that the results of a differential PPM1E expression in early Braak stages 
is trustworthy (Figure 3.5).  
 
Moreover, this study determined that the PPM1E(1-557) protein levels are correlated 
with its mRNA levels in a linear manner (Figure 3.9). Although proteins are also 
subjected to specific and unspecific degradation by proteases, they are usually 
considered to be more stable than RNAs. Even if both, PPM1E mRNA and protein 
were subjected to considerable degradation, it would be highly unlikely that protein and 
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mRNA and their normalization factors Cyclophilin B (mRNA) and Į-Tubulin (protein) 
would be degraded in a concerted manner. Thus the correlation of protein and mRNA 
levels of PPM1E further substantiates that PPM1E is involved in or regulated by early 
Alzheimer’s disease development as represented by Braak staging. 
4.1.2 The truncation of PPM1E is conserved in all investigated organisms 
Among the available insight into PPM1E one important point is that PPM1E is C-
terminally truncated in such a manner that two nuclear localization sites are cleaved off 
from the rest of the phosphatase, which then still contains the catalytic domain and also 
N-terminal regions which are presumably required for substrate and cofactor interaction 
(Kitani et al., 2006). Such a truncation offers the very efficient possibility to determine 
the site of PPM1E activity – nucleus or cytoplasm - by cleavage of the protein. 
Therefore this study aimed to gain further insight into PPM1E truncation. 
 
Rat PPM1E is carboxy-terminally truncated after proline 554, which was demonstrated 
by mass spectrometric analysis (Kitani et al., 2006). Rat PPM1E proline 554 is analog 
to proline 557 in the human PPM1E sequence. This study demonstrated vice versa that 
introduced vectors, which encode for full-length human PPM1E or only the truncated 
human PPM1E(1-557), result indeed in expression of proteins which run at the same 
height of approximately 80 kDa in electrophoresis (Figure 3.6). This complements the 
mass spectrometric data and indicates that the truncation mechanism is conserved in 
rat and human PPM1E.  
 
Meanwhile the mechanism of the truncation remains mostly in the dark. Interestingly, 
the truncation mechanism is not restricted to neuronal or even mammalian cells but 
was also found in Sf9 cells and even E.coli cells which ectopically expressed full-length 
PPM1E (Figure 3.4; expression in E.coli not shown). Although others found a 
predominance of the full length PPM1E form in Sf9 cells (Kitani et al., 2006), the Sf9 
cells and expression conditions in this study yielded predominantly truncated PPM1E. 
The truncation mechanism therefore might be either autoproteolytic or dependent on 
the presence of a protease, which is conserved in pro- and eukaryotes. Additionally, 
the mechanism is most likely a truncation on the protein level and does not represent 
the presence of mRNA splice variants because others have shown that only one 
transcript for full length PPM1E is detectable in Northern Blot analysis (Takeuchi et al., 
2001). 
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Both the full-length and the truncated PPM1E run slower in the gelelectrophoresis than 
their actual molecular weight would indicate (Kitani et al., 2006). It has been suggested 
before that this indicates abnormal behaviour of PPM1E on SDS-PAGE (Kitani et al., 
2003). In SDS-PAGE proteins are subjected to a denaturing heating step and then 
saturated with negatively charged SDS molecules according to the protein size. Usually 
thereby a separation of molecules according to their size is facilitated. The slower 
running behaviour of PPM1E and PPM1E(1-557) might for example indicate a reduced 
negative overall charge of both proteins or a denaturation-insensitive complex 
formation with another protein. One structural feature in the PPM1E sequence which 
might contribute to a reduced negative charge is a glutamate-rich, highly acid stretch in 
the N-terminal region of PPM1E (Appendix A 1).  
 
Presumably the truncation of PPM1E regulates whether the phosphatase is transported 
into the nucleus or resides in the cytosol and thereby allows regional distribution of 
PPM1E activity. Here it is interesting to note, that the extend of post-translational 
removal of the C-terminal end differs between cell types (Figure 3.4). The ratio 
between truncated and full length PPM1E is for example greater in COS-7 cells than in 
Sf9 cells (Kitani et al., 2006). The present study found that the ratio is especially 
changed in favour of PPM1E(1-557) in H4 neuroglioma cells, in which no full length 
form is detectable (Figure 3.4). Although others found that PPM1E in the rat brain is not 
detectable in the full length form at all (Kitani et al., 2006), the anti-PPM1E(ENS) 
antibody, which was generated on behalf of this study, was able to detect also the full 
length form of PPM1E in rat brain extracts (Figure 3.10). This indicates that a lack of 
the full length form, in presence of the truncated PPM1E, might be attributable to the 
limited sensitivity of the respective antibody.  
4.1.3 The levels of PPM1E are comparable in R. norvegicus and H. sapiens 
PPM1E(1-557) is in all analysed human and rat brain samples the predominant PPM1E 
form (Figure 3.7). While the variability in the ratio between full length and trunctated 
PPM1E in human brain samples seemed to be high, as determined by visual 
assessment, the direct comparison with adult rat brain samples indicated that human 
and rat PPM1E are comparable in that the truncated form is the predominant form and 
in that the ratio between full-length and truncated PPM1E appears to be in the same 
range.  
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This study analysed sub-samples (~60 mg) from human brain, which were broadly 
classified from the Netherlands Brain Bank (NBB) as frontal or temporal cortex. It is 
therefore possible that intra-cortical differences in the human frontal cortex, might be 
one reason for the apparent variability between the PPM1E/PPM1E(1-557) ratios of 
different donors. Therefore this variability might either indicate that the extent of full 
length PPM1E is highly variable in different areas of frontal cortex, or that the variability 
exists between donors.  
 
No final statement can be made about differences in the absolute levels of PPM1E in 
rat and in human brain specimen, because it cannot be assumed that the anti-
PPM1E(AGC) antibody binds to both proteins with the same affinity. However, the anti-
PPM1E(AGC) antibody was derived to an immunization peptide against the very first 
18 N-terminal amino acids of PPM1E which are identical in rat and human PPM1E 
(Table 2.8 and Appendix A 3). Therefore it is at least likely that the antibody binds to 
both proteins with similar affinity. The same careful assumption can be made for the full 
length and the trunctated form of PPM1E. The statement that the truncated form of 
PPM1E is the predominant one is based on the assumption that the anti-PPM1E(AGC) 
antibody binds to the full-length and the trunctated form with the same affinity. 
However, others have also seen a dominance of the truncated PPM1E form over the 
full-length form with antibodies, which were directed against different antigenic 
sequences in PPM1E (Kitani et al., 2006). It is therefore likely that any statement about 
the ratio between PPM1E and PPM1E(1-557) is not biased due to differential affinities 
of the antibody. 
4.1.4 The PPM1E expression rises during development 
The PPM1E expression in rat embryos on embryonal day (E) 9, 13 and 17 is 
considerably lower than in the adult rat (Figure 3.10). However PPM1E(1-554) 
expression is nevertheless clearly detectable in immunoblot analysis of E17 
hippocampus and other E17 brain samples (Figure 3.10). The PPM1E(1-554) level in 
E13 embryos was lower than that in E17 embryos and no expression could be detected 
on embryonal day 9 (Figure 3.10). It is interesting to note the initial development of 
synapses and dendritic spines was described to fall between the embryonal days E9 
and E10 (Li and Sheng, 2003). 
 
A third anti-PPM1E(AGC) antibody-positive signal was detected in the immunoblots of 
E9 and E13 embryos and in E17 olfactory bulb (Figure 3.10). It has a size of 
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approximately 207 kDa and might therefore correspond to several multimeric variants 
of PPM1E(1-554) or PPM1E. However, no assumptions about the nature of the 
multimer can be made here because the two already existing PPM1E forms and the 
abnormal running behaviour of both forms in SDS-PAGE pose too many potential 
explanations.  
 
Interstingly, in dissociated hippocampal culture no expression of PPM1E(1-554) can be 
found one day after the preparation of the culture from rat E17 hippocampi (Figure 
3.11). This might indicate a reduction in PPM1E expression as a consequence of the 
disruption of the cellular network during culture preparation. This thought finds further 
basis in the fact, that the PPM1E  expression in the neuronal culture rises with 
maturation of the culture considerably. The expression then stays constant 
approximately between day-in-vitro (DIV) 8 and DIV 20. With respect to data from 
Kitani et al. (2006), which showed that PPM1E is accumulated in the postsynaptic 
compartment, it is noteworthy that dissociated neurons exhibit considerably different 
spine morphology during the first week than in more mature cultures: During the first 
week in culture, the majority of dendritic spine-like structures resemble long filopodia 
without synaptic contacts and the majority of synapses are on short stubby-shaped 
spines (Biederer and Scheiffele, 2007;Papa et al., 1995). In contrast, in weeks two, 
three and four of the cultures, headless spines constitute a progressively smaller 
fraction of the population and are, on average, shorter than spines with heads. 
 
For this study much effort was put into establishing reproduceably wealthy dissociated 
cultures. However, as described by others before, it was frequently observed that the 
mature hippocampal cultures started to deteriorate after DIV 21 (Banker and Goslin, 
2002). A rising PPM1E expression was also observed usually at or after DIV 21 (Figure 
3.11). The deterioration in old hippocampal cultures, which is associated with a loss in 
the integrity of the neuritic network and even a progressing detachment of neuronal 
soma from the growth substrate, could have influenced PPM1E expression levels.  
 
Interestingly, a second side project to this study found that the PPM1E expression level 
is also dependent on the growth substrate: PPM1E levels were lower on the favoured 
substrate polystyrol than on glass slides, on which the neuronal network tends to be 
not as well as on polystyrol as determined by visual inspection (Diploma thesis D. 
Kampmann 2010, Appendix A 10).  
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4.1.5 PPM1E changes its localization during development  
PPM1E is localized mainly in the cytoplasm and weakly also in the nucleus in adult rat 
and human neurons (Figures 3.12 and 3.15). This had already been shown by Kitani et 
al. (2006) who also made a detailed analysis of several human brain areas. The 
authors found additionally that very few large neurons of the mesencephalic trigeminal 
and facial nuclei instead showed an accumulation of PPM1E expression in the nucleus. 
This study showed that the cytoplasmic concentration of PPM1E is conserved between 
Homo sapiens and Rattus norvegicus and moreover also in the model system of 
dissociated rat neuronal culture after a certain level of culture maturation has been 
reached (Figures 3.12, 3.15 and 3.17).  
 
Kitani et al. (2006) had proposed on the basis of immunolabeling of young DIV 6 
hippocampal neurons that PPM1E is enriched in the neuronal nucleus. This provided 
the basis for the hypothesis that PPM1E and PPM1F act as nuclear and cytoplasmatic 
equivalents and that the main target kinase for PPM1E is the nuclear CaMKIV. 
Interestingly this hypothesis now will have to be amendet. This study confirmed that 
PPM1E is concentrated in the nucleus of young dissociated neurons and showed that 
this is a temporary phenomenon (Figure 3.17). During maturation of the neuronal 
culture the predominant localization of PPM1E is gradually changed towards the 
cytoplasm. The exact timepoint during maturation and also the extend to which the 
nucleus was depleted of PPM1E, varied between culture batches. Provided that indeed 
CaMKIV and CaMKII are target kinases of PPM1E as proposed by Takeuchi et al. 
(2001) and Kitani et al. (2006), PPM1E would have the chance to dephosphorylate 
both kinases at different timepoints during the neuronal maturation. PAK1 is mainly 
localized in the cytoplasm and can be recruited for example to focal adhesions upon its 
activation and would therefore also be a potential target of PPM1E in later 
differentiation stages of the neuronal culture (Kreis and Barnier, 
2009;Dharmawardhane et al., 1999). 
 
In one aspect, this study was interested in finding out whether this situation in primary 
neuronal culture finds an equivalent in the development of the intact rat brain. It was 
indeed found that PPM1E is enriched in the nucleus of E17 rat brain specimen, in 
contrast to the predominantly cytoplasmatic localization in the adult animal (Figure 
3.16). Although no intermediate ages have been investigated it is reassuring for the 
choice of model system that the young dissociated, cultured neurons show the same 
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PPM1E expression pattern than seen in the embryonic E17 brain of which they were 
prepared. 
 
The detected PPM1E expression in the younger embryonal stages E9 and E13 is very 
weak (Figure 3.10 and 3.16). However it seems that the slight PPM1E expression in 
these ages is not as restricted to the nucleus as on E17. Due to the very weak signal of 
the anti-PPM1E(ENS) antibody no conclusion is drawn from this. More sensitive 
methods like the in situ hybridization of short nucleotides, which are complementary to 
the PPM1E mRNA sequence, to rat embryonic brain samples, might gain reliable 
insight into PPM1E expression in these young embryonal ages in the future. 
 
Although the localization of PPM1E changes with increasing culture maturity, the ratio 
between full length and truncated PPM1E remains largely unchanged as discussed 
above (Figure 3.11). This indicates that the truncation is not the mechanism which 
solely regulates the localization of PPM1E activity. While presumably only the full 
length form of PPM1E can be transported into the nucleus, it has been suggested on 
the basis of cellular fractionates that the truncation can also happen inside the nucleus 
(Kitani et al., 2006). Western blot analysis of cellular fractionates of rat brain 
demonstrated that truncated PPM1E is endogenously also present in the nucleus of 
cells (Kitani et al., 2006). The authors further showed that the full length form of 
PPM1E was found in the nucleus as well as in the cytoplasm.  
4.1.6 PPM1E is enriched in the post-synaptic compartment and at sites of high 
metabolic activity 
It has been suggested that PPM1E is enriched at synaptic sites because electron 
microscopic analyses with anti-PPM1E antibodies showed a stronger signal in the post-
synaptic compartment of dendritic spines in rat hippocampus (Kitani et al., 2006). 
Indeed this localization was conserved in the human brain and in rat hippocampal 
culture: In human frontal cortex small globular sites, which were enriched in PPM1E, 
were co-localized with the high affinity glutamate transporter ‘excitatory amino acid 
carrier 1’ (EAAC1) which is responsible for re-uptake of the neurotransmitter glutamate 
from the synaptic cleft (Figure 3.18). Moreover, PPM1E was not co-localized with the 
pre-synaptic protein GAD67 (glutamic acid decarboxylase 67-kDa isoform) indicating a 
strictly post-synaptic localization also in the human brain (Figure 3.19).  
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The analysis of postsynaptic PPM1E localization was repeated in dissociated neuronal 
culture, to validate the culture further as a suitable model system. Small globular 
enrichment of PPM1E can also be found here opposed to the presynaptic marker 
Synaptophysin and in close spatial correlation with dendritic spines (Figure 3.22). The 
conserved localization of PPM1E in human and rat brain as well as in rat dissociated 
hippocampal culture strengthens the argument that phenotypic effects of PPM1E 
observed in primary culture allow conclusions about potential effects in brain. 
 
To shed light on the cause for the occasionally occurring fragmented expression 
pattern of PPM1E in neurites (compare Figure 3.2), the potential co-localization of 
PPM1E with larger sub-cellular structures was investigated. PPM1E was not found to 
co-localize with endoplasmic reticulum, the golgi apparatus or F-actin. However, sites 
of globular enrichment of PPM1E showed also accumulation of mitochondria (Figure 
3.23). The PPM1E globules are not co-localized with the mitochondria, but merely 
enriched in the same neuritic section. This might indicate that PPM1E is enriched at 
sites of high metabolic activity. Interestingly, growing evidence suggests that 
mitochondrial dysfunction is one of the key intracellular lesions associated with the 
pathogenesis of Alzheimer’s disease (Eckert et al., 2003;Castellani et al., 2002). 
Therefore a potential connection between PPM1E and mitochondrial activity could be 
an interesting research subject for the future.  
 
This study investigated the effects of PPM1E on dendritic spines (see below), therefore 
it has to be stated that mitochondria are rarely found within spines in mature neurons 
but that they are essential for the formation and maintenance of spines and synapses 
(Li et al., 2004). Molecular manipulations, which reduced mitochondria content in 
dendrites, lead to a loss of spines and synapses in primary dissociated hippocampal 
neurons, while an increase in dendritic mitochondria enhanced the number and 
plasticity of spines and synapses (Li et al., 2004). Thus, dendritic mitochondria seem to 
be essential for the support of synapses. 
 
The globular structure of the PPM1E enriched sites in the neuritic compartment 
suggests that PPM1E might be located inside a vesicle. This was not analysed in 
further detail in the current study, however a number of vesicular structures come into 
consideration. For example mitochondria-derived vesicles (MDVs), which have recently 
been shown to transport cargo from the mitochondria to the peroxisomes (Neuspiel et 
al., 2008). Other types of vesicles which might accumulate together with mitochondria 
at sites of high metabolic activity might also be candidates for the PPM1E transport. 
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Life-imaging would enable the researcher to follow the route of PPM1E transport, and it 
will be interesting to investigate in the future whether vesicular structures facilitate the 
transport of PPM1E. 
4.2 Effects of PPM1E 
A gene like PPM1E, which is transcriptionally up-regulated in early Alzheimer’s disease 
could be part of an adaptive answer of the cell to even earlier changes in the brain, but 
could also be involved in the early steps of disease development. In case the gene 
would be up-regulated as part of an adaptive signaling cascade, the gene might have a 
neuroprotective effect or, in contrast, trigger apoptotic cascades. Both effects could be 
protective for the underlying cellular network. In the present study no pro-apoptotic 
effect of PPM1E was observed. Therefore the characterization of PPM1E as potential 
drug target for Alzheimer’s disease continued with the analysis of whether PPM1E is 
neuroprotective or induces Alzheimer-like degenerative phenotypes in primary 
neuronal culture. 
4.2.1 Suitability of rat primary neurons as a model system 
The identification of suitable model systems is a major issue for the Alzheimer’s 
disease research community. Many resources have been spent on the establishment 
of mouse models, and none of them can model the complete Alzheimer’s disease 
phenotype found in humans. This is not surprising because even closer relatives of 
Homo sapiens, like non-human primates, do not develop the whole range of 
Alzheimer’s disease related changes in the brain (Rosen et al., 2009). Thus, the 
dissociated primary neuronal model used in this study has not the pretence to 
investigate more than the concerned PPM1E-mediated pathway of spine- and 
neuritogenesis. Additionally, primary neuronal culture can of course not claim to make 
any predictions of cognitive phenotypes, but can solely draw analogies. 
 
The primary culture is a valid model for the investigation of neuritic arborization and 
spine development. The fact that aspects of PPM1E truncation and localization were 
comparable between the culture and human and rat brain as discussed above, 
strengthens the relevance of the culture in the investigation of PPM1E effects.  
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These considerations are especially important for the investigation of PPM1E because 
the phosphatase is not conserved in Drosophila melanogaster20, another model system 
which is frequently used to analyse neurodegenerative diseases (Cauchi and Van Den 
Heuvel, 2006;Ghosh and Feany, 2004;Muqit and Feany, 2002). Moreover, although 
other members of the putative PPM1E signaling pathway, like dPAK, dPIX and CaMKII, 
are conserved in the fruitfly, ectopic PPM1E expression did not lead to considerable 
phenotypic effects on neuronal development in the fly eye or the central nervous 
system (Appendix A 9). 
4.2.2 Ectopic PPM1E expression affects the expression levels of CaMKIV and 
potentially of CaMKIIĮ and PAK1 
Although three target kinases, CaMKIV, CaMKII and PAK1, have been proposed for 
PPM1E, for none of them the PPM1E activity has been shown in a model in which 
neurodegeneration was investigated. The most relevant in vivo result showed that 
knock-down of PPM1E during zebrafish embryogenesis leads to an increase in 
apoptotic cells in brain and spinal cord (Nimura et al., 2007). This was assigned to the 
regulation of CaMKIV by PPM1E, because it has been found that CaMKIV is important 
for the regulation of apoptotic events (Walters et al., 2002;Wayman et al., 
2000;McGinnis et al., 1998). Moreover, the authors stated that PPM1E significantly 
decreased phospho-CaMKIV in ionomycin-stimulated Neuro2a cells (Nimura et al., 
2007). Ionomycin stimulation of Neuro2a cells leads to an erratic rise of CaMKIV 
phosphorylation. 
 
The in vitro activity of human PPM1E on a phosphorylated peptide modeled after the 
CaMKII phosphorylation site was confirmed in this study (Figure 3.24). Additionally the 
phosphorylation of CaMKIV, CaMKII and PAK1 was investigated with quantitative 
immunoblots in lysates of primary neuronal cultures which ectopically expressed 
considerable amounts of PPM1E (Figure 3.29 to to Figure 3.33). Phosphorylation-
specific antibodies were available for all kinases, although the anti-phosphoPAK 
antibody recognized also other Type I PAKs (PAK2 and PAK3) as discussed below.  
 
A faster investigation of the phosphorylation of the kinases for example by 
immunolabeling of fixed monolayer cell culture was not feasible because all three 
                                               
20 compare sequence alignment with closest homolog of PPM1E (Ppm1-PA) in Drosophila melanogaster in Appendix A 
6. 
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kinases21 were expressed throughout the network of dendrites and axons in mature 
neurons. Meanwhile PPM1E was only visibly expressed in the dendrites. The dense 
axonal meshwork around the dendrites did not allow a proper visualization of the 
extend of phosphorylation in the dendrite (Figure 3.31 for phospho CaMKIIĮ 
immunolabeling). 
 
Surprisingly, quantitative immunoblots of ectopically PPM1E expressing and control 
cultures revealed no significant difference in the phosphorylation level of these kinases 
(Figures 3.30, 3.32 and 3.33). Instead, the expression of the kinases itself appeared to 
be influenced by the PPM1E expression considerably. CaMKIV expression was 
significantly higher on the mRNA level and also by trend increased on the protein level 
in cultures with a higher PPM1E level, whereas the expression of CaMKIIĮ was only by 
trend higher on the mRNA and protein level. The levels of PAK1 were also not 
significantly affected but showed a strong trend toward a decrease on the protein level. 
The overall level of phosphorylated protein was for all three kinases not significantly 
affected, and only for CaMKIV the levels of phosphorylated kinase were significantly 
reduced when they were normalized to the overall expression level of the protein.  
PAK1 is highly related to PAK2 and PAK3 (together they are referred to as Group I 
Pak), with which it shares conserved phosphorylation sites (Bokoch, 2003). PAK1 
phosphorylation was investigated in cortical instead of hippocampal culture because 
others found that PAK1 here is the main PAK species (Jacobs et al., 2007). It can 
therefore validly be claimed that, although the phospho-PAK-specific antibody would 
also recognized PAK2 and PAK3, their contribution can be neglected in this case.  
 
Notably, it can be concluded that the phosphorylation levels of the kinases were clearly 
not as affected as their expression levels. This unexpected effect did however show 
that PPM1E levels do have a severe influence on the investigated pathway. The effects 
on the expression levels of CaMKIIĮ and PAK1 seem contradictory because a rising 
CaMKIIĮ concentration exerts positive influence on the stabilization of filamentous 
actin, while decreased levels of PAK1 could have the opposite effect (compare 
pathway in Figure 1.6). This might indicate a compensatory mechanism of the cell. 
However, both kinases have multiple functions therefore no conclusion can be drawn at 
this point. Moreover, the absolute levels of phosphorylated, active forms were not 
strongly affected for any of the three proposed effector kinases. 
   
                                               
21 Several publications state that CaMKIV is expressed exclusively in the nuclei of brain. However this study observed 
that CaMKIV is located in the nucleus during the first two weeks of a primary neuronal culture and then translocates, 
similar to PPM1E, into the cytoplasm (data not shown).   
DISCUSSION - 4.2 Effects of PPM1E 
 
142 
 
An additional technical problem with the manufacture of highly concentrated adeno-
associated viruses (AAV), encoding the PPM1E activity mutant R241A, interfered in the 
present study with the proper incorporation of equal numbers of negative controls into 
the immunoblot quantification of kinases (Figures 3.30, 3.32 and 3.33). The low yield of 
rAAV_PPM1E(R241A) virus after purification was most likely associated with the vector 
DNA molecule: The virus particle number from the mutant-encoding virus preparation 
was considerably lower in all but one virus preparation than that from PPM1E-encoding 
viruses. Meanwhile the concerned activity mutant constructs were sequenced and did 
not show any nucleotide exchanges. Moreover the concerned constructs led to a 
comparable expression level of the mutants in transfected neurons as determined by 
anti-Myc-tag labelling (Figure 3.27), and the integrity of the PPM1E(R241A) protein is 
not affected as shown in a successful highly concentrated virus preparation which was 
able to induce a high level of PPM1E(R241A) expression (Figure 3.28). This 
preparation and one that was slightly less concentrated were successfully used for a 
number of infections of the neuronal culture (Figures 3.30 D and 3.32 D). 
 
These few successful controls at least indicate that the effects on CaMKIIĮ and 
CaMKIV are true effects. In summary, clearly this study cannot confirm prior data from 
in vitro and cell line experiments, which showed a reduction in phosphorylation of these 
kinases by PPM1E. Rather, a modulatory effect for kinase expression is suggested by 
these results. Surprisingly the trends in expression of CaMKs and PAK1 are 
oppositional, although all three kinases in their active state act as positive stabilizers or 
modulators on the actin cytoskeleton. Most likely, this adaptation of the kinase 
expression could represent a compensatory reaction of the cellular metabolism. This 
would not be surprising in the case of these three kinases because they are all crucial 
for several functions of the cell. For example, PAK1 controls the correct morphology, 
orientation, and radial migration of neurons in the cerebral cortex (Causeret et al., 
2009). CaMKIIĮ and CaMKIV fulfil additional functions in the structural stabilization of 
spines and in the CREB-mediated transcription initiation respectively (Jourdain et al., 
2003;Pratt et al., 2003;Silva et al., 1998a;Silva et al., 1998b). 
4.2.3 PPM1E expression affects the stabilization of dendritic spines  
Ectopic PPM1E expression in dissociated hippocampal neurons led specifically to a 
decrease in the number of mushroom-shaped spines and a decrease in the length of 
the group of stubby spines (Figures 3.34 and 3.35). Expression of the PPM1E activity 
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mutants of PPM1E(R241A) and PPM1E(D479N) had no effect on the dendritic spines 
compared with EGFP expressing control neurons. 
 
A loss of spines has also been observed very early during the development of 
Alzheimer’s disease (Selkoe, 2002a). Therefore the reduced mushroom spine number 
in cultured neurons which have higher levels of PPM1E shows an interesting analogy 
to the increased PPM1E levels in AD-affected individuals (von der Kammer, 2009). 
Mushroom spines are considered to be the most stabilized spine structures and have 
also been referred to as “memory” spines, because they putatively facilitate the long-
term stabilization of neuronal circuits which are crucial for memory retention 
(Tackenberg et al., 2009).  
 
The putative PPM1E target kinases CaMKII and PAK1 are involved in the regulation of 
F-actin in the dendritic spines (compare pathway in Figure 1.6; (Saneyoshi et al., 
2010)). They positively influence the stabilization of F-actin by promoting the 
phosphorylation-mediated inactivation of the F-actin-severing protein cofilin. Cofilin and 
a related actin depolymerising factor (ADF) bind to actin filaments and thereby induce 
structural changes that promote depolymerisation and severing of actin filaments 
(Bamburg, 1999;McGough and Chiu, 1999;McGough et al., 1997). A lack of mushroom 
spines and a reduction in stubby spine length in mature primary neurons due to 
increased levels of PPM1E, indicates that the phosphatase negatively influences the 
stabilized F-actin cytoskeleton in these spines.  
 
Inversely, the down-regulation of PPM1E influenced only the group of stubby spines 
while the numbers and morphology of thin and mushroom-shaped spines was not 
affected (Figure 3.40). Stubby spines of neurons with a lower endogenous PPM1E 
level were shorter and had a smaller head size. Additionally the overall stubby spine 
number was increased in these neurons considerably. The reduction of PPM1E levels 
in these neurons appears to have enhanced new spine formation, although these new 
spines obviously do not develop into highly stabilized, large or long spine structures.  
Since spines are dependent on pre-synaptic input for their stabilization, the lack of this 
input might have hindered the stabilization of the new spine structures. 
 
A particular cause for concern in the use of RNA interference is that shRNA molecules 
mimic precursors of another class of small RNA molecules, the microRNAs, and 
thereby might cause side effects attributable to competition for endogenous microRNAs 
processing molecules. Off-target mRNA degradation as well as induction of interferon 
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response have been reported for shRNA use (Jackson and Linsley, 2004;Persengiev et 
al., 2004). Therefore this study included a negative control shRNA. This negative 
control shRNA (hshRNA4) did not show any effect on dendritic spines compared with 
untreated controls (Figure 3.40). This suggests that the effects of anti-PPM1E shRNAs 
have a basis in the down-regulation of PPM1E expression. 
 
It remains unclear whether PPM1E requires the activity of the guanosine exchange 
factor ARHGEF6 for its putative activity on PAK1 (Koh et al., 2002), because a 
complementary increase in ARHGEF6 expression in the neurons did not lead to a 
stronger effect on the dendritic spines (Figure 3.42). This might indicate that the 
endogenous concentration of ARHGEF6 was not limiting to PPM1E activity or that the 
primary mode of action which influences the spine number and morphology is not 
mediated through PPM1E activity on PAK1 but on CaMKII.  
 
A moderate increase in ARHGEF6 levels had no effect on dendritic spines in the 
present study (Figure 3.42). However, mutations in ARHGEF6 are associated with 
degenerative spine phenotypes in vivo in the nonspecific X-linked and X-chromosomal 
specific mental retardation (Govek et al., 2004;Kutsche et al., 2000;Yntema et al., 
1998).  
 
A number of other members of the same F-actin regulating pathway exhibit similar 
deteriorating influence on dendritic spines like PPM1E. For example, the experimental 
enhancement of CaMKII signaling induces spine formation and increases synapse 
number (Jourdain et al., 2003;Bienvenu et al., 2000;Allen et al., 1998). Phenotypically, 
PAK1 has also been implicated in regulating dendritic spine shapes (Penzes et al., 
2003;Meng et al., 2002). 
 
Defects in some of pathway members are also associated with mental retardation: In 
Angelman syndrome, a disorder in which a maternal null mutation of the Ube3a 
ubiquitin ligase gene causes mental retardation and for which the mechanism is still 
unclear, a misregulation of CaMKII localization and function has been implicated 
(Weeber et al., 2003). Additionally, mutations in the CaMKII/IV effector LIMK-1 have 
been linked to William’s syndrome, a mental disorder with abnormal spine morphology 
(Kaufmann and Moser, 2000;Bellugi et al., 1999;Bamburg, 1999;Frangiskakis et al., 
1996). PAK family members have been genetically linked to several forms of mental 
retardation and spine dysgenesis in humans (Newey et al., 2005;Ramakers, 2002). 
Non-functional PAKs that impact dendritic spine morphogenesis are described for 
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several PAK family members in conjunction with AD (PAK1: (Zhao et al., 2006); PAK3: 
(McPhie et al., 2003); PAK5: (Matenia et al., 2005)), and X-linked mental retardation 
(PAK3: (Gedeon et al., 2003;Bienvenu et al., 2000;Allen et al., 1998)). 
 
The relevance of the pathway is further emphasized by the connection of the actin-
binding proteins cofilin and the isoform A of drebrin to Alzheimer’s disease: Cofilin and 
the related actin depolymerising factor (ADF) bind to actin filaments and thereby induce 
structural changes that promote depolymerisation and severing of actin filaments 
(Bamburg, 1999;McGough and Chiu, 1999;McGough et al., 1997). It has been shown 
that soluble Aȕ peptides, which are also discussed as causative factors for AD, activate 
the actin depolymerising factor cofilin (Maloney and Bamburg, 2007). Moreover, the 
level of the F-actin stabilizing protein drebrin A is markedly reduced in the brains of AD 
patients (Counts et al., 2006;Hatanpää et al., 1999;Harigaya et al., 1996). In mature 
hippocampal culture, Aȕ peptides have been shown to down-regulate the levels of 
drebrin A (Lacor et al., 2007;Hatanpää et al., 1999). Additional studies indicate that 
drebrin is involved in the pathogenesis of the disease (Lacor et al., 2007;Zhao et al., 
2006;Mahadomrongkul et al., 2005;Calon et al., 2004).  
 
The abnormally modulated numbers and distorted morphologies of dendritic spines in 
AD and in other mental disorders indicate that fully functional dendritic spines are 
required for proper brain function (Selkoe, 2002a). PPM1E levels exert a strong 
influence specifically on the group of mushroom spines, which are thought to be 
especially important for the retention of memory. This indicates that elevated PPM1E 
levels might indeed play a role in the progressive deterioration of dendritic spine 
number and morphology which is found in Alzheimer’s disease. 
4.2.4 PPM1E expression affects the complexity of the dendritic arbor  
The proposed PPM1E target kinase CaMKIV enables in concert with the activation of 
LIMK-1 the neurite outgrowth in a Neuro-2a murine neuroblastoma cell line (Takemura 
et al., 2009). Therefore the dendrite arbor in neurons with an increased PPM1E 
expression was investigated, although the morphology in neurons with moderate 
increases in PPM1E expression was not strikingly changed at the first visual 
impression (Figure 3.37 A). The PPM1E expression was experimentally dysregulated 
on DIV 7 in the neurons. After approximately 2 weeks of PPM1E dysregulated 
expression the dednritic arbor was analysed. Higher levels of PPM1E decreased the 
number of primary dendrites, which are defined as dendrites which branch off directly 
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from the neuronal soma, significantly and in a concentration-dependent manner. 
Meanwhile PPM1E active site mutants did not influence the neuronal arbor compared 
with EGFP expressing control neurons (Figures 3.37). Moreover the arbor was not 
significantly affected on DIV 17, while the number of roots was significantly reduced by 
DIV 21 (Figure 3.38). The reduction in primary dendrites in neurons with higher PPM1E 
expression is accompanied by a reduced overall length of the dendritic arbor. Due to 
the maturity of the primary culture at the date of analysis and the onset of the effect 
only after DIV 17, it is highly likely that the visible effects on primary dendrite number 
are attributable rather to retraction of existing dendrites than to outgrowth of new 
neurites.  
 
Interestingly, also the down-regulation of PPM1E activity by shRNAs, which were 
directed against endogenous PPM1E, negatively affected the number of primary 
dendrites (Figure 3.41). For the analysis of dendrite arborization two shRNAs against 
rat PPM1E were employed to control the specificity of the effect. Both shRNAs reduced 
the number of primary dendrites to different extends. The variation of the severity of 
this effect between the two anti-PPM1E shRNAs, might be attributable to different 
extends of PPM1E downregulation (Figure 3.41). This different extend of 
downregulation might for example result from different affinities of the shRNA 
sequences to the mRNA of rat PPM1E. 
 
A similar bi-directionally negative effect on the neurite outgrowth of neurons has been 
shown for the CaMKIV target kinase LIMK-1. Knockdown or inhibition, but also 
overexpression of LIMK-1 suppress neurite outgrowth and it was shown that these 
effects involve the phosphorylation of the actin-filament dissassemling factor cofilin 
(Endo et al., 2007;Tursun et al., 2005;Rosso et al., 2004;Endo et al., 2003). Cofilin is 
inactivated by LIMK-1 mediated phosphorylation. The fact that deregulation of LIMK-1 
or PPM1E in both directions causes similar effects, indicates that a proper balance of 
the activity of this pathway is required for homeostasis of the dendritic arbor.  
  
PPM1E apparently has a dual functionality in the regulation of the actin cytoskeleton in 
spines and in the dendrites. Dystrophic dendrites are frequently found also in the brains 
of Alzheimer’s disease patients. They are especially enriched close to amyloid plaques. 
The fact that both of the investigated neuronal phenotypes find analogs in the AD-
affected brain, substantiates the hypothesis that PPM1E might play a role in early 
disease developments. 
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5 CONCLUSIONS AND OUTLOOK 
 
Suitability of PPM1E as drug target for neurodegenerative diseases 
The present study showed that increased levels of PPM1E have a degenerative effect 
on the number of dendritic mushroom spines and on the dendritic arbor. Additionally it 
was demonstrated that the previously shown elevation of PPM1E mRNA levels in early 
stages of Alzheimer’s disease is also reflected on the protein level. This indicates that 
the phosphatase might play a role in AD disease development.  
 
PPM1E could be recommended as a potential drug target for the treatment of 
Alzheimer’s disease, because its expression is brain and neuron-specific. Thus it would 
be feasible to specifically address neuronal signalling pathways through the inhibition 
of PPM1E. However, low amounts of PPM1E expression have been found in Northern 
Blot analysis of testis (Kitani et al., 2003;Takeuchi et al., 2001). Side effects on this 
organ should therefore be critically examined.  Additionally, the inhibition of PPM1E 
would have to be dosed carefully to avoid side effects on the sensitive LIMK-1 / cofilin 
signaling pathway which regulates neuritic arborisation and which has negative 
regulatory effects when it is overtly overstimulated but also when it is strongly inhibited. 
 
A problem might be posed by the development of suitable PPM1E inhibitors. In the 
past the identification of phosphatase inhibitors has been proven difficult, due to their 
relatively large catalytic site. However, the substrate specificity of PPM1E and PPM1F 
is presumeably facilitated by specific binding to the respective substrate with that part 
of the E/Fhd domain, which is not part of the PP2C domain region. Additionally PPM1E 
contains N- and C-terminal stretches which are exclusive for PPM1E and not present in 
PPM1F. It should therefore be feasible to identify a molecule which specifically inhibits 
PPM1E, based on these distinct structural features.  
 
Additionally it would be a most interesting research subject for the future to further 
elucidate the correlation between the truncation of PPM1E and its subcellular 
localization. Moreover, an investigation of the tight spatial association of PPM1E and 
enrichment of mitochondria in dendrites might be interesting for the Alzheimer research 
community, because it has been suggested that defects in mitochondria are associated 
with AD.  
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Clearly, many challenges remain, but the present study has shown that PPM1E is 
potentially threatening for the maintenance of proper spine and dendritic arbor 
morphology in the AD-affected brain. Therefore PPM1E might be a promising new drug 
target for Alzheimer’s disease. 
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APPENDIX 
A 1. Alignment of human PPM1E and PPM1F protein sequences 
PPM1F            ------------------------------------------------------------ 
PPM1E            MAGCIPEEKTYRRFLELFLGEFRGPCGGGEPEPEPEPEPEPEPESEPEPEPELVEAEAAE 60 
                                                                             
 
PPM1F            MSSGAPQKSSPMASGAEETPGFLDTLLQDFPALLNPED---------------------- 38 
PPM1E            ASVEEPGEEAATVAATEEGDQEQDPEPEEEAAVEGEEEEEGAATAAAAPGHSAVPPPPPQ 120 
                  *   * :.:. .:.:**     *.  :: .*: . *:                       
 
PPM1F            --PLP--WKAPGTVLSQEEVEGELAELAMGFLGSRKAPPPLAAALAHEAVSQLLQTDLSE 94 
PPM1E            LPPLPPLPRPLSERITREEVEGESLDLCLQQLYKYNCPSFLAAALARATSDEVLQSDLSA 180 
                   ***   :. .  :::******  :*.:  * . :.*. ******: : .::**:***  
       Glu cluster in PPM1F 
PPM1F            FRKLPREEEEEEEDDDEEEKAPVTLLDAQSLAQSFFNRLWEVAGQWQKQVPLAARASQRQ 154 
PPM1E            H-YIPKETDGTEG---------TVEIETVKLARSVFSKLHEICCSWVKDFPLRRRP-QLY 229 
                 .  :*:* :  *          .. ::: .**:*.*.:* *:. .* *:.**  *. *   
 
PPM1F            WLVSIHAIRNTRRKMEDRHVSLPSFNQLFGLSDPVNRAYFAVFDGHGGVDAARYAAVHVH 214 
PPM1E            YETSIHAIKNMRRKMEDKHVCIPDFNMLFNLEDQEEQAYFAVFDGHGGVDAAIYASIHLH 289 
                 : .*****:* ******:**.:*.** **.*.*  ::*************** **::*:* 
 
PPM1F            TNAARQPELPTDPEGALREAFRRTDQMFLRKAKRERLQSGTTGVCALIAGATLHVAWLGD 274 
PPM1E            VNLVRQEMFPHDPAEALCRAFRVTDERFVQKAARESLRCGTTGVVTFIRGNMLHVAWVGD 349 
                 .* .**  :* **  ** .*** **: *::** ** *:.***** ::* *  *****:** 
 
PPM1F            SQVILVQQGQVVKLMEPHRPERQDEKARIEALGGFVSHMDCWRVNGTLAVSRAIGDVFQK 334 
PPM1E            SQVMLVRKGQAVELMKPHKPDREDEKQRIEALGGCVVWFGAWRVNGSLSVSRAIGDAEHK 409 
                 ***:**::**.*:**:**:*:*:*** ******* *  :..*****:*:*******. :* 
 
PPM1F            PYVSGEADAASRALTGSEDYLLLACDGFFDVVPHQEVVGLVQSHLTRQQGSGLRVAEELV 394 
PPM1E            PYICGDADSASTVLDGTEDYLILACDGFYDTVNPDEAVKVVSDHLKENNGDSSMVAHKLV 469 
                 **:.*:**:** .* *:****:******:*.*  :*.* :*..**..::*..  **.:** 
 
PPM1F            AAARERGSHDNITVMVVFLRDP-------------QELLEGGNQGEGD------------ 429 
PPM1E            ASARDAGSSDNITVIVVFLRDMNKAVNVSEESDWTENSFQGGQEDGGDDKENHGECKRPW 529 
                 *:**: ** *****:******              :: ::**::. **             
                                            ź 
PPM1F            PQAEG------------------------------------------------------- 434 
PPM1E            PQHQCSAPADLGYDGRVDSFTDRTSLSPGSQINVLEDPGYLDLTQIEASKPHSAQFLLPV 589 
                 ** :                                                         
 
PPM1F            -------------------RRQDLPSSLPEP----------------------ETQAPPR 453 
PPM1E            EMFGPGAPKKANLINELMMEKKSVQSSLPEWSGAGEFPTAFNLGSTGEQIYRMQSLSPVC 649 
                                    .::.: *****                       :: :*   
 
PPM1F            S----------------------------------------------------------- 454 
PPM1E            SGLENEQFKSPGNRVSRLSHLRHHYSKKWHRFRFNPKFYSFLSAQEPSHKIGTSLSSLTG 709 
                 *                                                            
 
PPM1F            ---------------------------------------------- 
PPM1E            SGKRNRIRSSLPWRQNSWKGYSENMRKLRKTHDIPCPDLPWSYKIE 755 
  
Symbols: “*” the residues in that column are identical in all sequences in the alignment. “:” 
conserved substitutions as defined in Material and Methods section. “." semi-conserved 
substitutions as defined in Material and Methods section.  
 
PPM1E/1F homology domain (E/Fhd) as defined by Kitani et al. (2006) shaded in light 
grey. Catalytic PP2C phosphatase domain in bold letters (Tada et al., 2006). Protein 
phosphatase 2C motif shaded in yellow. Sequences complementary to immunization 
peptides used in antibody production in red letters. Nucleotides required for ARHGEF7 
binding are underlined (Koh et al., 2002). The carboxyl terminal proline of truncated 
PPM1E(1-557) is indicated by an arrowhead (ź) (Kitani et al., 2006). Nuclear 
localization sites are shaded in black (Takeuchi et al., 2004). Sites that have been 
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mutated to created single-amino acid mutants for this study are shaded in green. 
Glutamate-rich N-terminal region underlined with dots. 
 
A 2. Alignment of PPM1E transcripts 
Alignment of ‘Homo sapiens protein phosphatase 1E (PP2C domain containing) 
(PPM1E)’ (NM_014906, 755 aa), ‘KIAA1072 protein’ (AB028995, 759aa) and ‘Homo 
sapiens PP2CH mRNA’ (AF260269, 766 aa). 
 
NM_014906          --MAGCIPEEKTYRRFLELFLGEFRGPCGGGEPEPEPEPEPEPEP--ESEPEPEPELVEA 56 
AB028995           AAMAGCIPEEKTYRRFLELFLGEFRGPCGGGEPEPEPEPEPEPEPEPESEPEPEPELVEA 60 
AF260269           --MAGCIPEEKTYRRFLELFLGEFRGPCGGGEPEPEPEPEPEPEPEPESEPEPEPELVEA 58 
                   *******************************************  ************* 
 
NM_014906          EAAEASVEEPGEEAATVAATEEGDQEQDPEPEEEAAVEGEEEEEGAATAAAAPGHSAVPP 116 
AB028995           EAAEASVEEPGEEAATVAATEEGDQEQDPEPEEEAAVEGEEEEEGAATAAAAPGHSAVPP 120 
AF260269           EAAEASVEEPGEEAATVAATEEGDQEQDPEPEEEAAVEGEEEEEGAATAAAAPGHSAVPP 118 
                   ************************************************************ 
 
NM_014906          PPPQLPPLPPLPR---------PLSERITREEVEGESLDLCLQQLYKYNCPSFLAAALAR 167 
AB028995           PPPQLPPLPPLPR---------PLSERITREEVEGESLDLCLQQLYKYNCPSFLAAALAR 171 
AF260269           PPPQLPPLPPLPRPLSERITPRPLSERITREEVEGESLDLCLQQLYKYNCPSFLAAALAR 178 
                   *************         ************************************** 
 
NM_014906          ATSDEVLQSDLSAHYIPKETDGTEGTVEIETVKLARSVFSKLHEICCSWVKDFPLRRRPQ 227 
AB028995           ATSDEVLQSDLSAHYIPKETDGTEGTVEIETVKLARSVFSKLHEICCSWVKDFPLRRRPQ 231 
AF260269           ATSDEVLQSDLSAHYIPKETDGTEGTVEIETVKLARSVFSKLHEICCSWVKDFPLRRRPQ 238 
                   ************************************************************ 
 
NM_014906          LYYETSIHAIKNMRRKMEDKHVCIPDFNMLFNLEDQEEQAYFAVFDGHGGVDAAIYASIH 287 
AB028995           LYYETSIHAIKNMRRKMEDKHVCIPDFNMLFNLEDQEEQAYFAVFDGHGGVDAAIYASIH 291 
AF260269           LYYETSIHAIKNMRRKMEDKHVCIPDFNMLFNLEDQEEQAYFAVFDGHGGVDAAIYASIH 298 
                   ************************************************************ 
 
NM_014906          LHVNLVRQEMFPHDPAEALCRAFRVTDERFVQKAARESLRCGTTGVVTFIRGNMLHVAWV 347 
AB028995           LHVNLVRQEMFPHDPAEALCRAFRVTDERFVQKAARESLRCGTTGVVTFIRGNMLHVAWV 351 
AF260269           LHVNLVRQEMFPHDPAEALCRAFRVTDERFVQKAARESLRCGTTGVVTFIRGNMLHVAWV 358 
                   ************************************************************ 
 
NM_014906          GDSQVMLVRKGQAVELMKPHKPDREDEKQRIEALGGCVVWFGAWRVNGSLSVSRAIGDAE 407 
AB028995           GDSQVMLVRKGQAVELMKPHKPDREDEKQRIEALGGCVVWFGAWRVNGSLSVSRAIGDAE 411 
AF260269           GDSQVMLVRKGQAVELMKPHKPDREDEKQRIEALGGCIVWFGAWRVNGSLSVSRAIGDAE 418 
                   *************************************:********************** 
 
NM_014906          HKPYICGDADSASTVLDGTEDYLILACDGFYDTVNPDEAVKVVSDHLKENNGDSSMVAHK 467 
AB028995           HKPYICGDADSASTVLDGTEDYLILACDGFYDTVNPDEAVKVVSDHLKENNGDSSMVAHK 471 
AF260269           HKPYICGDADSASTVLDGTEDYLILACDGFYDTVNPDEAVKVVSDHLKENNGDSSMVAHK 478 
                   ************************************************************ 
 
NM_014906          LVASARDAGSSDNITVIVVFLRDMNKAVNVSEESDWTENSFQGGQEDGGDDKENHGECKR 527 
AB028995           LVASARDAGSSDNITVIVVFLRDMNKAVNVSEESDWTENSFQGGQEDGGDDKENHGECKR 531 
AF260269           LVASARDAGSSDNITVIVVFLRDMNKAVNVSEESDWTENSFQGGQEDGGDDKENHGECKR 538 
                   ************************************************************ 
                                                ź 
NM_014906          PWPQHQCSAPADLGYDGRVDSFTDRTSLSPGSQINVLEDPGYLDLTQIEASKPHSAQFLL 587 
AB028995           PWPQHQCSAPADLGYDGRVDSFTDRTSLSPGSQINVLEDPGYLDLTQIEASKPHSAQFLL 591 
AF260269           PWPQHQCSAPADLGYDGRVDSFTDRTSLSPGSQINVLEDPGYLDLTQIEASKPHSAQFLL 598 
                   ************************************************************ 
 
NM_014906          PVEMFGPGAPKKANLINELMMEKKSVQSSLPEWSGAGEFPTAFNLGSTGEQIYRMQSLSP 647 
AB028995           PVEMFGPGAPKKANLINELMMEKKSVQSSLPEWSGAGEFPTAFNLGSTGEQIYRMQSLSP 651 
AF260269           PVEMFGPGAPKKANLINELMMEKKSVQSSLPEWSGAGEFPTAFNLGSTGEQIYRMQSLSP 658 
                   ************************************************************ 
 
NM_014906          VCSGLENEQFKSPGNRVSRLSHLRHHYSKKWHRFRFNPKFYSFLSAQEPSHKIGTSLSSL 707 
AB028995           VCSGLENEQFKSPGNRVSRLSHLRHHYSKKWHRFRFNPKFYSFLSAQEPSHKIGTSLSSL 711 
AF260269           VCSGLENEQFKSPGNRVSRLSHLRHHYSKKWHRFRFNPKFYSFLSAQEPSHKIGTSLSSL 718 
                   ************************************************************ 
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NM_014906          TGSGKRNRIRSSLPWRQNSWKGYSENMRKLRKTHDIPCPDLPWSYKIE 755 
AB028995           TGSGKRNRIRSSLPWRQNSWKGYSENMRKLRKTHDIPCPDLPWSYKIE 759 
AF260269           TGSGKRNRIRSSLPWRQNSWKGYSENMRKLRKTHDIPCPDLPWSYKIE 766 
                   ************************************************ 
Symbols and colours: Colours indicate different groups of amino acids: red: 
AVFPMILW = small (small+ hydrophobic (incl. aromatic -Y)); blue: DE = acidic; 
magenta: RK = basic; green = STYHCNGQ = hydroxyl + amine + basic – Q. 
Consensus symbols: “*” the residues in that column are identical in all sequences in the 
alignment. “:” conserved substitutions have been observed. “." semi-conserved 
substitutions are observed. 
 
PPM1E/1F homology domain (E/Fhd) as defined by Kitani et al. (2006) shaded in light 
grey. Catalytic PP2C phosphatase domain in bold letters (Tada et al., 2006). Protein 
phosphatase 2C motif shaded in yellow. Nucleotides required for ARHGEF7 binding 
are underlined (Koh et al., 2002). The carboxyl terminal proline of truncated PPM1E(1-
557) is indicated by an arrowhead (ź) (Kitani et al., 2006). 
A 3. Alignment of human and rat PPM1E protein sequences   
hPPM1E          MAGCIPEEKTYRRFLELFLGEFRGPCGGGEPEPEPEPEPEPEPESEPEPEPELVEAEAAE 60 
rPPM1E          MAGCIPEEKTYRRFLELFLGEFRGPCGGGEPEPEPESEPEP------EPEAELVAAEAAE 54 
                ************************************.****      ***.*** ***** 
 
hPPM1E          ASVEEPGEEAATVAATEEGDQEQDPEPEE-----EAAVEGEEEEEGAATAAAAPGHSAVP 115 
rPPM1E          ASGEDPGEDAATVEAAEEGVQDQDPEPEEEAVEEEAAAEGEEEEE--EEEAAAPGHSAVP 112 
                ** *:***:**** *:*** *:*******     ***.*******     ********** 
 
hPPM1E          PPPPQLPPLPPLPRPLSERITREEVEGESLDLCLQQLYKYNCPSFLAAALARATSDEVLQ 175 
rPPM1E          PPQPQLPPLPPLPRPLSERITREEVEGESLDLCLQQLYKYNCPSFLAAALARATSDEVLQ 172 
                ** ********************************************************* 
 
hPPM1E          SDLSAHYIPKETDGTEGTVEIETVKLARSVFSKLHEICCSWVKDFPLRRRPQLYYETSIH 235 
rPPM1E          SDLSAHCIPKETDGTEGTVEIETVKLARSVFSKLHEICCNWVKDFPLRRRPQIYYETSIH 232 
                ****** ********************************.************:******* 
       protein phosphatase 2C motif 
hPPM1E          AIKNMRRKMEDKHVCIPDFNMLFNLEDQEEQAYFAVFDGHGGVDAAIYASIHLHVNLVRQ 295 
rPPM1E          AIKNMRRKMEDKHVCIPDFNMLFNLEDQEEQAYFAVFDGHGGVDAAIYASVHLHVNLVRQ 292 
                **************************************************:********* 
 
hPPM1E          EMFPHDPAEALCRAFRVTDERFVQKAARESLRCGTTGVVTFIRGNMLHVAWVGDSQVMLV 355 
rPPM1E          EMFPHDPAEALCRAFRVTDERFVQKAARESLRCGTTGVVTFIRGNMLHVAWVGDSQVMLV 352 
                ************************************************************ 
 
hPPM1E          RKGQAVELMKPHKPDREDEKQRIEALGGCVVWFGAWRVNGSLSVSRAIGDAEHKPYICGD 415 
rPPM1E          RKGQAVELMKPHKPDREDEKQRIEALGGCVVWFGAWRVNGSLSVSRAIGDAEHKPYICGD 412 
                ************************************************************ 
 
hPPM1E          ADSASTVLDGTEDYLILACDGFYDTVNPDEAVKVVSDHLKENNGDSSMVAHKLVASARDA 475 
rPPM1E          ADSASTVLDGTEDYLILACDGFYDTVNPDEAVKVVSDHLKENNGDSSMVAHKLVASARDA 472 
                ************************************************************ 
 
hPPM1E          GSSDNITVIVVFLRDMNKAVNVSEESDWTENSFQGGQEDGGDDKENHGECKRPWPQHQCS 535 
rPPM1E          GSSDNITVIVVFLRDMNKAVNVSEESDWTENSFQGGQEDGGDDKENHGECKRPWPQHQCS 532 
                ************************************************************ 
                    ź 
hPPM1E          APADLGYDGRVDSFTDRTSLSPGSQINVLEDPGYLDLTQIEASKPHSAQFLLPVEMFGPG 595 
rPPM1E          APADLGYEGRVDSFTDRTSLSPGPQINVLEDPDYLDLTQIETSKPHSTQFLPPVEMIGPG 592 
                *******:***************.********.********:*****:*** ****:*** 
 
hPPM1E          APKKANLINELMMEKKSVQSSLPEWSGAGEFPTAFNLGSTGEQIYRMQSLSPVCSGLENE 655 
rPPM1E          APKKA-YVNELIMEESSVTPSQPERSGAGELLVSFNLGSTGQQICRMENLSPVYSGLENE 651 
                *****  :***:**:.** .* ** *****: .:*******:** **:.**** ****** 
 
hPPM1E          QFKSPGNRVSRLSHLRHHYSKKWHRFRFNPKFYSFLSAQEPSHKIGTSLSSLTGSGKRN- 714 
rPPM1E          QFKSPGKRASRLYHLRHHYSKRQRGFRFNPKFYSFFSAQESSRKIGISLSSLTRSGKRNK 711 
                ******:*.*** ********: : **********:****.*:*** ****** *****  
 
hPPM1E          RIRSSLPWRQNSWKGYSENMRKLRKTHDIPCPDLPWSYKIE 755 
rPPM1E          MLRSSLPWRENSWEGYSGNM-AIRKRNNISCPDLPWDYKI- 750 
                 :*******:***:*** **  :** ::*.******.***  
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Symbols: “*” the residues in that column are identical in all sequences in the alignment. 
“:” conserved substitutions as defined in Material and Methods section. “." semi-
conserved substitutions as defined in Material and Methods section.  
 
PPM1E/1F homology domain (E/Fhd) as defined by Kitani et al. (2006) shaded in light 
grey. Catalytic PP2C phosphatase domain in bold letters (Tada et al., 2006). Protein 
phosphatase 2C motif shaded in yellow. Sequences complementary to immunization 
peptides used in antibody production in red letters. Nucleotides required for ARHGEF7 
binding are underlined (Koh et al., 2002). The carboxyl terminal proline of truncated 
PPM1E(1-557) is indicated by an arrowhead (ź) (Kitani et al., 2006). Nuclear 
localization sites are shaded in black (Takeuchi et al., 2004).  
A 4. Alignment of human and rat ARHGEF6 protein sequences 
humanARHGEF6      MNPEEQIVTWLISLGVLESPKKTICDPEEFLKSSLKNGVVLCKLINRLMPGSVEKFCLDP 60 
ratARHGEF6        MNPEERVVTWLISLGVLESPKKTICDPEEFLKSSLKNGVVLCKLISRLLPGSVEKYCQEP 60 
                  *****::**************************************.**:******:* :* 
 
humanARHGEF6      QTEADCINNINDFLKGCATLQVEIFDPDDLYSGVNFSKVLSTLLAVNKATEDQLSERPCG 120 
ratARHGEF6        QTEADCIDNINDFLKGCATLQVEVFEPDDLYSGANFSKVLNTLLAVNKATEDQLSERPCG 120 
                  *******:***************:*:*******.******.******************* 
 
humanARHGEF6      RSSSLSAANTSQTNPQGAVSSTVSGLQRQSKTVEMTENGSHQLIVKARFNFKQTNEDELS 180 
ratARHGEF6        RSSSLSATTSSQTNPQAAVPSTTPEQQSEEKAAEMTENGSHQLIVKARFNFKQTNEDELS 180 
                  *******:.:******.**.**..  * :.*:.*************************** 
 
humanARHGEF6      VCKGDIIYVTRVEEGGWWEGTLNGRTGWFPSNYVREIKSSERPLSPKAVKGFETAPLTKN 240 
ratARHGEF6        VCKGDIIYVTRVEEGGWWEGTLNGRTGWFPSNYVREIKPSERPLSPKAVKGFDTAPLTKN 240 
                  **************************************.*************:******* 
 
humanARHGEF6      YYTVVLQNILDTEKEYAKELQSLLVTYLRPLQSNNNLSTVEVTSLLGNFEEVCTFQQTLC 300 
ratARHGEF6        YYTVVLQNILDTEKEYAKELQSLLVTYLRPLQSNNNLSTVEFTCLLGNFEEVCTFQQTLC 300 
                  *****************************************.*.**************** 
 
humanARHGEF6      QALEECSKFPENQHKVGGCLLSLMPHFKSMYLAYCANHPSAVNVLTQHSDELEQFMENQG 360 
ratARHGEF6        QALEECSKSPENQHKVGGCLLNLMPHFKSMYLAYCANHPSAVNVLTQHSDDLERFMENQG 360 
                  ******** ************.****************************:**:****** 
 
humanARHGEF6      ASSPGILILTTNLSKPFMRLEKYVTLLQELERHMEDTHPDHQDILKAIVAFKTLMGQCQD 420 
ratARHGEF6        ASSPGILILTTSLSKPFMRLEKYVTLLQELERHMEDTHPDHQDILKAIIAFKSLMGQCQD 420 
                  ***********.************************************:***:******* 
 
humanARHGEF6      LRKRKQLELQILSEPIQAWEGEDIKNLGNVIFMSQVMVQYGACEEKEERYLMLFSNVLIM 480 
ratARHGEF6        LRKRKQLELQILSEPIQAWEGDDIKTLGNVIFMSQVVMQHGACEEKEERYFLLFSSVLIM 480 
                  *********************:***.**********::*:**********::***.**** 
 
humanARHGEF6      LSASPRMSGFIYQGKIPIAGTVVTRLDEIEGNDCTFEITGNTVERIVVHCNNNQDFQEWL 540 
ratARHGEF6        LSASPRMSGFMYQGKVPIAGMVVTRLDEIEGNDCTFEITGSTVERIVVHCNNNQDFQEWM 540 
                  **********:****:**** *******************.******************: 
 
humanARHGEF6      EQLNRLIRGPASCSSLSKTSSSSCSAHSSFSSTGQPRGPLEPPQIIKPWSLSCLRPAPPL 600 
ratARHGEF6        EQLNRLTKGPASCSSLSKTSSSSCSTHSSFSSTGQPRGPLEPPQIIKPWSLSCLRPAPPL 600 
                  ****** :*****************:********************************** 
 
humanARHGEF6      RPSAALGYKERMSYILKESSKSPKTMKKFLHKRKTERKPSEEEYVIRKSTAALEEDAQIL 660 
ratARHGEF6        RPSAALGYKERMSYILKESSKSPKTMKKFLHKRKTERKTSEEEYVIRKSTAALEEDAQIL 660 
                  **************************************.********************* 
 
humanARHGEF6      KVIEAYCTSANFQQGHGSSTRKDSIPQVLLPEEEKLIIEETRSNGQTIMEEKSLVDTVYA 720 
ratARHGEF6        KVIEAYCTSASFQQG----TRKDSVPQVLLPEEEKLIIEETRSNGQTIIEEKSLVDTVYA 716 
                  **********.****    *****:***********************:*********** 
 
humanARHGEF6      LKDEVRELKQENKRMKQCLEEELKSRRDLEKLVRRLLKQTDECIRGESSSKTSILP 776 
ratARHGEF6        LKDEVKELKQENKKMKQCLEEELKSRKDLEKLVRKLLKQTDESIRAESSSKTSILQ 772 
                  *****:*******:************:*******:*******.**.*********  
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Symbols: “*” the residues in that column are identical in all sequences in the alignment. 
“:” conserved substitutions as defined in Material and Methods section. “." semi-
conserved substitutions as defined in Material and Methods section.  
 
Sequences which are complementary to immunization peptides which were used in 
antibody production in red letters. Sites required for binding of PPM1E and PPM1F are 
shaded yellow. 
 
A 5. Alignment of human ARHGEF6 and ARHGEF7 protein sequences 
hARHGEF7_t2      MNSAEQTVTWLITLGVLESPKKTISDPEGFLQASLKDGVVLCRLLERLLPGTIEKVYPEP 60 
hARHGEF7_t3      MNSAEQTVTWLITLGVLESPKKTISDPEGFLQASLKDGVVLCRLLERLLPGTIEKVYPEP 60 
hARHGEF7_t4      MNSAEQTVTWLITLGVLESPKKTISDPEGFLQASLKDGVVLCRLLERLLPGTIEK----- 55 
hARHGEF7_t1      ------------------------------------------------------------ 
hARHGEF6         MNPEEQIVTWLISLGVLESPKKTICDPEEFLKSSLKNGVVLCKLINRLMPGSVEKFCLDP 60 
                                                                              
 
hARHGEF7_t2      RSESECLSNIREFLRGCGASLRLE---------------------TFDANDLYQGQNFNK 99 
hARHGEF7_t3      RSESECLSNIREFLRGCGASLRLELLFPPSQPPQHLVTTILLSASTFDANDLYQGQNFNK 120 
hARHGEF7_t4      ---------------------------------------------TFDANDLYQGQNFNK 70 
hARHGEF7_t1      ------------------------------------------------------------ 
hARHGEF6         QTEADCINNINDFLKGCAT----------------------LQVEIFDPDDLYSGVNFSK 98 
                                                                              
 
hARHGEF7_t2      VLSSLVTLNKVTADIGLGSDSVCARPSSHRIKSFDSLGSQSLHTRTSKLFQGQYRSLDMT 159 
hARHGEF7_t3      VLSSLVTLNKVTADIGLGSDSVCARPSSHRIKSFDSLGSQSLHTRTSKLFQGQYRSLDMT 180 
hARHGEF7_t4      VLSSLVTLNKVTADIGLGSDSVCARPSSHRIKSFDSLGSQSLHTRTSKLFQGQYRSLDMT 130 
hARHGEF7_t1      ----------------------------------------------------------MT 2 
hARHGEF6         VLSTLLAVNKATEDQ--LSERPCGRSSSLSAANTSQTNPQGAVSSTVSGLQRQSKTVEMT 156 
                                                                           ** 
 
hARHGEF7_t2      DNSNNQLVVRAKFNFQQTNEDELSFSKGDVIHVTRVEEGGWWEGTLNGRTGWFPSNYVRE 219 
hARHGEF7_t3      DNSNNQLVVRAKFNFQQTNEDELSFSKGDVIHVTRVEEGGWWEGTLNGRTGWFPSNYVRE 240 
hARHGEF7_t4      DNSNNQLVVRAKFNFQQTNEDELSFSKGDVIHVTRVEEGGWWEGTLNGRTGWFPSNYVRE 190 
hARHGEF7_t1      DNSNNQLVVRAKFNFQQTNEDELSFSKGDVIHVTRVEEGGWWEGTLNGRTGWFPSNYVRE 62 
hARHGEF6         ENGSHQLIVKARFNFKQTNEDELSVCKGDIIYVTRVEEGGWWEGTLNGRTGWFPSNYVRE 216 
                 :*..:**:*:*:***:********..***:*:**************************** 
 
hARHGEF7_t2      VKASEKPVSPKSGTLKSPPKGFDTTAINKSYYNVVLQNILETENEYSKELQTVLSTYLRP 279 
hARHGEF7_t3      VKASEKPVSPKSGTLKSPPKGFDTTAINKSYYNVVLQNILETENEYSKELQTVLSTYLRP 300 
hARHGEF7_t4      VKASEKPVSPKSGTLKSPPKGFDTTAINKSYYNVVLQNILETENEYSKELQTVLSTYLRP 250 
hARHGEF7_t1      VKASEKPVSPKSGTLKSPPKGFDTTAINKSYYNVVLQNILETENEYSKELQTVLSTYLRP 122 
hARHGEF6         IKSSERPLSPK------AVKGFETAPLTKNYYTVVLQNILDTEKEYAKELQSLLVTYLRP 270 
                 :*:**:*:***      . ***:*:.:.*.**.*******:**:**:****::* ***** 
 
hARHGEF7_t2      LQTSEKLSSANISYLMGNLEEICSFQQMLVQSLEECTKLPEAQQRVGGCFLNLMPQMKTL 339 
hARHGEF7_t3      LQTSEKLSSANISYLMGNLEEICSFQQMLVQSLEECTKLPEAQQRVGGCFLNLMPQMKTL 360 
hARHGEF7_t4      LQTSEKLSSANISYLMGNLEEICSFQQMLVQSLEECTKLPEAQQRVGGCFLNLMPQMKTL 310 
hARHGEF7_t1      LQTSEKLSSANISYLMGNLEEICSFQQMLVQSLEECTKLPEAQQRVGGCFLNLMPQMKTL 182 
hARHGEF6         LQSNNNLSTVEVTSLLGNFEEVCTFQQTLCQALEECSKFPENQHKVGGCLLSLMPHFKSM 330 
                 **:.::**:.::: *:**:**:*:*** * *:****:*:** *::****:*.***::*:: 
 
hARHGEF7_t2      YLTYCANHPSAVNVLTEHSEELGEFMETKGASSPGILVLTTGLSKPFMRLDKYPTLLKEL 399 
hARHGEF7_t3      YLTYCANHPSAVNVLTEHSEELGEFMETKGASSPGILVLTTGLSKPFMRLDKYPTLLKEL 420 
hARHGEF7_t4      YLTYCANHPSAVNVLTEHSEELGEFMETKGASSPGILVLTTGLSKPFMRLDKYPTLLKEL 370 
hARHGEF7_t1      YLTYCANHPSAVNVLTEHSEELGEFMETKGASSPGILVLTTGLSKPFMRLDKYPTLLKEL 242 
hARHGEF6         YLAYCANHPSAVNVLTQHSDELEQFMENQGASSPGILILTTNLSKPFMRLEKYVTLLQEL 390 
                 **:*************:**:** :***.:********:***.********:** ***:** 
 
hARHGEF7_t2      ERHMEDYHTDRQDIQKSMAAFKNLSAQCQEVRKRKELELQILTEAIRNWEGDDIKTLGNV 459 
hARHGEF7_t3      ERHMEDYHTDRQDIQKSMAAFKNLSAQCQEVRKRKELELQILTEAIRNWEGDDIKTLGNV 480 
hARHGEF7_t4      ERHMEDYHTDRQDIQKSMAAFKNLSAQCQEVRKRKELELQILTEAIRNWEGDDIKTLGNV 430 
hARHGEF7_t1      ERHMEDYHTDRQDIQKSMAAFKNLSAQCQEVRKRKELELQILTEAIRNWEGDDIKTLGNV 302 
hARHGEF6         ERHMEDTHPDHQDILKAIVAFKTLMGQCQDLRKRKQLELQILSEPIQAWEGEDIKNLGNV 450 
                 ****** *.*:*** *::.***.* .***::****:******:*.*: ***:***.**** 
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hARHGEF7_t2      TYMSQVLIQCAGSEEKNERYLLLFPNVLLMLSASPRMSGFIYQGKLPTTGMTITKLEDSE 519 
hARHGEF7_t3      TYMSQVLIQCAGSEEKNERYLLLFPNVLLMLSASPRMSGFIYQGKLPTTGMTITKLEDSE 540 
hARHGEF7_t4      TYMSQVLIQCAGSEEKNERYLLLFPNVLLMLSASPRMSGFIYQGKLPTTGMTITKLEDSE 490 
hARHGEF7_t1      TYMSQVLIQCAGSEEKNERYLLLFPNVLLMLSASPRMSGFIYQGKLPTTGMTITKLEDSE 362 
hARHGEF6         IFMSQVMVQYGACEEKEERYLMLFSNVLIMLSASPRMSGFIYQGKIPIAGTVVTRLDEIE 510 
                  :****::* ...***:****:**.***:****************:* :* .:*:*:: * 
 
hARHGEF7_t2      NHRNAFEISGSMIERILVSCNNQQDLQEWVEHLQKQTKVTSVGNPTIKPHSVPSHTLPSH 579 
hARHGEF7_t3      NHRNAFEISGSMIERILVSCNNQQDLQEWVEHLQKQTKVTSVGNPTIKPHSVPSHTLPSH 600 
hARHGEF7_t4      NHRNAFEISGSMIERILVSCNNQQDLQEWVEHLQKQTKVTSVGNPTIKPHSVPSHTLPSH 550 
hARHGEF7_t1      NHRNAFEISGSMIERILVSCNNQQDLQEWVEHLQKQTKVTSVGNPTIKPHSVPSHTLPSH 422 
hARHGEF6         GNDCTFEITGNTVERIVVHCNNNQDFQEWLEQLNRLIRG---------PASCSSLSKTSS 561 
                 .:  :***:*. :***:* ***:**:***:*:*::  :          * * .* : .*  
 
hARHGEF7_t2      PVTPSSKHADSKPAPLTPAYHTLPHPSHHGTPHTTINWGPLEPPKTPKPWSLSCLRPAPP 639 
hARHGEF7_t3      PVTPSSKHADSKPAPLTPAYHTLPHPSHHGTPHTTINWGPLEPPKTPKPWSLSCLRPAPP 660 
hARHGEF7_t4      PVTPSSKHADSKPAPLTPAYHTLPHPSHHGTPHTTINWGPLEPPKTPKPWSLSCLRPAPP 610 
hARHGEF7_t1      PVTPSSKHADSKPAPLTPAYHTLPHPSHHGTPHTTINWGPLEPPKTPKPWSLSCLRPAPP 482 
hARHGEF6         --SSCSAHSS---------------FSSTGQPR-----GPLEPPQIIKPWSLSCLRPAPP 599 
                   :..* *:.                *  * *:     ******:  ************* 
 
hARHGEF7_t2      LRPSAALCYKEDLS-------KSPKTMKKLLPKRKPERKPSDEEFASRKSTAALEEDAQI 692 
hARHGEF7_t3      LRPSAALCYKEDLS-------KSPKTMKKLLPKRKPERKPSDEEFASRKSTAALEEDAQI 713 
hARHGEF7_t4      LRPSAALCYKEDLS-------KSPKTMKKLLPKRKPERKPSDEEFASRKSTAALEEDAQI 663 
hARHGEF7_t1      LRPSAALCYKEDLS-------KSPKTMKKLLPKRKPERKPSDEEFASRKSTAALEEDAQI 535 
hARHGEF6         LRPSAALGYKERMSYILKESSKSPKTMKKFLHKRKTERKPSEEEYVIRKSTAALEEDAQI 659 
                 ******* *** :*       ********:* ***.*****:**:. ************* 
 
hARHGEF7_t2      LKVIEAYCTSAKTRQTLNSTWQG----TDLMHN--HVLADDDQPSLDSLGRRSSLS---- 742 
hARHGEF7_t3      LKVIEAYCTSAKTRQTLNSTWQG----TDLMHN--HVLADDDQPSLDSLGRRSSLS---- 763 
hARHGEF7_t4      LKVIEAYCTSAKTRQTLNSTWQG----TDLMHN--HVLADDDQPSLDSLGRRSSLS---- 713 
hARHGEF7_t1      LKVIEAYCTSAKTRQTLNSSSRKESAPQVLLPEEEKIIVEETKSNGQTVIEEKSLVDTVY 595 
hARHGEF6         LKVIEAYCTSANFQQGHGSSTRKDSIPQVLLPEEEKLIIEETRSNGQTIMEEKSLVDTVY 719 
                 ***********: :*  .*: :       *: :  ::: :: :.. ::: ...**      
 
hARHGEF7_t2      --RLEPSDLSEDSDYDSIWTAHSYRMGSTSRKSCCSYISHQN--------------- 782 
hARHGEF7_t3      --RLEPSDLSEDSDYDSIWTAHSYRMGSTSRKSCCSYISHQN--------------- 803 
hARHGEF7_t4      --RLEPSDLSEDSDYDSIWTAHSYRMGSTSRKSCCSYISHQN--------------- 753 
hARHGEF7_t1      ALKDEVQELRQDNKKMKKSLEEEQRARKDLEKLVRKVLKNMNDPAWDETNL------ 646 
hARHGEF6         ALKDEVRELKQENKRMKQCLEEELKSRRDLEKLVRRLLKQTDECIRGESSSKTSILP 776 
                   : *  :* ::..  .    .. :     .*     :.: :                
 
Sequences complementary to immunization peptides used in antibody production 
highlighted in grey. Sites required for binding of PPM1E and PPM1F are shaded 
yellow. hARHGEF7_t1 = hARHGEF7_t5  = ȕ1PIX. 
 
Symbols and colours: Colours indicate different groups of amino acids: red: 
AVFPMILW = small (small and hydrophobic (incl.aromatic -Y)); blue: DE = acidic; 
magenta: RK = basic; green = STYHCNGQ = hydroxyl + amine + basic – Q. “*” the 
residues in that column are identical in all sequences in the alignment. “:” conserved 
substitutions as defined in Material and Methods section. “." semi-conserved 
substitutions as defined in Material and Methods section.“t” : transcript number or 
ARHGEF7.  
 
A 6. Alignment of human PPM1E with D. melanogaster CG10376-PA and Ppm1-
PA  
CG10376-PA      ------------------------------------------MSSDAIPASECAHLMEFK 18 
hPPM1E          MAGCIPEEKTYRRFLELFLGEFRGPCGGGEPEPEPEPEPEPEPESEPEPEPELVEAEAAE 60 
Ppm1-PA         ------------------------------------------------------------ 
                                                                             
 
CG10376-PA      RFLVSTAEKAAAVSEEVVSRSCVTRTANETYKVSGEERHAELVSAIWKQLETRG------ 72 
hPPM1E          ASVEEPGEEAATVAATEEGDQEQDPEPEEEAAVEGEEEEEGAATAAAAPGHSAVPPPPPQ 120 
Ppm1-PA         ------------------------------------------------------------ 
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CG10376-PA      ------CPAQFRIKLLHRSTQQLEQDLCFAKECEVTVE---GPPQYDLLKLQKFVASEFE 123 
hPPM1E          LPPLPPLPRPLSERITREEVEGESLDLCLQQLYKYNCPSFLAAALARATSDEVLQSDLSA 180 
Ppm1-PA         -----------MGQTLSEPVTTKDTACCANASYRVGSS---------------------- 27 
                             :   . .   .   *     .                           
 
CG10376-PA      KYILKLTDNSE------VDRLKDFADEAAPENCECHQQKEPLHTS---------AAVKNK 168 
hPPM1E          HYIPKETDGTEGTVEIETVKLARSVFSKLHEICCSWVKDFPLRRRPQLYYETSIHAIKNM 240 
Ppm1-PA         -------------------------------------------------------CMQGW 32 
                                                                       .::.  
 
CG10376-PA      PRKMEDRCVCLDRFGEMYELLDKT-TRFFGVFDGHSGSLSATYATSQLPQLLADQLKANP 227 
hPPM1E          RRKMEDKHVCIPDFNMLFNLEDQEEQAYFAVFDGHGGVDAAIYASIHLHVNLVRQEMFPH 300 
Ppm1-PA         RVDMEDAHT------HILSLPDDPQAAFFAVYDGHGGASVAKYAGKHLHKFITKRPEYRD 86 
                  .***  .       : .* *.    :*.*:***.*   * **  :*   :. :      
 
CG10376-PA      DPAAFSPDFYRNAFESAFLLADERFTQKKITSGTTSVCALITKDQLYIAWVGDSKALLVG 287 
hPPM1E          DPAEALCRAFRVTDERFVQKAAR----ESLRCGTTGVVTFIRGNMLHVAWVGDSQVMLVR 356 
Ppm1-PA         NSIEVALKKAFLDFDREMLQNGS---LDEQTAGCTAIVVLIRERRLYCANAGDSRAIACI 143 
                :.            :  .         ..  .* *.: .:*    *: * .***:.:    
 
CG10376-PA      KRTQLQLVKPHKPENPDERKRIETAGGTVLHAQGQWRVNGILNVARSIGDYSLEA----- 342 
hPPM1E          KGQAVELMKPHKPDREDEKQRIEALGGCVVWFG-AWRVNGSLSVSRAIGDAEHKP----- 410 
Ppm1-PA         SGMVHALSVDHKPNDAKESKRIMASGGWVEFNR----VNGNLALSRALGDFIYKKNLLKT 199 
                .     *   ***:  .* :** : ** *        *** * ::*::**   :       
 
CG10376-PA      ----VIA-EPDFVDVQLNEAHDFLVLGTDGLWDHVPESLIIETVYDSLADTTMKLDDIPK 397 
hPPM1E          ----YICGDADSASTVLDGTEDYLILACDGFYDTVNPDEAVKVVSDHLKENNGDSSMVAH 466 
Ppm1-PA         PEEQIVTAYPDVEVLDITEDLEFVLLACDGIWDVMSNFEVCQFVHKRIRDG-MEPELICE 258 
                     :   .*     :    ::::*. **::* :      : * . : :   . . : . 
 
CG10376-PA      LLIEAAKERD------SQDNITAVVVLLKPRHQIEHL----------------------- 428 
hPPM1E          KLVASARDAG------SSDNITVIVVFLRDMNKAVNVSEESDWTENSFQGGQEDGGDDKE 520 
Ppm1-PA         ELMNSCLSPDGHTGNVGGDNMTVILVCLLHNKSYEDLAVRCGGKR---KTPVETVGDIQD 315 
                 *: :. . .      . **:*.::* *   :.  .:                        
 
CG10376-PA      ------------------------------------------------------------ 
hPPM1E          NHGECKRPWPQHQCSAPADLGYDGRVDSFTDRTSLSPGSQINVLEDPGYLDLTQIEASKP 580 
Ppm1-PA         QSVKVVTPCSQGSSGSSTSRLGLG----FGLRESETPEANL------------------- 352 
                                                                             
 
CG10376-PA      ------------------------------------------------------------ 
hPPM1E          HSAQFLLPVEMFGPGAPKKANLINELMMEKKSVQSSLPEWSGAGEFPTAFNLGSTGEQIY 640 
Ppm1-PA         ------------------------------------------------------------ 
                                                                             
 
CG10376-PA      ------------------------------------------------------------ 
hPPM1E          RMQSLSPVCSGLENEQFKSPGNRVSRLSHLRHHYSKKWHRFRFNPKFYSFLSAQEPSHKI 700 
Ppm1-PA         ------------------------------------------------------------ 
                                                                             
 
CG10376-PA      ------------------------------------------------------- 
hPPM1E          GTSLSSLTGSGKRNRIRSSLPWRQNSWKGYSENMRKLRKTHDIPCPDLPWSYKIE 755 
Ppm1-PA         ------------------------------------------------------- 
                                                        
Symbols and colours: Colours indicate different groups of amino acids: red: 
AVFPMILW = small (small+ hydrophobic (incl.aromatic -Y)); blue: DE = acidic; 
magenta: RK = basic; green = STYHCNGQ = hydroxyl + amine + basic – Q. “*” the 
residues in that column are identical in all sequences in the alignment. “:” conserved 
substitutions as defined in Material and Methods section. “." semi-conserved 
substitutions as defined in Material and Methods section. 
 
PPM1E/F consensus phosphatase domain in highlighted in grey, PP2CĮ motif in 
yellow. Underlined nucleotide required for ARHGEF7 binding (Koh et al., 2002). 
PPM1E/1F homology domain (E/Fhd) as defined by Kitani et al. (2006) shaded in light 
grey. Protein phosphatase 2C motif shaded in yellow. Nucleotides required for 
ARHGEF7 binding are underlined (Koh et al., 2002).  
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A 7. Alignment of human ARHGEF6 with D. melanogaster rtGEF-PC  
hARHGEF6        ----------------------------------------MNPEEQIVTWLIS-----LG 15 
rtGEF-PC        MDQPLVVQAEYSFMGSNNDELCFQKGDVITVTQREDGGWWEGTLNDKTGWFPSNYVNECK 60 
                                                         .. :: . *: *        
 
hARHGEF6        VLESPKKTICDPE-----------EFLKSSLKNGVVLCKLINRLMPGSVEKFCLDPQTEA 64 
rtGEF-PC        VQLPLTETIRPPEEIQEYRSVVLKDLLDSERAHVAELQGLLENFLEPMQQTQILSQDEYA 120 
                *  . .:**  **           ::*.*.  : . *  *::.::    :.  *. :  * 
 
hARHGEF6        DCINNINDFLKGCATLQVEIFDPDD------LYSGVNFSKVLSTLLAVN----------K 108 
rtGEF-PC        QLMCNFVEIVRTHEDLLIQIEECNDRVGKLFLTSAPLMKKVHQAYCAAHPKAIVILDKYK 180 
                : : *: ::::    * ::* : :*      * *.  :.** .:  *.:          * 
 
hARHGEF6        ATEDQLSERPCGRSSSLSAANTSQTNPQGAVSSTVSGLQRQSKTVEMTENGS-------- 160 
rtGEF-PC        DELEKYMERQGAATPGLLVLTTGLSKPFRRLDKYSAMLQELERHMESSHPDRGDTQRSVA 240 
                   ::  **  . :..* . .*. ::*   :..  : **. .: :* :. .          
 
hARHGEF6        -HQLIVKARFNFKQTNEDELSVCKG--------------DIIYVTRVEEGGWWEG----- 200 
rtGEF-PC        VYKDIAATCSATRRQKELELQVLTGPVRGWQGQELSTLGDIIHMGSVAVGADHRDRYFVL 300 
                 :: *. :    :: :* **.* .*              ***::  *  *.  ..      
 
hARHGEF6        --------TLNGRTGWFPSN-----------------YVREIKSSERPLSPKAVKGFETA 235 
rtGEF-PC        FPQTLLFLSVSQRMSAFIYEGKLPLTGIIVNRLEDTDALKNAFEISSPLIDRIVAVCQGP 360 
                        ::. * . *  :                  :::  . . **  : *   : . 
 
hARHGEF6        PLTKNYYTVVLQNILDTEKEYAKELQSLLVTYLRPLQSNNNLSTVEVTSLLGNFEEVCTF 295 
rtGEF-PC        NEANKWVELLNANNPSLPMGIKRQLSNLSNSSLGHLNAAHLSQHLDSRGYCTRFSLCAYY 420 
                  ::::  ::  *  .      ::*..*  : *  *:: :  . ::  .   .*.  . : 
 
hARHGEF6        QQTLCQALEECSKFPENQHKVGGCLLSLMPHFK--------------------------- 328 
rtGEF-PC        SSPPCHVRPLRVTLPPSNYPATAPYANLSAHFARLVKGGGLRSAIVKMLLYPQARQSIDL 480 
                ... *:.     .:* .:: . .   .* .**                             
 
hARHGEF6        ---------------------------------------------------SMYLAYCAN 337 
rtGEF-PC        KRIALRKRRCHKASAKLKDLNTNQDSGQSELERQDAIELPTDSESYDDDFEDDFLHSCDS 540 
                                                                   . :*  * . 
 
hARHGEF6        ---------------------------------HPSAVNVLTQHSDELEQFMEN------ 358 
rtGEF-PC        DPFEYVQFYQNKRNDSMCNSTGTFVDHGTGARRHCSSINLIKLDSADTDEVLALNELKKE 600 
                                                 * *::*::. .* : ::.:         
 
hARHGEF6        --------------------------------------------------------QGAS 362 
rtGEF-PC        SLVIGSRALRALARKSTTRNSSVHTSTATLELGVGGSITNCVEEEPILKVKPSFSLQQQS 660 
                                                                        *  * 
 
hARHGEF6        SPGILILTTNLSKPFMRLEKYVTLLQELER------------------------------ 392 
rtGEF-PC        SDASSIFAARLGGAFTACENLASMPDDLSRESSIQEPPTPLPASPTERHSMPTIFVGNRF 720 
                * .  *:::.*. .*   *: .:: ::*.*                               
 
hARHGEF6        ------------------------------------------------------------ 
rtGEF-PC        NHSKNTEVYVPTWRDRQEMQNQSVDAKQDEELHSSSIDLPAACLSAPDKLQAELLYNYDE 780 
                                                                             
 
hARHGEF6        ------------------------------------------------------------ 
rtGEF-PC        ILEKPLQLHRELTPFPGHNLNSDKRVSHKSDSPSTGNAKTDPNLATRSSSTTELCIDTTS 840 
                                                                             
 
hARHGEF6        ------------------------------------------------------------ 
rtGEF-PC        KKRTTPSERSRDSIRRCISYQFLQMSNRPPPPPPPRRDPDLHLDTKCRCCENSQCPSPRS 900 
                                                                             
 
hARHGEF6        -------------------------------HMEDTHPDHQDILKAIVAFKTLMGQCQDL 421 
rtGEF-PC        SDSGMAGSCTITSPDPPNPESYFPMEAAGHDMLDNVEPERFDVCGMFREKFLTPEATQDV 960 
                                                :::..*:: *:   :          **: 
 
hARHGEF6        RKRKQLELQILSEPIQAWEGED----IKNLGNVIFMSQVMVQYGACEEKEERYLMLFSNV 477 
rtGEF-PC        VDLSEEQPQLSDEPTTPTNRKEEPTCITSAQVQVNTRSIFLPSSSSMDETNRNVPANNIL 1020 
                 . .: : *: .**  . : ::    *..    :   .:::  .:. :: :* :   . : 
 
hARHGEF6        LIMLSASPRMSGFIYQG----------KIP------IAGTVVTRLDEIEGND-------C 514 
rtGEF-PC        FSSSSADQLEPQATFRSGMYAHWWKKERLPPEVVRGIAHAYNKSLPSKDSKDSGSVCSSC 1080 
                :   **.   .   ::.          ::*      ** :  . * . :.:*       * 
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hARHGEF6        TFEITGNTVERIVVHCNNNQDFQEWLEQLNRLIR-------------------------- 548 
rtGEF-PC        FCSLGASGYSEGALYCSVCQNCADYYNGSVTSTTNTTTTTSSASCPLCSEDEGMIAPTHD 1140 
                  .: ..  .. .::*.  *:  :: :                                  
 
hARHGEF6        ------------------------------------------------------------ 
rtGEF-PC        SSSLDCPICNGRIASGAEEGKQSEMDRRPGNLRIPVEWYPVYLAGGMSPPSSHILLPPGG 1200 
                                                                             
 
hARHGEF6        -----------------------GPASCSSLSKTSSSSCSAHSSFSSTGQPRGPLEPPQI 585 
rtGEF-PC        RPPATPSSIPAGSSSGGSHSHQGSPATNSMSHHKRSQSFNHHLSYNQYTPTQPPPHHLHP 1260 
                                       .**: *   :. *.* . * *:..   .: * .  :  
 
hARHGEF6        IKPWSLSCLRPAPPLRPSAALGYKERMSYILKESSKSPKTMKKFLHKRKTERK------- 638 
rtGEF-PC        PQPPSLPSHLGASGPRSSSAQTPNSKTAAPLQASSMDASPAIQAAAAAAAAAVGMGVPSA 1320 
                 :* **..   *.  *.*:*   :.: :  *: ** ....  :      :           
 
hARHGEF6        ---PSEEEYVIRKSTAALEEDAQILKVIEAYCTSANFQQGHGSSTR-------------- 681 
rtGEF-PC        RKGSTKANWTISCLRPTPPLRPSLLNATSGSGSGSGGSGGGGSSSSNALASYCSGRKNQP 1380 
                   .:: ::.*    .:    ..:*:. ..  :.:. . * ***:                
 
hARHGEF6        ---KDSIPQVLLPEEEKLIIEETRSNGQTIMEEKSLVDTVYALKDEVRELKQENKRMKQC 738 
rtGEF-PC        TYEEDALVLRVFEAYCAAYQNNARNTIHSGLENEDMTPTLRQLWTAIRQMQQDMSQIKLQ 1440 
                   :*::   ::        :::*.. :: :*::.:. *:  *   :*:::*: .::*   
 
hARHGEF6        LEEELKSRRDLEKLVRRLLKQTDECIRGESSSKTSILP 776 
rtGEF-PC        INEERALRADLQQLLMQHLETSSVSSGANTPKC----- 1473 
                ::**   * **::*: : *: :. .  .::..       
 
Symbols and colours: Colours indicate different groups of amino acids: red: 
AVFPMILW = small (small+ hydrophobic (incl.aromatic -Y)); blue: DE = acidic; 
magenta: RK = basic; green = STYHCNGQ = hydroxyl + amine + basic – Q. “*” the 
residues in that column are identical in all sequences in the alignment. “:” conserved 
substitutions as defined in Material and Methods section. “." semi-conserved 
substitutions as defined in Material and Methods section. Sites required for binding of 
PPM1E and PPM1F are shaded yellow.  
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A 8. Comparison of His-PPM1E purification by Ni-NTA and by size-exclusion 
chromatography 
Excerpt from: „Expression, purification and characterisation of PPM1E and 
PPM1F”; Bachelor-Thesis, Daniel Siebert, Hochschule Furtwangen University 
(Villingen-Schwenningen) and Evotec Neurosciences (Hamburg); 1st examiner Prof. Dr. 
Ulrike Salat, 2nd examiner M. Sc. Lene Jessen; Hamburg, August 27th 2009; from: 
Results 3.4 Purification of His-PPM1E, Myc-PPM1E mutants G276D, R241A, D273A, 
D479N and His-PPM1F. 
 
Figure DS12: SDS-PAGE and Western 
Blot of the His-PPM1E His-tag 
purification. Left side: Coomassie 
stained SDS-polyacrylamide gel 
(SimplyBlue™ SafeStain), no visible 
bands of 75 kDa and 100 kDa PPM1E 
species (framed in red), flow-through, 
40 mM peak and also 150 mM elution 
lots of contaminations are visible. Right 
side: Western Blot (Į-PPM1E, 1 min 
exposure time), cell lysate three 
significant bands (60 kDa, 75 kDa, 100 
kDa), the flow-through almost only one 
significant band (100 kDa), 40 mM 
wash main band at 75 kDa and 150 
mM elution main band at 100 kDa 
(framed in red). [page 59; emphasis 
added] 
 
 
Figure DS14: SDS-PAGE and 
Western Blot of the His-PPM1E SEC 
with purified flow-through Left side: 
Coomassie stained SDS-
polyacrylamide gel (PhastGel® Blue 
R), no visible bands of 75 kDa and 100 
kDa PPM1E species (framed in red) 
visible. Right side: Western Blot (Į-
PPM1E, 20 min exposure time), two 
band detected (75 kDa and 100 kDa) 
in fraction A5 and A6 (framed in red). 
[Note: SEC: size-exclusion 
chromatography][page 61; emphasis 
added] 
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A 9. PPM1E has no macroscopic effect on D. melanogaster neuronal cells 
Drosophila melanogaster as a model system 
A convenient model system for neurodegeneration is the fruit fly Drosophila (D.) 
melanogaster due to the relative ease with which it is amenable to genetic 
manipulation. It has been a useful genetic model for several neurodegenerative 
diseases in the past (Cauchi and Van Den Heuvel, 2006;Ghosh and Feany, 2004;Muqit 
and Feany, 2002). Additionally, several pathway members, among them PAK, 
ARHGEF and CaMK are conserved in the fly. 
 
The D.melanogaster genome contains distantly related homologues of human PPM1E. 
The closest homologues, with absolute sequence identity of 27 % and 21 % to human 
PPM1E, are the PP2C-like serine/threonine phosphatase CG10376-PA and the 
predicted transcript Ppm1-PA (Appendix A 6). No function has been assigned to either 
one of them yet. Both show considerable sequence homology in the phosphatase 
domain and the CG10376-PA primary sequence is homologous in the amino-terminal 
ARHGEF binding motif. CG10376-PA and human PPM1E are 33 % identical and 68 % 
semi-conserved between the aa 150 and 490 in human PPM1E sequence. This stretch 
comprises the ARHGEF binding and the E/Fhd phosphatase domains. Neither of the 
proposed homologues is conserved in the carboxy-terminal PPM1E domain which 
encodes two nuclear localization signals. 
 
The closest homolog of the human ARHGEF6 in D. melanogaster is  rtGEF-PC,  also  
referred to as dPIX, a rho-type guanine exchange factor with 31 % sequence identity 
(Appendix A 7). rtGEF-PC plays a major role in regulating postsynaptic structure and 
protein localization at the Drosophila glutamatergic neuromuscular junction (Parnas et 
al., 2001;Werner and Manseau, 1997). rtGEF-PC contains a pleckstrin homology, a 
RhoGEF and a SH3 domain which is required for dPAK binding. The SH3-domain, 
required for dPAK binding, is conserved (Parnas et al., 2001) and amino acids 578 to 
719 (in human ARHGEF6), which are required for PPM1E binding, are semi-conserved 
by 92 % in rtGEF-PC.  
 
Established Drosophila melanogaster transgenic lines  
Drosophila (D.) melanogaster lines that contain P-element insertions with the human 
PPM1E gene were crossed to driver lines P{elav-GAL4} and P{gmr-GAL4} to 
overexpress hPPM1E in the complete central nervous system (Figure A9.1) and the 
eye respectively. The fly lines express hPPM1E(1-557) in the same truncated fashion 
APPENDIX 
 
160 
 
as described for the H4_PPM1E cell line and no full length form of PPM1E is 
detectable (Figure A9.1). The strength of protein expression depends on the location of 
the random P-element-mediated insertion on the chromosomes and is therefore 
variable between the fly lines (Figure A9.1; (Spradling et al., 1995)). Lines with different 
expression levels of PPM1E gene and PPM1E insertions on chromosome 2 (line 2.2 
and 2.5 in Figure A9.1) or 3 (line 3.1 in Figure A9.1) were used for further experiments 
to assess the effect of PPM1E on D.melanogaster neurons. 
 
 
Figure A9.1: D. melanogaster 
PPM1E line crosses to elav-GAL4 
express PPM1E(1-557). 15 µg fly 
protein extracts per lane. Detection 
with anti-PPM1E(AGC). elav: elav-
GAL4 coding chromosome; +: 
wildtype chromosome.  
  
  
Ectopic PPM1E expression showed no effects in D.melanogaster 
PPM1E expression was induced in crosses to the gmr-GAL4 driver line which drives 
expression under the control of the UAS promoter in all cells behind the morphogenic 
furrow of the fly eye, including photoreceptors (Freeman, 1996). Overexpression of 
PPM1E in the retinal tissue induced no eye phenotype (data not shown). The eye 
phenotype was assessed under the light microscope.  
 
PPM1E expression was additionally induced in the complete central nervous system 
with the elav – GAL4 driver (Koushika et al., 1996). w1118 or elav-GAL4 driver line flies 
were crossed to three PPM1E lines. Larvae were normal in size and concession of 
developmental stages as visualized under the light microscope in comparison with 
elav-GAL4 crosses to w1118. The flies showed no obvious deterioration in motor 
function. Therefore the lifespan of the flies was evaluated. The lifespan of 70 flies was 
recorded and no consistent difference in the lifespan in elav-GAL4 crosses to PPM1E 
fly lines was visible (Figure A9.2). A slight reduction in the lifespan of the crosses to the 
PPM1E lines 2.2 and 2.5 was not significant. PPM1E line 2.2 control crosses in w1118 
background also showed a slight, however not significant reduction in life span.  
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Figure A9.2: Survival  of  D.melanogaster PPM1E fly lines (A) without and (B) with 
induction of expression in the central nervous system by elav-GAL4. Lines 2.2 and 
3.1: stronger PPM1E expression; line 2.5: weaker PPM1E expression. Lines 2.2 and 
2.5 carry the PPM1E gene on chromosome 2; line 3.1 carries PPM1E gene on 
chromosome 3. n=70.  
 
No further experiments were conducted with the established PPM1E fly lines. 
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A 10. Influence of growth substrate on PPM1E expression in primary 
hippocampal culture 
Excerpt from: „Untersuchungen zum Einfluss von Stressfaktoren wie beta-
Amyloid Oligomeren auf die Phosphatase PPM1E in neuronaler Primärzellkultur” 
(“Analysis of the influence of stress factors like beta-amyloid oligomers on the 
phosphatase PPM1E in primary neuronal cell culture”); Diploma-Thesis 
(Fachhochschule), Dorothee Kampmann, Hochschule für Angewandte Wissenschaften 
Hamburg and Evotec AG (Hamburg); 1st examiner Prof. Dr. Ernst A. Sanders, 2nd 
examiner Dr. Heinz von der Kammer; Hamburg, March 23rd 2010 
 
 
y-axis: [PPM1E expression normalized to Cyclophilin [B]] 
x-axis: [untreated samples] 
 
German description of figure (original): 
 
„Abb. 1: PPM1E-mRNA-
Expressionsunterschied von 
unbehandelten DIV 24-Primärneuronen 
auf unterschiedlichen 
Wachstumsuntergrundbedingungen. 
Wachstumsuntergrundbedingungen: ohne 
DG oder mit DG Marienfeld (Mar). 
Mittelwerte ± Standardabweichung nach 
qRT-PCR über 8 Wells einer 24-well 
Zellkulturplatte (mit oder ohne DG), 
normalisiert gegen Cyclophilin; n=8. „ 
 
 
English description of figure (translation): 
 
“Figure 24: Difference in PPM1E mRNA 
expression in untreated DIV 24 primary 
neurons on different growth substrate 
conditions. 
Growth substrate conditions: without 
[glass] coverslips [on cell culture dish 
plastic] or with [glass] coverslips obtained 
from Marienfeld (Mar). Mean values ± 
standard deviation after qRT-PCR with > 8 
samples from one 24 well cell culture dish 
(with or without coverslips), normalized to 
Cylcophilin; n=8.” 
[without coverslips] 
[with coverslips] 
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